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Abstract: Type 3 innate lymphoid cells (ILCs) mediate tissue homeostasis and protection, primarily at
mucosal sites. Their profile is tightly controlled by the tissue microenvironment and can shift toward pro-
duction of the type 1 cytokine IFN￿ in an inflammatory setting. Likely because ILC3 and natural killer
(NK) cells are developmentally divergent innate lymphocyte lineages in mice, the plasticity of ILC3s
with respect to cytotoxic function has been neglected. Since ROR￿t-expressing progenitors, however,
contribute to NK cell generation in humans, we aimed to address this knowledge gap both in vitro and
in vivo, using humanized mice. We could demonstrate that after exposure to IL-12 and IL-15, human
ILC3s up-regulate expression of the master regulator of cytotoxic function Eomes and also the type 1
immunity associated transcription factor T-bet, albeit to a lesser extent. Transcriptional profiling and
flow cytometric analysis revealed acquisition of key NK cell features like expression of CD94, NKG2A,
NKG2C, CD56 and CD16 as well as enhanced responsiveness towards IL-2, IL-12 and IL-15. Function-
ally, expanded ILC3s gain the capacity to produce IFN￿ among other NK cell-associated cytokines and
chemokines. In addition they express cytolytic effector molecules such as granzymes and perforin and
mount a cytotoxic response against the classical NK targets K562. They show slower and lower cytolytic
activity compared to conventional NK cells, likely a result of a less potent activation or a distinct cytolytic
mechanism. Importantly, we observed differences in cytotoxic potential between tonsil and spleen ILC3
subsets, which might indicate tissue-specific imprinting. In addition, a fraction of the ILC3s retains their
phenotype despite the inflammatory cues, which suggests that not all ILC3s are primed to respond with
differentiation to inflammation. In light of these findings and as helper CD4+ T cells can also switch on
a cytotoxic program in symptomatic Epstein Barr virus (EBV) infection, we studied ILC3s in vivo under
EBV-driven inflammatory conditions. A short-term exposure of autologous unmanipulated ILC3s in that
setting seems to induce expression of CD94. However, transfer of IL-2 and IL-7 expanded ILC3s prior
to virus inoculation had no consistent effects on EBV infection and pathogenesis, which though could be
due to loss of the transferred cells.
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Zusammenfassung	  
	   Typ	  3	  natürliche	   lymphoide	  Zellen	   (type	  3	   innate	   lymphoid	  cells,	   ILC3s)	  unterstützen	   sowohl	   Gewebshomöostase	   als	   auch	   -­‐schutz,	   massgeblich	   an	  Schleimhautoberflächen.	  Ihr	  Profil	  wird	  eng	  vom	  Gewebeumfeld	  kontrolliert	  und	  kann	   durch	   ein	   Entzündungsmilieu	   zur	   Produktion	   des	   Typ	   1	   Zytokins	   IFNg	  angeregt	   werden.	   Wahrscheinlich	   weil	   in	   Mäusen	   ILC3s	   und	   natürliche	  Killerzellen	   (NK)	   in	   ihrer	   Entwicklung	   innerhalb	   der	   Familie	   der	   natürlichen	  Lymphozyten	   unterschiedlicher	   Abstammung	   sind,	   ist	   die	   Frage	   der	   Plastizität	  von	   ILCs	  bezüglich	   zytotoxischer	  Funktionen	  bisher	   vernachlässigt	  worden.	  Da	  RORgt	   exprimierende	   Vorläufer	   jedoch	   im	   Menschen	   zur	   Entstehung	   von	   NK	  Zellen	   beitragen,	   zielten	   wir	   in	   der	   hier	   vorgelegten	   Arbeit	   darauf	   ab,	   diese	  Wissenslücke	   sowohl	   in	   vitro	   als	   auch	   in	   vivo,	   in	   humanisierten	   Mäusen,	   	   zu	  schliessen.	  	   Wir	  konnten	  zeigen,	  dass	  humane	  ILC3s	  nach	  Zugabe	  von	  IL-­‐12	  und	  IL-­‐15	  die	   Expression	   des	   Hauptregulators	   für	   zytotoxische	   Funktionen	   EOMES	   und	  auch,	   in	   geringerem	   Masse,	   den	   Typ	   1	   Immunitätstranskriptionfaktor	   T-­‐bet,	  hochregulieren.	  Transkriptions-­‐	  und	  durchflusszytometrische	  Analysen	  ergaben	  die	   Aneignung	   von	   NK	   Schlüsseleigenschaften	   wie	   der	   Expression	   von	   CD94,	  NKG2A,	   NKG2C,	   CD56	   und	   CD16,	   sowie	   eine	   erhöhte	   Antwortbereitschaft	  gegenüber	   IL-­‐2,	   IL-­‐12	   und	   IL-­‐15.	   Funktionell	   erwerben	   expandierte	   ILC3s	   die	  Eigenschaft	   IFNg	   neben	   anderen	   NK	   Zell-­‐assoziierten	   Zytokinen	   und	  Chemokinen	   zu	   produzieren.	   Zusätzlich	   exprimieren	   sie	   zytolytische	  Effektormoleküle	   wie	   Granzyme	   und	   Perforin,	   und	   üben	   eine	   zytotoxische	  Antwort	  gegen	  die	  klassische	  NK	  Zielzelle	  K562	  aus.	  Sie	  zeigen	   im	  Vergleich	  zu	  konventionellen	  NK	  Zellen	  eine	  langsamere	  und	  niedrigere	  zytolytische	  Aktivität,	  wahrscheinlich	   als	   ein	   Resultat	   geringerer	   Aktivierung	   oder	   unterschiedlicher	  zytolytischer	   Mechanismen.	   Wichtigerweise	   haben	   wir	   Unterschiede	   im	  zytotoxischen	   Potential	   zwischen	   Mandel-­‐	   und	   Milz-­‐ILC3s	   beobachtet,	   die	   auf	  eine	   gewebsspezifische	   Prägung	   hinweisen	   könnten.	   Zusätzlich	   erhält	   ein	   Teil	  der	   ILC3s	   ihren	   Phänotyp	   trotz	   entzündungsbedingter	   Reize,	   was	   darauf	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hindeutet,	   dass	   nicht	   alle	   ILC3s	   in	   der	   Lage	   sind	  mit	   einer	  Differenzierung	   auf	  Entzündung	  zu	  antworten.	  	   In	   Anbetracht	   dieser	   Befunde	   und	   da	   auch	   CD4+	   Helfer-­‐T-­‐Zellen	   ein	  zytotoxisches	   Programm	   während	   symptomatischer	   Epstein	   Barr	   Virus	   (EBV)	  aktivieren	  können,	  haben	  wir	  ILC3s	  in	  vivo	  unter	  EBV	  induzierten	  entzündlichen	  Konditionen	  untersucht.	  Eine	  kurzfristige	  Stimulation	  autologer	  unmanipulierter	  ILC3s	  unter	  diesen	  Bedingungen	  schien	  die	  Expression	  von	  CD94	  zu	  induzieren.	  Allerdings	   hatte	   der	   Transfer	   IL-­‐2	   und	   IL-­‐7	   expandierter	   ILC3s	   vor	   Virusgabe	  keine	   konsistenten	   Effekte	   auf	   die	   EBV	   Infektion	   und	   Pathogenese,	   was	  allerdings	  am	  Verlust	  der	  transferierten	  Zellen	  liegen	  könnte.	  	  	   Da	   ILC3s	   ebenso	   häufig	   wie	   NK	   Zellen	   an	   Schleimhautoberflächen	  vorkommen,	   könnten	   diese	   eine	   schnelle	   Quelle	   zytotoxischer	   Vorläuferzellen	  darstellen.	   Diese	   Fähigkeit	   könnte	   für	   die	   Immuntherapie	   in	   Virusinfektionen	  oder	  Krebserkrankungen	  ausgenutzt	  werden,	  in	  Anbetracht	  dessen	  sind	  weitere	  
in	  vivo	  Untersuchungen	  zum	  Schicksal	  und	  der	  funktionellen	  Kapazität	  der	  ILC3s	  während	  einer	  Entzündung	  notwendig.	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Summary	  
	   Type	   3	   innate	   lymphoid	   cells	   (ILCs)	   mediate	   tissue	   homeostasis	   and	  protection,	   primarily	   at	  mucosal	   sites.	   Their	   profile	   is	   tightly	   controlled	  by	   the	  tissue	  microenvironment	  and	  can	  shift	  toward	  production	  of	  the	  type	  1	  cytokine	  IFNγ	  in	  an	  inflammatory	  setting.	  Likely	  because	  ILC3	  and	  natural	  killer	  (NK)	  cells	  are	  developmentally	  divergent	  innate	  lymphocyte	  lineages	  in	  mice,	  the	  plasticity	  of	   ILC3s	   with	   respect	   to	   cytotoxic	   function	   has	   been	   neglected.	   Since	   RORγt-­‐expressing	  progenitors,	  however,	  contribute	  to	  NK	  cell	  generation	  in	  humans,	  we	  aimed	  to	  address	  this	  knowledge	  gap	  both	  in	  vitro	  and	  in	  vivo,	  using	  humanized	  mice.	   We	   could	   demonstrate	   that	   after	   exposure	   to	   IL-­‐12	   and	   IL-­‐15,	   human	  ILC3s	  up-­‐regulate	  expression	  of	  the	  master	  regulator	  of	  cytotoxic	  function	  Eomes	  and	   also	   the	   type	   1	   immunity	   associated	   transcription	   factor	   T-­‐bet,	   albeit	   to	   a	  lesser	   extent.	   Transcriptional	   profiling	   and	   flow	   cytometric	   analysis	   revealed	  acquisition	  of	  key	  NK	  cell	  features	  like	  expression	  of	  CD94,	  NKG2A,	  NKG2C,	  CD56	  and	   CD16	   as	   well	   as	   enhanced	   responsiveness	   towards	   IL-­‐2,	   IL-­‐12	   and	   IL-­‐15.	  Functionally,	  expanded	  ILC3s	  gain	  the	  capacity	  to	  produce	  IFNγ	  among	  other	  NK	  cell-­‐associated	   cytokines	   and	   chemokines.	   In	   addition,	   they	   express	   cytolytic	  effector	   molecules	   such	   as	   granzymes	   and	   perforin	   and	   mount	   a	   cytotoxic	  response	   against	   the	   classical	  NK	   target	   cell	   line	  K562.	   They	   show	   slower	   and	  lower	  cytolytic	  activity	  compared	  to	  conventional	  NK	  cells,	  likely	  as	  a	  result	  of	  a	  less	   potent	   activation	   or	   a	   distinct	   cytolytic	   mechanism.	   Importantly,	   we	  observed	   differences	   in	   cytotoxic	   potential	   between	   tonsil	   and	   spleen	   ILC3	  subsets,	  which	  might	  indicate	  tissue-­‐specific	  imprinting.	  In	  addition,	  a	  fraction	  of	  the	   ILC3s	   retains	   their	   phenotype	   despite	   the	   presence	   of	   inflammatory	   cues,	  which	   suggests	   that	   not	   all	   ILC3s	   are	  primed	   to	   respond	  with	   a	   differentiation	  program	  to	  inflammation.	  	  In	   light	  of	  these	  findings	  and	  as	  helper	  CD4+	  T	  cells	  can	  also	  switch	  on	  a	  cytotoxic	  program	  in	  symptomatic	  Epstein	  Barr	  virus	  (EBV)	  infection,	  we	  studied	  ILC3s	  in	  vivo	  under	  EBV-­‐driven	  inflammatory	  conditions.	  A	  short-­‐term	  exposure	  of	  autologous	  unmanipulated	  ILC3s	  in	  that	  setting	  seems	  to	  induce	  expression	  of	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Introduction	  
	  
I. Human	  immune	  system	  overview	  	  Human	   immune	   responses	   are	   classically	   divided	   into	   two	   branches,	  innate	   and	   adaptive.	   The	   innate	   arm	   of	   immunity,	   including	   complement,	  phagocytic	   leukocytes	   and	   innate	   lymphoid	   cells,	   is	   rapidly	  mobilized,	   broadly	  specific	  as	  it	  relies	  on	  germ	  line-­‐encoded	  receptors	  and	  generally	  short-­‐lived.	  It	  not	   only	   serves	   as	   a	   first	   line	   of	   defense	   against	   invading	   pathogens	   but	   also	  modulates	  the	  development	  of	  an	  appropriate	  adaptive	  response,	  mediated	  by	  B	  and	   T	   lymphocytes.	   These	   cells	   undergo	   a	   process	   termed	   somatic	  recombination	  –	  the	  random	  gene	  rearrangements	  in	  the	  immunoglobulin	  and	  T	  cell	   receptor	   (TCR)	   loci,	   which	   create	   a	   diverse	   repertoire	   of	   highly	   specific	  receptors	   with	   the	   potential	   to	   recognize	   a	   vast	   array	   of	   pathogens.	   Adaptive	  immunity	   is	   thus	   characterized	   by	   specific	   antigen	   recognition.	  Moreover,	   it	   is	  able	   to	   generate	   a	   faster	   and	  more	   vigorous	   response	   upon	   rechallenge,	   i.e.	   to	  form	  memory	  (Murphy	  and	  Weaver,	  2016).	  This	  view	  of	  the	  immune	  system	  as	  two	   separate	   branches	   however	   is	   oversimplified,	   as	   there	   is	   a	   constant	   and	  complex	  interplay	  between	  the	  innate	  and	  adaptive	  systems,	  whose	  boundaries	  become	  blurred	  with	  discoveries	  of	  lymphocytes	  with	  innate-­‐like	  features	  like	  γδ	  T	   cells	   or	   studies	   of	   natural	   killer	   (NK)	   cells	   showing	   memory-­‐like	   behavior	  (Lanier	  and	  Sun,	  2009).	  	  
II. Innate	  lymphoid	  cells	  (ILCs)	  overview	  	  ILCs	   are	   innate	   effectors	  with	   important	   roles	   in	   inflammation,	   defense	  against	   pathogens	   or	   transformed	   cells	   as	   well	   as	   tissue	   homeostasis	   and	  remodeling.	   They	   have	   lymphoid	   morphology	   and	   originate	   from	   a	   common	  lymphoid	   progenitor	   (CLP)	   but	   are	   independent	   of	   recombination-­‐activating	  genes	   (RAGs)	   activity	   and	   are	   negative	   for	   lineage	   (Lin)	  markers	   such	   as	   CD3.	  The	  ILC	  family	  comprises	  NK	  cells	  and	  the	  recently	  identified	  helper	  populations.	  The	  latter	  are	  regarded	  as	   innate	  counterparts	  of	  T	  helper	  (Th)	  cells	  and	  based	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on	   their	   cytokine	   profile	   and	   transcription	   factor	   expression	   are	   divided	   into	  group	  1	  (ILC1;	  Th1-­‐like),	  group	  2	  (ILC2;	  Th2-­‐like)	  and	  group	  3	  (ILC3;	  Th17/22-­‐like).	  NK	  cells	  are	  classified	  as	  ILC1s	  but	  are	  segregated	  from	  the	  rest	  due	  to	  their	  cytotoxic	   properties	   (Figure	   A)	   (Gronke	   et	   al.,	   2016;	   Vivier	   et	   al.,	   2016).	   ILCs	  have	  strict	  tissue	  division	  at	  steady	  state	  with	  NK	  cells	  constituting	  the	  majority	  of	   ILCs	   (>	   95%)	   in	   peripheral	   blood	   (PB),	   spleen	   and	   bone	   marrow	   (BM),	  whereas	  in	  barrier	  tissues	  (tonsil,	  adenoid,	  skin,	  but	  not	  lung)	  other	  ILCs	  prevail.	  Importantly,	   ILCs	   are	   highly	   heterogeneous	   in	   frequency	   as	  well	   as	   phenotype	  across	   tissues	  and	   individuals,	   indicating	   flexibility	  governed	  by	  environmental	  and/or	  genetic	  factors	  (Simoni	  et	  al.,	  2017).	  	  This	  project	  focuses	  on	  ILC3	  and	  ILC1	  cell	  types,	  therefore	  ILC2s	  are	  not	  described	  in	  detail.	  	  
	  
Figure	  A	  Simplified	  overview	  of	  human	  ILC	  subset	  characteristics	  The	   ILC	   family	   is	   comprised	   of	   3	   subgroups.	   Type	   1	   cells	   are	   characterized	   by	   T-­‐bet	  expression	  and	  secretion	  of	  the	  Th1	  cytokine	  IFNγ.	  NK	  cells	  and	  intraepithelial	  (ie)ILC1	  belong	  to	  this	  group,	  but	  are	  distinguished	  by	  their	  cytotoxic	  properties	  contributed	  to	  Eomes	  expression.	  Type	  2	  cells	  express	  GATA3	  and	  produce	  Th2	  cytokines.	  Type	  3	  cells	  express	  RORγt	   and	   are	   characterized	   by	   IL-­‐22	   secretion.	  Markers	   defining	   the	   human	  ILCs	  subsets	  are	  indicated	  above.	  Figure	  is	  based	  on	  (Mjösberg	  and	  Spits,	  2016)	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III. ILC	  development	  
	  
A. In	  mice	  	  
1. Development	  	  ILCs	   derive	   from	   hematopoietic	   stem	   cells	   (HSCs)	   through	   a	   CLP,	   a	  developmental	   intermediate	   that	   has	   lost	   the	   potential	   to	   produce	  myeloid	   or	  erythroid	   lineages.	   Further	   commitment	   to	   the	   ILC	   fate	   has	   been	   extensively	  studied	  in	  recent	  years	  and	  a	  diverging	  point	  of	  innate	  and	  adaptive	  lymphocytes	  has	   been	   identified	   in	   murine	   bone	   marrow	   (BM)	   among	   integrin	   α4β7+	  lymphoid	  progenitors	  (αLPs),	  which	  have	  lost	  FMS-­‐like	  tyrosine	  kinase	  3	  (Flt3)	  expression	  (Gronke	  et	  al.,	  2016).	  This	  early	  ILC	  progenitor	  (EILP)	  has	  high	  levels	  of	  T	  cell	  factor	  1	  (TCF-­‐1,	  encoded	  by	  Tcf7),	  a	  protein	  associated	  so	  far	  with	  T	  cell	  fate	  specification,	   low	  or	  no	  expression	  of	  IL-­‐7Rα	  (CD127)	  (unlike	  the	  CLP:	  Lin-­‐Sca-­‐1loc-­‐kit(CD117)loFlt3+IL-­‐7Rα+)	   and	   many	   transcripts	   for	   Nfil3	   and	   Tox,	  encoding	  crucial	  drivers	  of	  ILC	  development.	  The	  EILP	  has	  no	  capacity	  for	  T	  or	  B	  cell	  generation	  but	  can	  give	  rise	  to	  all	  four	  ILC	  subsets	  as	  well	  as	  dendritic	  cells	  (DCs).	   Despite	   evidence	   for	   compensatory	   mechanisms,	   data	   from	   mixed	   BM	  chimeras	   with	   Tcf7−/−	   LSK	   (Lin−Sca-­‐1+c-­‐Kit+)	   progenitors,	   a	   population	   that	  includes	   HSCs,	   suggests	   that	   the	   predominant	   pathway	   of	   ILC	   differentiation	  under	  steady	  state	  conditions	  is	  TCF-­‐1–dependent	  (Yang	  et	  al.,	  2015).	  A	  separate	  IL-­‐7Rα+	   ILC	   committed	  precursor	  has	   been	  described	   in	  mouse	   fetal	   liver	   (FL)	  and	  BM	  that	  through	  successive	  expression	  of	  α4β7	  and	  CXCR6	  loses	  B	  and	  T	  cell	  potential,	   respectively	   (Possot	   et	   al.,	   2011).	   Downstream	   of	   these	   progenitors,	  there	   is	   evidence	   for	   a	   branching	   event	   where	   the	   development	   pathways	   of	  conventional	  (c)NK	  cells,	  defined	  as	  cytotoxic	  eomesodermin	  (Eomes)+	  cells,	  and	  the	   rest	   of	   the	   ILCs	   diverge.	   For	   example,	   GATA-­‐3	   ablation	   within	   the	  hematopoietic	   system	   (using	   Vav-­‐Cre	   mice)	   results	   in	   loss	   of	   all	   CD127+	   ILCs	  whereas	  splenic	  cNK	  cells	  are	  not	  significantly	  affected.	  This	  seems	  to	  be	  due	  to	  an	  arrest	  in	  development	  as	  αLP	  (but	  not	  CLP)	  numbers	  are	  greatly	  diminished	  in	   fetal	   liver	   and	   although	   all	   CD127+	   ILCs	   express	   GATA3	   (albeit	   at	   different	  levels),	   its	   inactivation	   in	  already	  mature	  cells	   leads	  to	  reduction	  only	   in	  ILC2s,	  the	  latter	  demonstrating	  its	  requirement	  in	  ILC2	  maintenance	  (Yagi	  et	  al.,	  2014).	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Notably,	  the	  drastic	  effect	  of	  GATA3	  on	  αLPs	  but	  not	  cNK	  cells	  (no	  assessment	  of	  functionality),	   suggests	   existence	   of	   an	   alternative	   pathway	   of	   NK	   cell	  development.	   Moreover,	   a	   common	   helper-­‐like	   ILC	   precursor	   (CHILP)	   has	  recently	   been	   described	   among	   BM	   cells	   that	   is	   Lin-­‐Sca-­‐1loc-­‐kit+Flt3-­‐α4β7+IL-­‐7Rα+CD25-­‐CD27+CD224(2B4)+	  and	  expresses	  inhibitor	  of	  DNA	  binding	  2	  (Id2),	  a	  transcriptional	   repressor	   of	   E	   proteins,	   which	   control	   early	   T	   and	   B	   cell	  development.	  The	  progeny	  of	  CHILPs	  after	   adoptive	   transfer	   in	  vivo	  was	   found	  mainly	   in	   the	   small	   intestine	   and	   liver,	   consistent	   with	   its	   expression	   of	   the	  mucosal-­‐homing	   integrin	   α4β7,	   and	   comprised	   all	   ILCs	   with	   the	   exception	   of	  Eomes+	   NK	   cells.	   Of	   note,	   whether	   the	   NKp46+T-­‐bet+RORγt-­‐	   population	   was	  derived	   from	   plastic	   ILC3s	   (discussed	   below)	   or	   represented	   a	   separate	   ILC1	  lineage	  was	  not	  investigated	  in	  vivo	  but	  ILC1-­‐only	  wells	  were	  generated	  in	  clonal	  cultures	   (3	   weeks	   on	   OP9-­‐DL1	   plus	   IL-­‐2,	   IL-­‐7	   and	   stem	   cell	   factor	   (SCF,	   c-­‐kit	  ligand))	   (unclear	   whether	   gated	   for	   Eomes)	   (Klose	   et	   al.,	   2014).	   Additional	  restriction	   in	   the	   helper	   ILC	   lineage	   choices	   is	   induced	   by	   the	   promyelocytic	  leukemia	   zinc	   finger	   (PLZF,	   encoded	   by	   Zbtb16),	   whose	   expression	   represses	  lymphoid	  tissue	  inducer	  (LTi)	  cell	  potential	  (Constantinides	  et	  al.,	  2015).	  Further	  differentiation	   is	   mediated	   by	   the	   expression	   of	   lineage-­‐defining	   transcription	  factors.	  An	  overview	  of	  the	  described	  developmental	  stages	  is	  shown	  in	  Figure	  B.	  	  Differentiation	   towards	   ILC3s	   is	   dependent	   on	   RAR-­‐related	   orphan	  receptor	   gamma	   (RORγt).	   This	   was	   early	   demonstrated	   for	   LTis	   as	   RORγt-­‐deficient	   mice	   lack	   this	   subset	   as	   well	   as	   lymphoid	   structures,	   such	   as	   lymph	  nodes	  (LNs)	  and	  Peyer's	  patches	  (PPs).	  Concurrently,	  during	  fetal	  life	  RORγt	  was	  found	  to	  be	  exclusively	  expressed	  in	  CD127+	  cells,	  which	  represent	  LTis	  or	  their	  precursors	   (Eberl	   et	   al.,	   2004).	   Interestingly,	   fetal	   α4β7+RORγt+	   precursors	  isolated	   from	   gut,	   in	   contrast	   to	   liver,	   already	   express	   transcripts	   for	   proteins	  like	   LTα,	   TRANCE,	   IL-­‐17a,	   suggesting	   functional	  maturation	  within	   the	   tissues	  (Cherrier	  et	  al.,	  2012).	  Using	  an	  inducible	  RORγt	  fate	  map	  (fm)	  system,	  Sawa	  et	  al	  showed	  that	  fetal	  and	  perinatal	  RORγt+CD3ε–	  cells	  could	  give	  rise	  to	  adult	  ILC3s,	  which	  are	  preferentially	  found	  in	  the	  lamina	  propria	  (LP)	  (Sawa	  et	  al.,	  2010).	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Figure	  B	  Model	  of	  murine	  ILC	  development	  ILCs	  derive	  from	  a	  CLP.	  Precursors	  to	  all	  ILC	  lineages	  are	  found	  among	  α4β7+	  lymphoid	  progenitors	   (αLPs).	   Downstream	   of	   these,	   cytotoxic	   and	   helper	   ILC	   development	  separates	   as	   only	   the	   latter	   are	   dependent	   on	   GATA3	   and	   common	   helper-­‐like	   ILC	  precursor	   (CHILP)	  was	   identified	   in	   BM.	   PLZF	   expression	   represses	   LTi	   potential	   and	  further	   lineage	   choices	   are	  based	  on	   the	   specific	   transcription	   factors	   for	   each	   subset.	  Figure	   is	  based	  on	   	  (Constantinides	  et	  al.,	  2015;	  Gronke	  et	  al.,	  2016;	  Klose	  et	  al.,	  2014;	  Possot	  et	  al.,	  2011;	  Yagi	  et	  al.,	  2014;	  Yang	  et	  al.,	  2015)	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  The	   majority	   of	   intestinal	   ILC3s	   at	   birth	   is	   positive	   for	   CCR6	   (NKp46-­‐CD117hiCD4+/-­‐)	   and	   resembles	   fetal	   LTi	   cells.	   Thereafter	   a	   CCR6-­‐	   population	  expands	   that	   contains	   an	   NKp46+T-­‐bet+	   subset.	   To	   investigate	   their	  developmental	  relationship,	  Klose	  et	  al	   isolated	  each	  population	  from	  the	  small	  intestine	   of	  RorcGfp/+	  mice	   and	   transferred	   it	   into	   alymphoid	   animals.	  Whereas	  CCR6+	   ILC3s	   remained	  negative	   for	  both	  markers,	  CCR6-­‐	   ILC3s	  up	   regulated	  T-­‐bet,	   followed	  by	  NKp46.	   	  Notably,	  Tbx21-­‐/-­‐	  mice	  did	  not	  generate	  NKp46+	  ILC3s	  (Klose	  et	  al.,	  2013).	  Helper	  (h)ILC1s	  were	  also	  absent	  (shown	  for	  LP),	  whereas	  their	  numbers	  remained	  normal	   in	  mice	  deficient	   in	  RORγt	  or	  Eomes	  (Klose	  et	  al.,	   2014).	  Hence,	  murine	  hILC1	  development	   is	   dependent	  on	   the	  Th1-­‐specific	  transcription	   factor	   T-­‐bet,	   which	   is	   also	   required	   for	   the	   differentiation	   of	  NKp46+	  ILC3s.	  A	  BM	  progenitor	  with	  no	  B/T/DC	  potential	  but	  the	  ability	  to	  generate	  NK	  has	   also	   been	   reported.	   Its	   phenotype	   overlaps	   with	   the	   CHILP	   but	   for	   α4β7	  expression,	   which	   or	   its	   capacity	   to	   generate	   other	   ILC	   subsets	   were	   not	  investigated	  (Fathman	  et	  al.,	  2011).	  Commitment	  towards	  the	  NK	  cell	   lineage	  is	  marked	  by	  acquisition	  of	  CD122	  (IL-­‐2/15Rβ)	  (Rosmaraki	  et	  al.,	  2001),	  which	  is	  essential	   for	   IL-­‐15	   signal	   transduction.	   The	   NK	   precursor	   (NKP)	   is	   itself	  independent	   of	   IL-­‐15	   and	   negative	   for	   NK-­‐specific	   markers	   such	   as	   NK1.1	  (Vosshenrich	  et	  al.,	  2005).	  Maturation	  to	  cNK	  cells	  is	  associated	  with	  acquisition	  of	   CD49b	   and	   variable	   expression	   Ly49	   receptors	   as	   well	   as	   an	   increase	   in	  transcripts	   for	   perforin	   (encoded	   by	   Prf1).	   Eomes	   is	   critical	   for	   this	   step	   as	  
Eomesflox/floxVav-­‐Cre+	  mice	  have	  a	  drastic	  reduction	  in	  this	  population.	  Moreover,	  deletion	  of	  Eomes	  from	  mature	  NK	  cells	  results	  in	  reversion	  of	  this	  phenotype	  to	  NK1.1+CD49b-­‐,	   indicating	   the	   latter	   constitutes	   a	   developmental	   intermediate	  (also	   shown	   in	   vitro)	   (Gordon	   et	   al.,	   2012).	   	   This	   NK1.1+CD49b-­‐	   subset	  constitutively	   expresses	   the	   tumor	   necrosis	   factor	   (TNF)–related	   apoptosis-­‐inducing	   ligand	  (TRAIL,	  encoded	  by	  TNFSF10),	   is	  present	   in	   the	   fetus	  and	  after	  birth	   persists	   predominantly	   in	   the	   liver	   (Gordon	   et	   al.,	   2012;	   Takeda	   et	   al.,	  2005)	  and	  its	  differentiation	  from	  the	  NKP	  and/or	  maintenance	  is	  dependent	  on	  T-­‐bet	  (Gordon	  et	  al.,	  2012;	  Klose	  et	  al.,	  2014).	  Even	  though	  cNK	  cells	  can	  develop	  in	   absence	   of	   T-­‐bet,	   with	   its	   close	   homologue	   Eomes	   being	   able	   to	   partially	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substitute	   for	   its	   function	   (Daussy	   et	   al.,	   2014;	   Pikovskaya	   et	   al.,	   2016),	  compensatory	   mechanisms	   might	   account	   for	   this.	   With	   the	   identification	   of	  precursors	  that	  give	  rise	  to	  T-­‐bet+Eomes-­‐	  but	  not	  Eomes+	  NK1.1+	  cells	  however	  (Constantinides	   et	   al.,	   2015;	   Klose	   et	   al.,	   2014;	   Yagi	   et	   al.,	   2014),	   it	   has	   been	  argued	   that	   these	  populations	   represent	   two	  distinct	   lineages,	  with	   the	   former	  being	   the	   so-­‐called	   hILC1s.	   To	   establish	   whether	   a	   linear	   developmental	  relationship	   exists,	   several	   groups	   have	   performed	   adoptive	   transfer	  experiments	   of	   the	   hILC1	   population	   under	   steady	   state	   conditions.	   When	  purified	  as	  Eomes-­‐	  using	  EomesGfp/+	  reporter	  mice,	  the	  recovered	  cells	  kept	  their	  original	  phenotype	  (Daussy	  et	  al.,	  2014),	  whereas	  when	  purified	  as	  TRAIL+(DX5-­‐)	  they	  showed	  tissue-­‐specific	  differentiation	  with	   induction	  of	  CD49b	  and	  Eomes	  favored	  in	  spleen	  and	  BM,	  but	  restricted	  in	  liver	  (Gordon	  et	  al.,	  2012;	  Takeda	  et	  al.,	   2005).	   Daussy	   et	   al	   argued	   that	   differences	   arise	   from	   a	   minor	   Eomes+	  fraction	   within	   the	   TRAIL+	   population,	   but	   they	   also	   observed	   that	   BM	  microenvironment	  suppressed	  T-­‐bet	  expression	  in	  spleen	  and	  liver-­‐derived	  cells	  (Daussy	   et	   al.,	   2014).	   Curiously,	   ectopic	   expression	   of	   Eomes	   in	   T-­‐bet+	   cells	  results	  in	  acquisition	  of	  CD49b	  and	  Ly49	  receptors	  among	  hILC1s	  (Pikovskaya	  et	  al.,	   2016).	   Even	   though	  microenvironment	   dictates	   specific	   programs	   and	   cNK	  cells	   transition	   through	   an	  NK1.1+CD49b-­‐	   intermediate,	   this	   does	   not	   preclude	  cells	  with	  similar	  phenotype	  to	  originate	  from	  distinct	  progenitors.	  Thus,	  in	  mice	  NK	  cell	  development	  diverges	  from	  that	  of	  helper	  ILCs.	  	  
2. Cytokine	  requirements	  	  Generation	  and	  homeostasis	  of	  NK	  cells	  requires	  IL-­‐15.	  It	  binds	  a	  receptor	  composed	   of	   the	   subunits	   CD122	   and	   CD132	   (also	   know	   as	   common	   gamma	  chain,	  γc),	  both	  shared	  with	  IL-­‐2	  and	  required	  for	  signal	  transduction,	  and	  a	  third	  specific	   component	   IL15Rα,	  which	   increases	   the	   affinity	   of	   the	   complex	   for	   its	  ligand	   by	   100-­‐fold.	   IL-­‐15	   acts	   via	   a	   mechanism	   called	   trans-­‐presentation,	  whereby	   cells	   bearing	   IL15Rα,	   expressed	   by	   hematopoietic	   and	   parenchymal	  cells,	   bind	   IL-­‐15	   and	   trans-­‐present	   it	   to	   the	   responding	   cell.	   It	   has	   been	  demonstrated	   that	   the	   same	   cell	   must	   express	   both	   proteins,	   which	   form	   a	  complex	   before	   reaching	   the	   plasma	   membrane	   that	   is	   later	   shed	   from	   the	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surface	   of	   presenting	   cells,	   reflecting	   the	   finding	   that	   all	   circulating	   IL-­‐15	  detected	  in	  mouse	  as	  well	  as	  human	  serum	  is	  coupled	  to	  IL15Rα.	  Mice	  deficient	  in	   IL-­‐15	   or	   its	   receptor	   components	   lack	   mature	   NK	   cells	   (among	   other	  populations)	   (Huntington,	   2014).	   However,	   this	   defect	   was	   reversed	   in	   IL15-­‐/-­‐	  mice	   by	   exogenous	   administration	   of	   the	   cytokine	   (Di	   santo,	   2006)	   as	   NKPs	  develop	   normally	   in	   the	   absence	   of	   γc	   cytokines	   (Vosshenrich	   et	   al.,	   2005).	  Recently,	  Ohs	  et	  al	  demonstrated	   that	  NK	  development	   can	  bypass	  γc	   signaling	  when	  exposed	  to	  the	  proinflammatory	  cytokine	  IL-­‐12,	  e.g.	  during	  viral	  infection.	  The	  generated	  cells	  are	  however	  distinct	  from	  cNK	  cells;	  they	  display	  low	  surface	  levels	  of	  NK1.1	  and	  NKp46	  and	  exhibit	  a	  more	  immature	  profile	  as	  revealed	  by	  transcriptome	   analysis	   but	   are	   CD122+CD49b+Eomes+	   and	   exert	   tumor	   control	  (Ohs	  et	  al.,	  2016).	  Single	  or	  combined	  deficiencies	  in	  IL-­‐2,	  -­‐4	  and	  -­‐7	  (on	  a	  Rag-­‐/-­‐	  background)	  have	   been	   shown	   to	   have	   no	   impact	   on	   NK	   development	   or	   function	  (Vosshenrich	   et	   al.,	   2005).	   IL-­‐7	   however	   is	   required	   for	   ILC3	   development	  and/or	  homeostasis.	  This	  dependence	  was	  revealed	  by	  analysis	  of	  intestinal	  ILC	  populations	  from	  mice	  deficient	  in	  IL-­‐7,	  CD127	  or	  CRLF2	  (together	  with	  CD127	  forms	   the	   thymic	   stromal	   lymphopoietin	   (TSLP)	   receptor).	  NKp46-­‐	   ILC3s	  were	  virtually	   absent	   in	   CD127-­‐/-­‐	   mice,	   whereas	   only	   a	   partial	   (but	   significant)	  reduction	  was	  observed	   in	   the	  others,	  suggesting	  redundancy	   in	   IL-­‐7	  and	  TSLP	  roles	   (Vonarbourg	   et	   al.,	   2010).	   In	   contrast,	   NKp46+	   ILC3s	   were	   almost	  undetectable	   in	  mice	   lacking	  IL-­‐7	  or	   its	  receptor,	  with	  the	   few	  remaining	  being	  RORγt-­‐	   (Satoh-­‐Takayama	   et	   al.,	   2010).	   Furthermore,	   when	   adult	   mice	   were	  treated	  with	  α-­‐CD127	  blocking	  antibody	  (Ab)	  NKp46+	   ILC3	  numbers	  as	  well	  as	  RORγt	  expression	  among	  the	  residual	  cells	  were	  diminished.	  Taken	  together,	  this	  demonstrated	  the	  role	  of	  IL-­‐7	  in	  their	  maintenance	  (Vonarbourg	  et	  al.,	  2010).	  	  Although	  expression	  of	  CD127	  is	  used	  to	  distinguish	  hILC1	  from	  cNK	  cells,	  their	  numbers	   in	  knock-­‐out	   (KO)	  mice	  are	  weakly	  affected	  (if	  at	  all),	   indicating	  that	   IL-­‐7	   is	   dispensable	   for	   their	   development.	   Like	   cNK	   cells	   though,	   they	   are	  dependent	  on	  IL-­‐15	  (	  et	  al.,	  2014a).	  	  Notably,	  ex-­‐ILC3s	  are	  also	  greatly	  reduced	  in	  the	  absence	  of	  IL-­‐15	  (Klose	  et	  al.,	  2014),	  whereas	  their	  precursors	  NKp46+	  ILC3s	  are	  normally	  represented	  in	  IL15-­‐/-­‐	  mice	  (Satoh-­‐Takayama	  et	  al.,	  2008)	  and	  local	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IL-­‐15	   overexpression	   using	   transgenic	   (Tg)	   mice	   does	   not	   influence	   their	  numbers	  or	  RORγt	  expression	  (Satoh-­‐Takayama	  et	  al.,	  2010).	  Hence,	   IL-­‐15	   is	   required	   for	   the	   development	   of	   ILC1	   populations,	  whereas	  ILC3s	  are	  dependent	  on	  IL-­‐7	  receptor	  signaling.	  Interestingly,	  cytotoxic	  unconventional	  NK	   cells	   can	   arise	   in	   the	   absence	   of	   IL-­‐15	   under	   inflammatory	  conditions	  (Ohs	  et	  al.,	  2016).	  	  
B. In	  humans	  
	  
1. Development	  	  Development	   of	   human	   ILCs	   is	   less	   well	   characterized	   with	   more	  available	   data	   on	   differentiation	   of	   NK	   cells,	   being	   the	   longest	   recognized	  member	  of	  the	  family.	  NK	  cell	  precursors	  have	  been	  detected	  exclusively	  among	  CD34+/dimCD45RA+	   hematopoietic	   progenitor	   cells	   (HPCs),	  which	   represent	   the	  first	   stage	   in	   the	   NK	   cell	   differentiation	   model	   described	   by	   Freud	   et	   al.	   This	  model	  consists	  of	  four	  developmental	  intermediates	  that	  are	  naturally	  occurring	  in	  lymphoid	  tissues	  such	  as	  tonsils	  and	  LNs	  and	  are	  defined	  based	  on	  sequential	  acquisition	   of	   CD117	   and	   CD94	   and	   restriction	   in	   the	   T/DC	   potential	   (none	  generate	   B	   cells).	   These	   are	   stage	   1	   (CD34+CD117-­‐CD94-­‐),	   stage	   2	  (CD34+CD117+CD94-­‐),	  stage	  3	  (CD34-­‐CD117+CD94-­‐),	  and	  stage	  4	  (CD34-­‐CD117+/-­‐CD94+)	   cells.	   Freshly	   isolated	   stage	   3	   cells	   show	   no	   perforin	   expression,	  cytotoxicity	   or	   IFNγ	   production	   and	   were	   regarded	   as	   immature	   NK	   cells,	  whereas	  stage	  4	  represent	  CD56bright	  mature	  NK	  cells	  (Freud	  et	  al.,	  2006).	  	  With	   the	   description	   of	   ILC3s,	   it	   is	   now	   clear	   that	   stage	   3	   comprises	   a	  mixture	  of	  two	  populations	  or	  potentially	  (some)	  ILC3s	  give	  rise	  to	  NK	  cells.	  The	  latter	  hypothesis	   has	  been	   supported	  by	   the	   recent	   identification	  of	   a	   tonsillar	  CD94+NKp80-­‐	   population	   that	   has	   ILC3-­‐associated	   characteristics.	   These	   so-­‐called	  stage	  4a	  cells	  have	  a	  surface	  phenotype	  intermediate	  between	  ILC3s	  and	  NK	  cells	  but	  are	  functionally	  more	  similar	  to	  ILC3s	  and	  do	  not	  yet	  express	  T-­‐bet	  or	  Eomes,	  nevertheless	  in	  vitro	  and	  in	  vivo	  in	  the	  presence	  of	  IL-­‐15	  both	  stage	  3	  and	   4a	   give	   rise	   to	  mature	   NK	   cells	   (Freud	   et	   al.,	   2016).	   Thus,	   despite	   strong	  evidence	   in	   mice	   that	   cNK	   development	   diverges	   from	   that	   of	   other	   ILCs,	   it	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remains	   unclear	   how	   closely	   this	   reflects	   the	   human	   situation.	   In	   addition,	  lineage	  tracing	  studies	  have	  shown	  that	  cNK	  are	  RORγt-­‐fm	  negative(Klose	  et	  al.,	  2014),	  yet	  Scoville	  et	  al	  observed	  expression	  of	  RORC2	  (which	  encodes	  RORγt)	  in	  stage	  2	  cells,	  with	  higher	  protein	  levels	  within	  an	  IL-­‐1R1-­‐expressing	  subset.	  This	  precursor	   (Lin-­‐CD34+CD45RA+CD117+IL-­‐1R1+)	   is	   restricted	   towards	   the	   ILC	  lineage	  and	  gives	  rise	  to	  all	  subsets	  (Scoville	  et	  al.,	  2016).	  In	  concert	  with	  these	  findings	   low	  but	  consistent	  RORγt	  expression	  is	  detected	  in	  human	  PB	  (mRNA)	  and	   tonsillar	   CD56bright	   NK	   cells	   (Scoville	   et	   al.,	   2016)	   as	   well	   as	   in	   ILC2s	  (Mjösberg	   et	   al.,	   2011).	  These	   results	  however	   are	  not	   in	   agreement	  with	  data	  from	  Montaldo	   et	   al.,	  which	  demonstrated	   that	   tonsil	   stage	  2	   cells	   are	   lineage-­‐specified	  progenitors	   to	   ILC3s.	   In	   that	  study	  CD117	  was	  defined	  as	  a	  surrogate	  marker	   for	  RORγt	  expression,	   the	   latter	  confined	   to	  CD34+	  progenitors	  derived	  from	   tonsils	   and	   intestinal	   lamina	  propria	   but	   not	   umbilical	   cord	  blood	   (UCB),	  BM	  or	  thymus.	  Tonsil	  CD34dimCD117+	  cells	  had	  a	  transcriptome	  profile	  closer	  to	  ILC3s	  than	  NK	  cells,	  which	  by	  itself	  does	  not	  preclude	  NK	  cells	  being	  downstream	  of	  ILC3s	  in	  development,	  but	  they	  differentiated	  selectively	  towards	  ILC3s,	  with	  the	   few	   NK	   cells	   arguably	   derived	   from	   RORγt-­‐	   cells	   within	   these	   precursors	  (around	   10%)	   (Montaldo	   et	   al.,	   2014).	   These	   discrepancies	   between	   the	   two	  studies	  probably	  pertain	  to	  differences	  in	  culture	  conditions,	  as	  also	  CD34+/bright	  cells	  seemed	  to	  generate	  preferentially	  these	  two	  ILC	  populations	  with	  no	  report	  on	   any	   other	   lineage	   and	   the	   authors	   noted	   that	   SCF	   and	   aryl	   hydrocarbon	  receptor	  (AHR)	  ligands	  present	  in	  media	  favor	  ILC3	  differentiation	  (Montaldo	  et	  al.,	   2014).	   It	   is	   worth	   mentioning	   though	   that	   (with	   some	   variations	   between	  studies)	   only	   a	   small	   fraction	   of	   the	   stage	   2	   (and	   3)	   progeny	   are	   CD94+	   cells	  (Freud	  et	  al.,	  2006;	  2016;	  Scoville	  et	  al.,	  2016).	  Thus,	  although	  distinct	  cultures	  result	   in	   different	   outcomes	   and	   in	   vitro	   conditions	   seem	   to	   be	   inefficient	   in	  driving	  NK	  differentiation	  and	  full	  maturation,	  it	  is	  also	  possible	  if	  not	  likely	  that	  CD34dimCD117+	  stage	  2	  cells	  are	  not	   the	  only	  pathway	  of	  NK	  cell	  development.	  Supporting	   this	  notion,	  Moroso	  et	   al	   detected	   stage	  2	   and	  3	   cells	   in	   adult	   liver	  which	  displayed	  no	  transcripts	  for	  RORC,	  IL22	  or	  IFNγ	  but	  gave	  rise	  to	  functional	  NK	  cells	  (Moroso	  et	  al.,	  2011).	  Moreover,	  RORC–/–	  patients	  seem	  to	  have	  normal	  blood	  NK	  counts	  but	  absence	  of	  PB	  ILC3s	  as	  well	  as	  palpable	  axillary	  and	  cervical	  LNs	  (Okada	  et	  al.,	  2015).	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Figure	  C	  Model	  of	  human	  ILC	  development	  Downstream	  of	  the	  CLP,	  an	  NKp,	  present	  in	  BM/CB	  and	  fetal	  tissues	  has	  been	  identified	  (Renoux	  et	  al.,	  2015).	   ILCps	  that	  gives	  rise	   to	  all	  subsets,	   including	  NK	  cells	  have	  been	  isolated	   from	   PB	   (Lim	   et	   al.,	   2017)	   and	   tonsils	   (Scoville	   et	   al.,	   2016).	   ILC3-­‐specified	  progenitor	  has	  been	  purified	  from	  tonsils	  but	  is	  also	  present	  in	  intestinal	  lamina	  propria.	  Putative	   populations	   have	   dashed	   membrane.	   Unknown	   developmental	   steps	   are	  colored	  in	  grey.	  Dashed	  arrows	  represent	  origin	  of	  estimated	  precursor.	  Sizes	  in	  stage	  2	  and	   3	   cells	   indicate	   the	   frequency	   of	   the	   respective	   populations.	   Figure	   is	   based	   on	  (Collins	  et	  al.,	  2017;	  Lim	  et	  al.,	  2017;	  Montaldo	  et	  al.,	  2014;	  2015;	  Renoux	  et	  al.,	  2015;	  Scoville	  et	  al.,	  2016;	  Yu	  et	  al.,	  2013)	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Of	  note,	  the	  enrichment	  of	  ILC3/NK	  precursors	  in	  peripheral	  tissues,	  such	  as	   tonsils	   and	   intestinal	   lamina	  propria,	   compared	   to	  BM	  and	  PB	   (Freud	   et	   al.,	  2005;	   Montaldo	   et	   al.,	   2014)	   indicates	   ILC	   development	   outside	   the	   BM.	  Interestingly,	  NK	  precursors	   isolated	   from	  explanted	   liver	  grafts	  were	   found	   to	  be	  of	   recipient	  origin,	   indicating	   recruitment	   from	   the	  bloodstream	  (Moroso	  et	  al.,	  2011).	  	  In	   fetal	   tissues	   as	   well	   as	   UCB	   and	   BM,	   progenitors	   with	   similar	  phenotype	  to	  stage	  2	  cells	  but	  positive	  for	  CD7	  and	  CD10	  (stage	  2:	  CD7-­‐CD10-­‐/+)	  have	  been	  identified	  that	  are	  restricted	  to	  the	  NK	  cell	  lineage.	  When	  compared	  to	  upstream	   lymphoid-­‐primed	   or	   committed	   progenitors,	   Lin-­‐CD34+CD38+CD123-­‐CD45RA+CD7+CD10+CD127-­‐	  NKPs	  express	  more	  transcripts	  for	  NK-­‐related	  genes	  such	   as	  EOMES,	  Prf1,	   and	   IL2RB	  (encodes	   CD122).	   Of	   note,	   the	  NKP	   in	  mice	   is	  characterized	   by	   CD122	   surface	   expression,	   which	   in	   human	   is	   below	   the	  detection	  limit.	  	  The	  NKP	  commitment	  was	  demonstrated	  also	  in	  vivo	  where	  the	  authors	  were	   able	   to	   detect	   NK	   cells	   but	   no	   other	   populations	   11	  weeks	   after	  reconstitution	   of	   newborn	   NOD/SCIDγcnull	   (NSG)	   mice	   with	   only	   600	   UCB-­‐derived	  NKPs	  and	  without	  addition	  of	  human	  cytokines.	  NK	  development	  in	  this	  setting	  is	  quite	  surprising	  as	  it	  relies	  on	  mouse	  IL-­‐15	  that	  has	  poor	  reactivity	  on	  human	   cells	   and	   fails	   to	   induce	   their	   proliferation	   (Eisenman	   et	   al.,	   2002;	  Huntington	   et	   al.,	   2009)	   but,	   more	   importantly,	   the	   NOD	   background	   has	   an	  abnormal	   IL15	   expression	  with	  a	   subsequent	  NK	  cell	  defect	   (correctable	  by	   IL-­‐15/IL-­‐15Rα	  complexes	  injection)	  (Suwanai	  et	  al.,	  2010).	  NKPs,	  tonsil	  stage	  2	  IL-­‐1R1+	   and	   stage	   3	   cells	   in	  vivo	   generate	   CD16+	  NK	   cells	   (Freud	   et	   al.,	   2016).	   In	  
vitro	  CD16	  as	  well	  as	  KIR	  expression	  can	  be	  induced	  on	  CD56bright	  NK	  cells	  from	  PB	  with	  IL-­‐2	  or	  IL-­‐15	  stimulation	  (Romagnani	  et	  al.,	  2007).	  Moreover,	  CD56bright	  NK	   cells	   transferred	   into	   immunodeficient	  mice	   give	   rise	   to	   CD56dimCD16+	   NK	  cells	   (Chan	  et	   al.,	   2007;	  Huntington	   et	   al.,	   2009),	   	  with	   the	   latter	   also	   found	   to	  have	  shorter	  telomeres	  (Chan	  et	  al.,	  2007;	  Romagnani	  et	  al.,	  2007).	  These	  data,	  together	   with	   the	   identification	   of	   a	   PB	   CD94hiCD56dim	   population	   with	   an	  intermediate	   phenotype	   and	   functionality	   between	   CD56bright	   and	  CD94dimCD56dimCD16+	  NK	  cells	  (Yu	  et	  al.,	  2010),	  supports	  a	  linear	  differentiation	  model	   between	   the	   two	   subsets,	   a	   notion	   challenged	   by	   a	   recent	   report	   in	  macaques	   (Wu	   et	   al.,	   2014).	   Finally,	   CD57	   expression	   on	   CD56dim	   NK	   cells	   is	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associated	  with	  lower	  proliferative	  capacity	  and	  responsiveness	  to	  cytokines	  but	  increased	   cytotoxicity,	   consequently	   CD57+	   NK	   cells	   are	   designated	   terminally	  differentiated	  (Lopez-­‐Vergès	  et	  al.,	  2010).	  Thus,	   a	   fraction	   of	   human	   NK	   cells	   might	   also	   arise	   from	   a	   RORγt+	  progenitor,	  as	  do	  ILC3s.	  	  
2. Cytokine	  requirements	  	  In	  accordance	   to	  mouse	  data,	   IL-­‐15	  has	  been	  shown	  to	  maintain	  NK	  cell	  survival,	  induce	  their	  proliferation	  and	  differentiation.	  In	  vitro,	  IL-­‐15	  is	  sufficient	  for	   differentiation	   of	   CD34+	   BM	   cells	   towards	   cytotoxic	   NK	   cells	   (3	   weeks	  culture),	  even	  though	  alone	  it	  does	  not	  promote	  their	  proliferation	  (Mrózek	  et	  al.,	  1996).	  In	  humanized	  mice	  (discussed	  below),	  supplementation	  of	  IL-­‐15/IL-­‐15Rα	  complexes	  induced	  robust	  NK	  cell	  proliferation	  as	  well	  as	  differentiation	  towards	  a	   CD56loCD16+KIR+	   phenotype.	   Moreover,	   adoptively	   transferred	   CD56hiCD16-­‐KIRs-­‐	  or	  CD56loCD16+KIRs-­‐	  NK	  cells	  from	  fetal	  spleen	  into	  immunodeficient	  Rag2-­‐/-­‐Il2rg-­‐/-­‐	   mice	   acquired	   CD16	   and	   KIRs	   with	   IL-­‐15/IL-­‐15Rα	   for	   7	   days,	   thus	  confirming	  the	  role	  of	  IL-­‐15	  in	  NK	  differentiation	  (Huntington	  et	  al.,	  2009).	  	  IL-­‐2	  shows	   some	   redundancy	  with	   IL-­‐15	  as	  observed	   in	  a	  humanized	  mouse	  model	  with	  transgenic	  expression	  of	  human	  IL-­‐2.	  These	  mice	  had	  a	  predominant	  effect	  in	   the	  NK	  compartment,	  with	  both	  expansion	  and	  differentiation	  (Katano	  et	  al.,	  2015).	  Nevertheless,	  no	  change	   in	  NK	  cell	  numbers	  or	  activity	  was	  observed	   in	  an	   IL2RAnull	  (CD25)	  patient	  (Goudy	  et	  al.,	  2013),	  whereas	  they	  were	  absent	   in	  a	  patient	   with	   a	   deficiency	   in	   CD122	   (IL-­‐2/IL-­‐15Rβ)	   (not	   mapped	   to	   IL2RB)	  (Orange,	   2006),	   suggesting	   that	   IL-­‐2	   is	   not	   required	   for	   NK	   cell	   development.	  Finally,	  patients	  with	  defective	  IL7R	  expression	  have	  functional	  NK	  cells	  (Puel	  et	  al.,	   1998).	   Thus,	   IL-­‐15,	   but	   not	   IL-­‐2	   or	   IL-­‐7	   is	   required	   for	   human	   NK	   cell	  development.	  Patients	  with	  severe	  combined	  immunodeficiency	  (SCID),	  resulting	  from	  IL2RG	  or	  JAK3	  mutations,	  lack	  not	  only	  NK	  cells	  but	  also	  other	  ILC	  subsets	  (Vély	  et	  al.,	  2016a)	  and	  have	  no	  LNs	  (Facchetti	  et	  al.,	  1998),	  suggesting	  that	  as	  in	  mice	  (Satoh-­‐Takayama	  et	  al.,	  2010;	  Vonarbourg	  et	  al.,	  2010),	  human	  ILC3s	  rely	  on	  IL-­‐7	  for	  their	  development.	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IV. ILC	  subsets	  and	  their	  characteristics	  
	  
A. Group	  1	  ILCs	  	  
1. NK	  cells	  	  The	   prototypic	   member	   of	   this	   family	   are	   NK	   cells,	   which	   were	   first	  discovered	   in	  mice	   for	   their	   intrinsic	  ability	   to	   lyse	   tumor	  cell	   lines.	  They	  were	  later	  recognized	  not	  only	  as	  important	  players	  in	  cancer	  immunosurveillance	  but	  also	  in	  infection.	  NK	  cells	  survey	  the	  host	  for	  “stressed“,	  infected	  or	  transformed	  cells	   through	   expression	   of	   diverse	   set	   of	   receptors	   and	   exert	   their	   cytolytic	  activity	   through	   the	   release	   of	   cytotoxic	   granules	   containing	   perforin	   and	  granzymes	   (Gzms)	   or	   through	   death	   receptor-­‐induced	   apoptosis,	   mediated	   by	  molecules	   such	   as	   TRAIL	   or	   FasL.	   They	   are	   also	   potent	   producers	   of	   pro-­‐inflammatory	   cytokines,	  most	   notably	   IFNγ,	   and	   chemokines	   and	   thus	   are	   also	  able	   to	   modulate	   the	   immune	   response.	   Finally,	   NK	   cells	   rely	   on	   the	   T-­‐box	  transcription	   factors	  Eomes	  and/or	  T-­‐bet	   for	   their	  differentiation,	  maintenance	  and/or	   functionality.	   In	  mice,	  mature	  NK	   cells	   are	  Eomes+	  (Vivier	   et	   al.,	   2016).	  Thus,	  NK	  cells	  are	  the	  innate	  counterpart	  of	  cytotoxic	  CD8+	  T	  cells.	  	  
a. Receptors	  involved	  in	  target	  cell	  recognition	  	  NK	   cell	   diversity	   is	   generated	   by	   the	   variable	   expression	   of	   germ	   line-­‐encoded	   activating	   and	   inhibitory	   receptors.	   In	   humans,	   these	   include	   killer	  immunoglobulin-­‐like	  receptors	  (KIRs),	  natural-­‐killer	  group	  2	  (NKG2)	  receptors,	  and	   natural	   cytotoxicity	   receptors	   (NCRs),	   among	   others.	   The	   KIR	   family	  comprises	   activating	   and	   inhibitory	   receptors,	  which	   recognize	   epitopes	   of	   the	  highly	  polymorphic	  human	  leukocyte	  antigen	  (HLA)	  class	  I	  ligands	  HLA-­‐A,	  HLA-­‐B	  and	   HLA-­‐C.	   The	   inhibitory	   KIRs	   are	   involved	   in	   a	   process	   termed	   NK	   cell	  education	   or	   licensing,	   whereby	   the	   presence	   of	   both	   receptor	   and	   cognate	  ligand	   is	  necessary	   for	   the	   functional	   competence	  of	   the	  cell.	   If	   self-­‐HLA	  class	   I	  ligands	   are	   absent,	   NK	   cells	   remain	   hyporesponsive,	   which	   ensures	   self-­‐tolerance.	   The	  murine	   functional	   analogues	   of	   KIRs	   are	   the	   Ly49	   receptors.	   C-­‐
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type	   lectin	  NKG2	  family	  members	   form	  heterodimers	  with	  CD94	  and	  recognize	  HLA-­‐E	  (Qa1b	  in	  mice),	  which	  binds	  peptides	  from	  the	  leader	  sequence	  of	  class	  I	  molecules.	   Thus,	   NKG2	   receptors	   act	   complementary	   to	   KIRs	   by	   allowing	   NK	  cells	  to	  indirectly	  monitor	  HLA	  expression.	  If	  the	  latter	  is	  obstructed	  as	  a	  result	  of	  infection	  or	  transformation,	  the	  cell	  will	  be	  targeted	  for	  elimination	  owing	  to	  the	  lack	   of	   inhibition,	   an	   interaction	   known	   as	   “missing	   self“	   recognition.	   The	  inhibitory	  NKG2A	  and	  activating	  NKG2C	  and	  NKG2D	  receptors	  are	  present	  both	  in	  mice	  and	  humans.	  Of	  note,	  NKG2D	  constitutes	  an	  exception	  from	  the	  family	  as	  it	   is	   expressed	   as	   a	   homodimer	   and	   binds	   the	   stress-­‐	   or	   virus-­‐induced	   ligands	  MHC	   class	   I	   chain-­‐related	   protein	  A	   (MICA),	  MICB	   and	  UL-­‐16	   binding	   proteins	  (ULBPs)	   (in	   mice	   RAE1,	   H60	   and	  MULT1).	   NCRs	   are	   activating	   receptors	   that	  belong	   to	   the	   immunoglobulin	   superfamily	   and	  are	  grouped	   together	  based	  on	  functionality.	   They	   comprise	   NKp46	   (NCR1;	   CD335)	   (the	   only	   one	   found	   in	  mice),	  NKp44	  (NCR2;	  CD336)	  and	  NKp30	  (NCR3;	  CD337).	  NCRs	  are	  described	  to	  bind	   viral,	   bacterial,	   parasite	   as	  well	   as	   cellular	   ligands	   among	  which	   are	   viral	  hemagglutinins,	  the	  human	  cytomegalovirus	  (HCMV)	  tegument	  protein	  pp65	  and	  heparan	  sulfates	  whose	  expression	  pattern	  varies	  on	  tumor	  cells.	  Besides	  these,	  the	  low-­‐affinity	  IgG	  receptor	  CD16	  (FcγRIII)	  is	  also	  a	  potent	  activator	  of	  NK	  cells,	  through	   which	   they	   mediate	   antibody-­‐dependent	   cellular	   cytotoxicity	   (ADCC)	  (Björkström	   et	   al.,	   2016;	   Kruse	   et	   al.,	   2014;	   Pegram	   et	   al.,	   2011).	   Importantly,	  whereas	   inhibitory	   receptor	   expression	   (although	   poorly	   understood)	   is	  determined	   primarily	   by	   genetics	   and	   is	   strictly	   regulated,	   expression	   of	  activating	   and	   co-­‐stimulatory	   receptors	   like	   DNAX	   Accessory	   Molecule-­‐1	  (DNAM-­‐1,	  CD226)	   is	   largely	  affected	  by	  environmental	   factors	   (Horowitz	  et	  al.,	  2013).	  	  
b. NK	  subsets	  across	  tissues	  	  	   Human	   NK	   cells	   are	   defined	   as	   CD3-­‐NKp46+(CD94+/dim)	  and	   are	   divided	  according	   to	   CD56	   and	   CD16	   differential	   expression	   into	   CD56brightCD16-­‐	   and	  CD56dimCD16+	  cells.	  Whereas	  the	  former	  is	  enriched	  in	  tonsils	  and	  LNs	  and	  has	  primarily	   immunoregulatory	   functions,	   the	   latter	   is	   the	   predominant	   subset	   in	  PB	  and	  spleen	  and	  has	  potent	  cytotoxic	  activity.	  CD56dimCD16+	  cells	  can	  express	  
	   	   Introduction	  
	   22	  
in	   addition	   KIRs	   and	   CD57,	   a	   marker	   of	   NK	   terminal	   differentiation/antigen	  exposure	  (Björkström	  et	  al.,	  2016).	  Importantly,	  activation	  influences	  CD56	  and	  CD16	  expression,	  therefore	  this	  designation	  is	  relevant	  mostly	  for	  analysis	  of	  PB	  from	  healthy	  subjects.	  For	  example,	   in	  HIV-­‐infected	  patients	  an	  unconventional	  CD56-­‐CD16+/dim	   NK	   population	   expands	   that	   has	   low	   lytic	   activity	   (Spits	   et	   al.,	  2016).	   Whereas	   PB	   CD56bright	   cells	   are	   Eomes+	   but	   exhibit	   a	   variable	   T-­‐bet	  expression,	  CD56dim	  cells	  are	  EomesloT-­‐bethi	  (Knox	  et	  al.,	  2014).	  In	   mice	   NK	   cells	   do	   not	   express	   CD56	   but	   are	   positive	   for	   NK1.1	   (not	  expressed	  by	  all	  mouse	  strains)	  and	  the	  integrin	  α2	  (CD49b),	  recognized	  by	  the	  DX5	  antibody	  (Di	  santo,	  2006).	  Apart	   from	   blood	   and	   secondary	   lymphoid	   tissues	   (SLTs),	   NK	   cells	   are	  found	  in	  peripheral	  organs	  with	  the	  highest	  prevalence	  in	  liver,	  lung	  and	  uterus.	  To	   what	   extent	   these	   represent	   circulating	   NK	   cells	   transiently	   recruited	   to	  tissues	  or	  resident	  NK	  cells	  was	  not	  clear	  until	  the	  characterization	  of	  molecules	  governing	  cell	   trafficking	  or	  retention	  within	  organs	  and	  subsequent	  work.	  For	  example,	   NK	   cells,	   particularly	   the	   CD56dim	   subset,	   preferentially	   express	  sphingosine	   1-­‐phosphate	   (S1P)	   receptor	   5,	   which	   allows	   them	   to	   egress	   from	  tissues	  along	  an	  increasing	  S1P	  gradient.	  On	  the	  other	  hand,	  CD69	  was	  found	  to	  inhibit	  S1P-­‐1,	  respectively,	  CD69	  is	  rarely	  expressed	  in	  blood,	  but	  is	  found	  on	  the	  majority	  of	  NK	  cells	  within	   tissues	   such	  as	   liver	   and	   skin.	   Similar	  observations	  are	  made	   for	  CD49a	   (α1	   integrin),	  which	   in	   a	   complex	  with	  β1	  binds	   collagen,	  and	   CD103	   (αE	   integrin),	   which	   interacts	   with	   β7	   and	   bind	   E-­‐cadherin,	  expressed	  on	  epithelial	  cells.	  Based	  on	  these	  markers	  tissue-­‐resident	  populations	  can	  been	  distinguished	  (Björkström	  et	  al.,	  2016).	  	  Stegmann	   et	   al	   identified	   a	   CD69hiCXCR6+T-­‐betloEomeshi	   subset	   residing	  in	  liver	  with	  variable	  frequencies	  (5-­‐88%	  of	  total	  NK	  cells).	  CXCR6	  expression	  at	  steady	  state	  provides	  a	  mechanism	  for	  tissue	  retention	  in	  addition	  to	  CD69,	  as	  its	  ligand	   CXCL16	   is	   highly	   expressed	   by	   liver	   sinusoidal	   cells.	   	   CXCR6+	   NK	   cells	  show	   lower	   expression	  of	   cytotoxic	  molecules	   and	  pro-­‐inflammatory	   cytokines	  upon	  stimulation	  than	  their	  CXCR6-­‐	  counterparts,	  however	  TRAIL	   induction	  (in	  diseased	  liver)	  was	  demonstrated	  to	  be	  largely	  restricted	  to	  the	  former.	  Of	  note,	  whereas	   in	   mice	   liver-­‐resident	   CD49a+CD49b-­‐	   NK/ILC1	   cells	   constitutively	  express	  high	  levels	  of	  TRAIL,	  in	  healthy	  human	  livers	  its	  expression	  is	  negligible.	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Moreover,	   in	   mice	   these	   cells	   are	   T-­‐bet+Eomes-­‐	   and	   in	   humans	   they	   have	   the	  converse	  TF	  profile	  with	  CXCR6	  but	  not	  CD49a	  segregating	  the	  two	  (Stegmann	  et	  al.,	  2016).	  Marquardt	  et	  al	  characterized	  another	  intrahepatic	  CD49a+CD56brightT-­‐bet+Eomes−	  NK	  subset	  that	   is	  positive	   for	  KIRs	  (>80%,	  oligoclonal	  pattern)	  and	  NKG2C	  but	  negative	  for	  CD16	  and	  CD57.	  CD49a+	  NK	  cells	  express	  granzymes	  but	  only	   low	   levels	   of	   perforin	   and	   compared	   to	   CD49-­‐	   cells	   have	   lower	  degranulation	   capacity	   but	   are	   more	   potent	   cytokine	   producers.	   Interestingly,	  they	  were	  able	  to	  maintain	  their	  phenotype	  in	  long-­‐term	  culture	  (3	  weeks	  with	  IL-­‐15	  or	  NKG2C),	  suggesting	  CD49a+	  NK	  cells	  represent	  a	  stable	  subset,	  distinct	  from	   cNK	   cells.	   Of	   note,	   the	   subset	   represented	   on	   average	   2.3%	  of	   total	   CD3-­‐CD56+	   lymphocytes	   and	   was	   present	   in	   12	   out	   29	   livers	   examined	   (virtually	  absent	   in	   fetal	   livers),	   suggesting	   environmental,	   infectious	   or	   genetic	   factors	  might	   be	   driving	   the	   accumulation	   of	   this	   population	   (Marquardt	   et	   al.,	   2015).	  Overall,	   tissue-­‐resident	  NK	   cells	   seem	   to	   have	   distinct	   properties	   compared	   to	  cNK	  cells	  but	  also	  differ	  from	  their	  mouse	  NK/ILC1	  counterparts.	  Fuchs	  et	  al	  identified	  a	  CD103+	  ILC	  population	  within	  tonsil	  that	  has	  NK-­‐associated	   features,	   i.e.	   expression	   of	   CD94,	   T-­‐bet,	   Eomes,	   and	  NKp44	   (>75%).	  These	  cells	  were	  denoted	  as	  intraepithelial	  (ie)	  ILC1s,	  even	  though	  they	  have	  bi-­‐modal	   expression	   of	   perforin	   and	   granzymes	   and	   show	   cytolytic	   activity	   (in	  comparison	  to	  ILC3s	  but	  not	  reported	  for	  cNKs).	  Interestingly,	  they	  bear	  markers	  of	  exposure	  to	  TGFβ,	  which	  can	  maintain	  CD103	  expression	  on	  cultured	  cells	  (9	  days	  with	  IL-­‐15).	  In	  contrast,	  only	  few	  blood	  NK	  cells	  up-­‐regulated	  CD103	  under	  the	   same	   conditions	   or	   with	   addition	   of	   supernatant	   from	   intestinal	   epithelial	  cell	   lines.	   These	   observations	   prompted	   the	   notion	   that	   ieILC1	   and	   cNK	   cells	  might	   have	   alternative	   developmental	   pathway	   (Fuchs	   et	   al.,	   2013).	  Nevertheless,	   in	   an	   unbiased	   manner,	   using	   t-­‐Distributed	   Stochastic	   Neighbor	  Embedding	   (t-­‐SNE)	   analysis,	   Simoni	   et	   al	   showed	   that	   ieILC1s	   cluster	  with	  NK	  cells,	   indicating	  a	  close	  similarity	  between	  the	  two.	  ieILC1s	  are	  also	  positive	  for	  other	  tissue-­‐related	  markers	  such	  as	  CD49a,	  CD69,	  CXCR6	  (at	  steady	  state)	  and	  CD160,	  the	  latter	  shown	  to	  interact	  with	  herpes	  virus	  entry	  mediator	  (HVEM)	  on	  epithelia	   to	   promote	   host	   defense	   (Simoni	   et	   al.,	   2017).	   ieILC1s	   have	   been	  detected	  within	   the	  mucosal	   epithelium	   (only	  weakly	   in	   LP)	   in	   small	   intestine	  and	  colon	  (Fuchs	  et	  al.,	  2013),	  where	  their	  NKp44	  expression	  is	  lower	  compared	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to	  tonsil	  and	   is	  highly	  variable	  across	   individuals,	  demonstrating	  that	  NKp44	  is	  neither	   sufficient	   nor	   required	   to	   define	   this	   subset	   (Simoni	   et	   al.,	   2017).	  Therefore,	  ieILC1	  bear	  striking	  similarities	  to	  NK	  cells.	  	  
c. NK	  cell	  activation	  	  	  The	   dynamic	   balance	   of	   incorporated	   activating	   and	   inhibitory	   signals	  regulates	   cell	   activation.	   NK	   cells	   however	   respond	   not	   only	   to	   cell	   surface-­‐bound	   ligands	   but	   also	   other	   alert	   molecules	   such	   as	   Toll-­‐like	   receptor	   (TLR)	  ligands	  and	  strongly	  to	  cytokines	  such	  as	  type	  I	  interferons	  (IFN),	  interleukin‑12	  (IL‑12),	   IL‑15	  and	  IL‑18	  (Vivier	  et	  al.,	  2008).	  CD56brightCD16-­‐	  NK	  cells,	  especially	  from	  SLTs,	  are	  more	  responsive	  to	  DC	  stimulation	  than	  CD16+	  NK	  cells.	  They	  do	  so	  by	  IFNγ	  production	  and	  proliferation,	  whereas	  the	  former	  is	  induced	  by	  IL-­‐12,	  the	   latter	   is	   triggered	   by	   IL-­‐15	   (Ferlazzo	   et	   al.,	   2004).	   Combination	   of	   those	  cytokines	  has	  a	  synergistic	  effect	  with	  respect	  to	  IFNγ	  production	  and	  this	  is	  true	  also	  for	  CD103+ILC1s.	  IL-­‐12	  and	  IL-­‐18	  also	  show	  synergistic	  effect	  in	  NK	  cells	  but	  not	   in	  CD103+ILC1s	   (Fuchs	  et	   al.,	   2013).	  Thus,	   similar	   cytokines	   elicit	   cytokine	  production	  of	  NK	  cells	  and	  ILC1s.	  	  
2. Helper	  (h)	  ILC1s	  cells	  	  hILC1s	  are	  defined	  as	  CD127(IL-­‐7Rα)+T-­‐bet+(RORγt-­‐	   for	   	  mice)	  cells	   that	  produce	   high	   amounts	   of	   IFNγ	   in	   response	   to	   IL-­‐12	   and	   IL-­‐18	   and	   are	  distinguished	   from	   NK	   cells	   by	   their	   lack	   of	   Eomes	   expression	   and	   cytotoxic	  abilities	  (Bernink	  et	  al.,	  2013).	  	  The	  concept	  of	  an	   IFNγ-­‐producing	   ILC	  population	  distinct	   from	  NK	  cells	  originated	  from	  mouse	  studies,	  which	  showed	  that	  (1)	  CD127+	  ILCs	  development	  is	   completely	   abrogated	   in	   the	  absence	  of	  GATA3	  which	   is	  not	   the	   case	   for	  NK	  cells	  (Yagi	  et	  al.,	  2014)	  and	  (2)	  hepatic	  or	   intestinal	  Eomes-­‐NKp46+NK1.1+	  cells	  do	   not	   convert	   into	   Eomes+	   cells	   (Daussy	   et	   al.,	   2014;	   Klose	   et	   al.,	   2014).	   It	   is	  noteworthy	  that	  the	  latter	  was	  shown	  under	  physiologic	  conditions	  and	  not	  for	  spleen-­‐derived	   cells,	   which	   is	   important	   because	   isolated	   cells	   have	   skewed	  tropism	   and	   the	   tissue-­‐specific	   environment	  modulates	   cell	   phenotype.	   In	   line	  
	   	   Introduction	  
	   25	  
with	   this,	   lineage-­‐tracing	   studies	   have	   demonstrated	   that	   even	   at	   steady	   state	  intestinal	  NKp46+	  ILC3s,	  recovered	  from	  recipient	  colon	  or	  spleen,	  up	  regulate	  T-­‐bet	  at	  the	  expense	  of	  RORγt	  and	  acquire	  the	  ability	  to	  produce	  IFNγ	  (Klose	  et	  al.,	  2013;	  Vonarbourg	  et	  al.,	  2010).	  These	  cells	  termed	  ex-­‐ILC3s	  represent	  a	  fraction	  of	   hILC1s,	  which	   are	   recognized	   as	   a	   separate	   lineage	   only	   through	   the	   use	   of	  
Rorc(gt)-­‐CreTg	   x	   Rosa26RYfp/+	   (RORγt-­‐fm)	   mice.	   The	   further	   generation	   of	   a	  double-­‐reporter	   strain	   with	   EomesGfp/+	   allowed	   transcriptome	   comparison	  between	   cNK	   cells	   and	   hILC1s,	   distinct	   from	   ILC3s.	   Intestinal	   cNK	   cells	   highly	  express	  Ly49,	  cytotoxic	  granule	  effectors	  such	  as	  Prf1	  and	  GzmK,	  and	  molecules	  required	   for	  homing	  to	  (Ccr7),	  entry	  (Sell,	  encoding	  CD62L)	  and	  egress	  (S1pr5)	  from	  lymphoid	  organs,	  indicating	  they	  recirculate,	  whereas	  hILC1s	  had	  a	  tissue-­‐resident	   phenotype	   (Cxcr6,	   Itga1,	   encoding	   CD49a)	   (Klose	   et	   al.,	   2014).	  Moreover,	   although	   originally	   described	   as	   non-­‐cytotoxic,	   hepatic	   hILC1s	   have	  higher	   expression	   of	   genes	   encoding	   GzmC	   and	   TRAIL,	   with	   the	   latter	  constitutively	  expressed	  on	  the	  protein	  level	  (Daussy	  et	  al.,	  2014).	  In	   humans,	   an	   IFNγ-­‐producing	   Lin-­‐CD127+CRTH2-­‐CD117-­‐NKp44-­‐	   subset	  has	   been	   described	   in	   tonsils	   that	   lacks	   CD94,	   CD56,	   perforin	   and	   GzmB	   but	  expressed	  T-­‐bet	   (bi-­‐modal	  population).	  After	   long-­‐term	  expansion	   (4-­‐6	  weeks)	  with	   feeders	  and	  IL-­‐2,	  hILC1	  cells	  maintained	  their	  phenotype.	  Furthermore,	   in	  accordance	  with	  high	  transcripts	  for	  IL12RB2,	  activation	  (4	  days)	  with	  IL-­‐12	  plus	  IL-­‐2	   and/or	   IL-­‐18	   triggered	   IFNγ	   secretion	   (Bernink	   et	   al.,	   2013).	   Strikingly,	  RNAseq	   analysis	   of	   tonsil	   ILCs	   revealed	   no	   differential	   expression	   of	  Tbx21	   or	  
IL12RB2	  in	  putative	  hILC1s,	  which	  however	  expressed	  transcripts	  encoding	  TCR	  variable	  regions	  and	  other	  T	  cell-­‐associated	  molecules	  such	  as	  CD3	  chains,	  CD4,	  and	  CD5.	  The	  authors	  argued	  that	  as	  cytoplasmic	  CD3	  is	  induced	  in	  NK	  cells	  upon	  Notch	   signaling,	   similar	   mechanisms	   might	   account	   for	   their	   hILC1	   findings	  (Bjorklund	   et	   al.,	   2016).	  However,	   TCR	   gene	   rearrangement	   analysis	   has	   to	   be	  performed	   to	  ensure	   there	   is	  no	  T	   cell	   contamination	  because	  upon	  activation,	  TCR-­‐CD3	  complexes	  are	  down	  regulated,	  bringing	  these	  T	  cells	  closer	  to	  the	  Lin-­‐	  gate.	  In	  RORγt-­‐fm	  mice,	  Burkhard	  et	  al	  detected	  CD5	  expression	  in	  the	  ILC3	  gate	  after	  exclusion	  of	  CD3	  and	  TCRβ,	  which	  was	  absent	  when	  mice	  were	  crossed	  to	  
RAG1-­‐/-­‐	   mice,	   indicating	   these	   are	   T	   cells.	   CD5	   is	   up	   regulated	   upon	   TCR	  engagement,	   thus	   its	   addition	   to	   the	   lineage	   is	   recommended	   to	   avoid	   T	   cell	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contamination.	   (Burkhard	   et	   al.,	   2014)	   Indeed,	   Vely	   et	   al	   showed	   that	   most	  putative	  hILC1s	  express	  CD5	  (Vély	  et	  al.,	  2016a).	  Moreover,	  mass	  cytometry	  with	  t-­‐SNE	  analysis	  revealed	  no	  cluster	  corresponding	  to	  hILC1s	  and	  when	  tonsil	  Lin-­‐CD94-­‐CD127+CRTH2-­‐CD117-­‐NKp44-­‐	  cells	  were	  back	  gated,	  they	  fell	  into	  mostly	  T	  cell	   but	   also	   DC,	   ILC3	   and	   HPC	   clusters.	   Thus,	   human	   CD127+	   hILC1s	   remain	  controversial	  (Simoni	  et	  al.,	  2017).	  	  
B. Group	  2	  ILCs	  	  ILC2s	   are	   GATA-­‐3+	   cells	   that	   express	   CD127,	   CD117	   (tyrosine-­‐protein	  kinase	   Kit	   (c-­‐Kit)),	   and	   CD294	   (prostaglandin	   D2	   receptor	   2	   (CRTH2)).	   They	  produce	  in	  response	  to	  helminth	  infection	  or	  activation	  by	  IL-­‐25,	  IL-­‐33	  and	  TSLP,	  Th2	   cell	   signature	   cytokines	   such	   as	   IL-­‐5	   and	   IL-­‐13	   that	   drive	   eosinophilic	  inflammation	   as	   well	   as	   amphiregulin,	   important	   for	   tissue	   repair	   (Hazenberg	  and	  Spits,	  2014).	  	  
C. Group	  3	  ILCs	  	  ILC3s	  rely	  on	  RORγt	  for	  their	  development	  and	  function	  and	  are	  defined	  as	   CD127+CD117+CD294-­‐.	   In	   addition,	   they	   express	   IL-­‐23R	   and	   IL-­‐1R	   and	   in	  response	   to	   a	   combination	   of	   the	   respective	   cytokines	   mainly	   secrete	   IL-­‐22,	  which	  promotes	  epithelial	  tissue	  integrity,	  but	  also	  GM-­‐CSF	  and	  IL-­‐2.	  	  They	  also	  produce	  a	  number	  of	  TNF	  family	  members	  such	  as	   lymphotoxin	  (LT)	  α1β2	  and	  TNF	  that	  mediates	  lymphoid	  tissue	  formation.	  In	  addition,	  fetal	  LTi	  cells	  but	  not	  adult	  ILC3s	  produce	  the	  inflammation-­‐related	  cytokine	  IL-­‐17	  (Killig	  et	  al.,	  2014).	  	  ILC3s	  are	  subdivided	  according	  to	  NCR	  expression,	  specifically	  NKp44	  in	  humans	  and	  NKp46	  in	  mice.	  Unlike	  human,	  under	  physiologic	  conditions	  murine	  NKp46+	   ILC3s	   can	   produce	   not	   only	   IL-­‐22	   but	   also	   IFNγ	   and	   require	   T-­‐bet	   for	  their	   differentiation.	   Furthermore,	   whereas	   the	   chemokine	   receptor	   CCR6	   is	  uniformly	  expressed	  by	  human	  ILC3s	  (Killig	  et	  al.,	  2014),	  it	  dissects	  their	  mouse	  counterparts	   into	  CCR6+	   cells	   to	  which	   IL-­‐17	  expression	   is	   confined	  and	  CCR6-­‐	  cells,	  which	  gradually	  acquire	  T-­‐bet	  and	  consequently	  NKp46	  at	   the	  expense	  of	  IL-­‐22	  and	  LT	  expression	  (Klose	  et	  al.,	  2013).	  In	  humans,	  IL-­‐22	  secretion	  is	  largely	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restricted	  to	  the	  NKp44+	  subset	  (Hoorweg	  et	  al.,	  2012).	  Interestingly,	  triggering	  of	  NKp44	   rather	   induces	  TNF	   and	   IL-­‐2	   production	   and	  pro-­‐inflammatory	   gene	  pattern	   expression.	   Cytokine	   and	   NKp44	   engagement	   have	   a	   synergistic	   effect	  (Glatzer	  et	  al.,	  2013).	  Mass	   cytometry	   profiling	   of	   tonsil	   ILC3s	   revealed	   a	   high	   degree	   of	  heterogeneity	  in	  this	  subset	  and	  while	  NKp44	  clearly	  divided	  them,	  expression	  of	  other	  NCRs	  was	  scattered	  within	  the	  cluster.	  CD56	  showed	  a	  gradient	  expression	  that	   neither	   overlapped	   with	   NKp44	   or	   any	   other	   examined	   marker	   nor	   was	  mutually	  exclusive	  (Simoni	  et	  al.,	  2017).	  	  Finally,	   ILC3s	   are	   enriched	   in	   tonsils,	   adenoids	   and	   the	   intestine	   and	  uniformly	  express	  CD69,	  but	  not	  CD49a,	  CD103	  or	  CCR7	  (Simoni	  et	  al.,	  2017).	  	  
V. Role	  of	  ILC1s	  and	  ILC3s	  at	  steady	  state	  and	  disease	  
	  
A. Role	  of	  NK	  cells	  	  In	   patients	   and	   mouse	   models,	   NK	   cell	   immunodeficiencies	   that	   affect	  their	  numbers	  or	  function	  have	  been	  associated	  with	  high	  susceptibility	  to	  virus	  infections,	  especially	  by	  herpes	  viruses,	  as	  well	  as	  increased	  incidence	  of	  cancer.	  This	  indicates	  their	  importance	  in	  virus	  control	  and	  tumor	  immunosurveillance	  (Morvan	  and	  Lanier,	  2016;	  Orange,	  2006;	  Vivier	  et	  al.,	  2008).	  Truly	  NK-­‐specific	  deficiencies	  are	  rare	  but	  such	  patients	  manifest	  with	  Epstein–Barr	  virus	  (EBV)-­‐associated	  malignancies	   (Eidenschenk	  et	  al.,	  2006;	  Gineau	  et	  al.,	  2012;	  Shaw	  et	  al.,	   2012).	   NK	   cells	   have	   also	   been	   shown	   to	   mediate	   a	   graft-­‐versus-­‐leukemia	  (GvL)	   effect	   in	   patients	   receiving	   haplo-­‐identical	   hematopoietic	   (stem)	   cell	  (HSCT)	   transplantation,	  where	  KIR-­‐HLA	   interactions	  are	  mismatched	  (Vivier	  et	  al.,	   2016).	   Furthermore,	   an	   11-­‐year	   follow-­‐up	   study	   correlated	   high	   NK	   cell	  cytotoxic	  activity	  with	   reduced	  cancer	   risk	   (Vivier	  et	  al.,	  2008).	  Malignant	   cells	  might	   down-­‐regulate	   MHC	   class	   I	   or	   up-­‐regulate	   ligands	   for	   activating	   NK	  receptors	  which	  changes	   the	  balance	  of	   incorporated	  signals	  and	  renders	   them	  susceptible	   for	   lysis.	   For	   example,	   Klrk1	   (encoding	   NKG2D)-­‐deficient	   mice	  develop	  spontaneous	  tumors	  and	  there	  have	  been	  several	  reports	  of	  tumors	  that	  shed	  NKG2D	  ligands	  as	  decoys	  (Morvan	  and	  Lanier,	  2016).	   In	  vivo	  NK	  cell	  anti-­‐
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tumor	   activity	   has	   been	   demonstrated	   by	   targeting	   this	   subset	   with	   depleting	  antibodies.	   Notably,	   both	   NK1.1	   and	   asialo-­‐GM1	   are	   also	   expressed	   on	   T	   cell	  subsets	   and	   therefore	   interpretation	   has	   to	   be	   cautious	   (Vivier	   et	   al.,	   2008).	  Likewise,	  many	  NK	  deficiencies,	  characterized	  primarily	  by	  herpes	  virus-­‐related	  complications,	   also	   include	   absence	   of	   NKT	   cells	   (Orange,	   2006).	   Nonetheless,	  they	  seem	  to	  result	  from	  abnormal	  innate	  recognition	  such	  as	  through	  2B4	  and	  subsequently	   SAP,	   and	   patients	   with	   SAP	   mutations	   present	   with	   severe	   EBV	  infection	  (Fischer,	  2007;	  Parolini	  et	  al.,	  2000).	  NK	  cells	  have	  been	  demonstrated	  
in	   vivo	   to	   exert	   control	   over	   lytic	   EBV	   infection	   (Chijioke	   et	   al.,	   2013)	   during	  which	   ligands	   for	   NKG2D	   and	   DNAM-­‐1	   are	   elevated	   (Pappworth	   et	   al.,	   2007).	  Unlike	  EBV	  (Landtwing	  et	  al.,	  2016),	  CMV	  infection	  skews	  the	  total	  NK	  repertoire	  and	   drives	   clonal-­‐like	   expansion	   of	   memory-­‐like	   NKG2C+	   cells,	   implicating	   NK	  cells	   in	   CMV	   control	   (Béziat	   et	   al.,	   2012;	   Foley	   et	   al.,	   2012;	   Hendricks	   et	   al.,	  2014).	  Of	  note,	  CMV	  reactivation	  is	  also	  associated	  with	  reduced	  risk	  of	  leukemia	  relapse	   after	   allogeneic	   H(S)CT	   (Vivier	   et	   al.,	   2016).	   Hence,	   NK	   cells	   play	  important	  role	   in	  the	  immune	  control	  of	  viral	   infections,	  especially	  with	  herpes	  viruses,	  and	  cancer.	  Importantly,	  SCID	  patients	  with	  IL2RG	  or	   JAK3	  mutations,	  remained	  ILC-­‐deficient	   after	   non-­‐myeloablative	   HSCT.	   Neither	   circulating	   nor	   tissue-­‐infiltrating	   (CD3-­‐NKp46+	   in	   intestinal	   and	   skin	   tissue	   sections)	   ILCs	   were	  detected	  without	   complete	   donor	   chimerism.	   Strikingly,	   these	   patients	   did	   not	  show	   an	   apparent	   increased	   susceptibility	   to	   infection	   or	   tumor	   development	  long	   after	   reconstitution	   (7-­‐39	   years),	   which	   shows	   the	   redundancy	   of	   ILC	  function	   when	   T	   cells	   are	   present	   (Vély	   et	   al.,	   2016a).	   Of	   note,	   in	   mice	   an	  emergency	  NK-­‐cell	   lymphopoiesis	   from	  NKPs	   into	  NK1.1loNK46lo	   occurs	   under	  inflammatory	   conditions,	   induced	   by	   IL-­‐12	   (Ohs	   et	   al.,	   2016).	   Thus,	   one	   can	  envision	  a	  similar	  situation	  in	  humans.	  	  
B. Role	  of	  hILC1s	  	  hILC1s	  seem	  to	  have	  dual	  roles	   in	   infectious	  and	   inflammatory	  diseases.	  In	  mice	  during	  infection	  with	  the	  intracellular	  parasite	  Toxoplasma	  gondii	  hILC1s	  represent	  the	  majority	  of	  IFNγ-­‐	  and	  TNF-­‐producing	  ILCs	  and	  are	  able	  to	  attract	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inflammatory	  monocytes	   and	   control	   the	   parasite	   replication	   upon	   transfer	   in	  
Rag2-­‐/-­‐Il2rg-­‐/-­‐	  mice	   (Klose	   et	   al.,	   2014).	   Similarly,	   in	  Salmonella	   infection	   hILC1	  are	   the	   main	   innate	   source	   of	   IFNγ,	   however	   this	   has	   negative	   impact	   on	   the	  disease	  as	  depletion	  of	   ILCs	  (α-­‐Thy-­‐1	  Ab)	   improves	  clinical	  signs	  of	  colitis,	  also	  observed	   in	   Ifngr1–/–mice	  (Klose	  et	  al.,	  2013).	  Moreover,	  α-­‐CD40	  stimulation	   in	  
Rag-­‐/-­‐	  mice	  induces	  colitis,	  which	  is	  mediated	  by	  IFNγ+	  hILC1	  (including	  ex-­‐ILC3	  and	   ieILC1s)	   (Fuchs	   et	   al.,	   2013;	   Vonarbourg	   et	   al.,	   2010)	   as	  well	   as	   GM-­‐CSF+	  ILC3s	   (Pearson	   et	   al.,	   2016).	   Unfortunately,	   most	   studies	   with	   focus	   on	   ILCs	  either	   disregard	   the	   adaptive	   compartment	   or	   use	   Rag-­‐/-­‐	   mice;	   therefore,	   the	  relevance	   of	   these	   findings	   for	   protective	   immune	   responses	   in	   immune	  competent	  hosts	  remains	  unclear.	  	  In	  humans,	  putative	  hILC1s	  have	  been	   implicated	   in	   the	  pathogenesis	  of	  inflammatory	  conditions	  such	  as	   inflammatory	  bowel	  disease	  (IBD).	  Bernink	  et	  al	  reported	  an	  increase	  in	  the	  frequency	  of	  hILC1s	  at	  the	  cost	  of	  other	  ILCs	  in	  CD	  intestine	   (Bernink	   et	   al.,	   2013;	   2015).	   Patients	   with	   chronic	   obstructive	  pulmonary	  disease	  (COPD)	  have	  also	  significantly	  increased	  hILC1s	  at	  the	  cost	  of	  ILC2s	   that	   correlate	   with	   diminished	   lung	   function,	   disease	   severity	   and	  susceptibility	  to	  exacerbations.	  Moreover,	  inflammatory	  triggers	  associated	  with	  exacerbation	  of	  COPD	  such	  as	  respiratory	  tract	  infection	  with	  virus	  (influenza	  A),	  trigger	  loss	  of	  ILC2	  with	  a	  concomitant	  increase	  in	  hILC1s	  (Silver	  et	  al.,	  2016).	  	  Simoni	   et	   al	   found	   ieILC1	   to	   constitute	   a	  major	   fraction	   of	   the	   non-­‐cNK	  ILCs	   in	   pathological	   omentum	   adipose	   tissues	   (omentum	   AT)	   from	   obese	  patients,	  lung	  tumors,	  and	  colorectal	  tumors,	  where	  these	  cells	  show	  low	  NKp44	  expression	   and	   express	   low	   levels	   of	   cytotoxic	   granule	   effectors	   (Simoni	   et	   al.,	  2017).	   Fuchs	   et	   al	   also	   demonstrated	   higher	   frequency	   of	   ieILC1s	   within	  intraepithelial	   lymphocytes	   in	   Crohn’s	   disease	   (CD)	   compared	   to	   non-­‐IBD	  controls	   (Fuchs	   et	   al.,	   2013).	   However,	   both	   studies	   did	   not	   correlate	   these	  populations	  with	  disease	  severity	  and	  their	  role	  remains	  unclear.	  	  
C. Role	  of	  ILC3s	  	  In	  the	  mouse	  fetus,	  LTi	  cells	  are	  essential	  to	  initiate	  secondary	  lymphoid	  organ	   development.	   Through	   LTβ	   or	   TNF	   receptor	   triggering	   they	   induce	   the	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expression	  of	  adhesion	  molecules	  and	  chemokines	  such	  as	  vascular	  cell	  adhesion	  molecule-­‐1	  (VCAM-­‐1),	  intercellular	  adhesion	  molecule	  1	  (ICAM-­‐1)	  and	  CXCL13	  in	  stromal	  cells,	  thus	  recruiting	  other	  lymphocytes	  (Killig	  et	  al.,	  2014).	  In	  humans,	  peripheral	  LNs	  are	  present	  already	  at	  gestational	  week	  6,	  mesenteric	  LNs	   from	  about	  week	  14	  and	  subsequently	  the	  first	  signs	  of	  PPs	  are	  detected.	  Accordingly,	  
RORC-­‐expressing	   Lin-­‐CD45intCD127hi	   cells	   with	   LTi	   characteristics	   were	  described	   in	   first-­‐trimester	   mesentery	   and	   second-­‐trimester	   LNs,	   which	   in	  contrast	  to	  murine	  LTi	  cells	  lacked	  CD4	  expression	  (Cupedo	  et	  al.,	  2008).	  NKp44+	  ILC3	  were	   then	   found	   to	   colonize	   fetal	   intestine	  during	   late	   first	   trimester	   and	  later	  represent	  the	  majority	  of	  ILC3s	  there	  (Bernink	  et	  al.,	  2015;	  Hoorweg	  et	  al.,	  2012),	  indicating	  differentiation	  independent	  of	  microflora.	  	  Apart	   from	   lymphoid	   tissue	   formation,	   ILC3s	   play	   a	   role	   in	   the	  maintenance	   of	   epithelial	   tissue	   integrity	   and	   function.	   The	   IL-­‐22	   receptor	   is	  exclusively	   expressed	   on	   epithelial	   cells	   and	   its	   stimulation	   promotes	  proliferation	   and	   regeneration	   as	  well	   as	   production	   of	   antimicrobial	   peptides	  such	  as	  β	  defensins,	  mucus-­‐associated	  molecules	  and	  IL-­‐10.	  In	  mice,	  ILC3s	  play	  a	  role	   in	   intestinal	  homeostasis	  by	   restricting	   the	   commensal-­‐specific	  T	   cell	  pool	  through	  MHC	   class	   II	   presentation	   or	   by	   containing	   commensal	   dissemination.	  They	   also	   protect	   against	   pathogens	   such	   as	   Citrobacter	   rodentium,	   a	   murine	  analog	  for	  enteropathogenic	  and	  enterohemorrhagic	  Escherichia	  coli	  (Killig	  et	  al.,	  2014).	  Notably,	  most	  studies	  examined	  their	   function	   in	   the	  context	  of	  T	  and	  B	  cell	  deficiency,	  thus	  their	  importance	  when	  adaptive	  immunity	  is	  present	  has	  not	  been	   extensively	   investigated.	   For	   example,	   in	   the	   C.	   rodentium	   model	   their	  absence	  in	  T	  cell-­‐sufficient	  mice	  has	  little	  impact	  on	  control	  of	  infection	  (Song	  et	  al.,	  2015).	  Moreover,	  patients	  that	  exhibit	  a	  selective	  ILC	  deficiency	  are	  not	  more	  susceptible	  to	  disease	  (Vély	  et	  al.,	  2016a).	  	  Importantly,	   one	   of	   the	   initial	   descriptions	   of	   ILC3s	   was	   in	   a	   bacteria-­‐driven	  innate	  colitis	  model.	  In	  this	  study,	  Rag-­‐/-­‐Rorc-­‐/-­‐	  mice	  developed	  only	  mild	  intestinal	   inflammation,	   which	   demonstrated	   a	   role	   in	   driving	   pathology	  (Buonocore	  et	  al.,	  2010).	  Reinforcing	  this	  data,	  neutralization	  of	  IL-­‐17,	  GM-­‐CSF	  or	  IFNγ,	   produced	   by	   CCR6+,	   CCR6-­‐NKp46-­‐	   ILC3	   and	   ILC1	   cells,	   respectively,	  ameliorated	  pathology,	  whereas	  blockade	  of	   IL-­‐22	  had	  no	  effect	   (Buonocore	  et	  al.,	  2010;	  Pearson	  et	  al.,	  2016).	  One	  of	  the	  main	  ILC3	  activators,	  IL-­‐23,	  has	  been	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associated	  with	   autoimmune	   and	   chronic	   inflammatory	   disorders	   such	   as	   IBD	  and	   psoriasis.	   In	   IBD,	   intestinal	   CD3-­‐	   cells	   show	   increased	   transcripts	   for	   IL22	  and	  IL17A/F.	  Moreover,	  CD127+CD56-­‐	  ILCs	  accumulate	  in	  the	  intestines	  of	  CD	  but	  not	   ulcerative	   colitis	   patients	   and	   are	   the	   main	   (if	   not	   only)	   source	   of	   IL-­‐17	  (Geremia	   et	   al.,	   2011).	   Surprisingly,	   in	   a	   clinical	   trial	   treatment	   of	   CD	   patients	  with	  α-­‐IL-­‐17A	  Ab	  worsened	  the	  disease.	  Both	  cytokines	  are	  also	  involved	  in	  the	  pathogenesis	   of	   psoriasis	   and	   NCR+	   ILC3	   cells	   are	   increased	   in	   affected	   skin,	  suggesting	  they	  might	  contribute	  to	  the	  pathology	  {PhD:2016ip}.	  	  ILC3s	  have	  been	   found	  also	   in	  colorectal	  and	   lung	  tumors	  (Simoni	  et	  al.,	  2017).	   In	   colorectal	   cancer	   (CRC),	   IL-­‐22	   expression	   is	   significantly	   higher	   in	  tumor	   tissue	   compared	   to	   adjacent	   healthy	   sections.	   The	   majority	   of	   IL-­‐22-­‐producing	  cells	  are	  T	  cells,	  but	  a	  fraction	  is	  within	  the	  Lin-­‐	  gate.	  In	  a	  mouse	  model	  of	  colitis-­‐associated	  CRC,	  ILC	  depletion	  as	  well	  as	  blocking	  of	  IL-­‐22	  ameliorated	  the	  disease	  (Hazenberg	  and	  Spits,	  2014).	  In	  non-­‐small	  cell	  lung	  cancer	  (NSCLC),	  NCR+	   ILC3s	   accumulate	   at	   the	   edge	   of	   tumor-­‐associated	   tertiary	   lymphoid	  structures	   (TLSs),	   which	   are	   predictive	   of	   favorable	   prognosis.	   In	   co-­‐culture	  experiments	   with	   NSCLC	   cell	   lines	   expressing	   NCR	   ligands,	   tumor-­‐infiltrating	  NCR+	   ILC3s	   (both	   ex	   vivo	   and	   expanded)	   produced	   TNF	   and	   IL-­‐8,	   which	  were	  reduced	   in	   the	   presence	   of	   α-­‐NKp44	   Ab	   (only	   weakly	   affected	   by	   blocking	   of	  NKp30).	   Moreover,	   they	   induced	   adhesion	   molecule	   expression	   on	   human	  endothelial	   cells,	   but	   did	   not	  modify	   their	  migration,	   suggesting	   no	   angiogenic	  effects	  (Carrega	  et	  al.,	  2015).	  In	  mice,	  IL-­‐12-­‐driven	  suppression	  of	  B16	  melanoma	  is	   mediated	   by	   NKp46+	   ILC3s,	   but	   the	   exact	   mechanism	   remains	   enigmatic.	  Transferred	   NKp46+RORγt-­‐fm+CD3-­‐	   cells	   could	   suppress	   tumor	   growth,	   but	   so	  does	   injection	   of	   αNK1.1	   Ab,	   which	   depletes	   ILC1	   but	   not	   NKp46+	   ILC3	  (NK1.1dim).	   Curiously,	   tumors	   are	   still	   repressed	   in	  mice	   deficient	   in	   IL-­‐22,	   IL-­‐17A,	  IFNγ	  or	  its	  receptor,	  perforin	  and	  LTβR	  (Eisenring	  et	  al.,	  2010).	  Thus,	  ILC3s	  seem	  to	  restrict	  or	  support	  tumors	  dependent	  on	  the	  type	  of	  malignancy.	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VI. Plasticity	  of	  hILCs	  
	  
A. In	  mice	  	  ILC	   identity	   is	   highly	   modulated	   by	   the	   microenvironment.	   The	  abundance	  of	  ILC3s	  in	  the	  intestine	  has	  prompted	  investigation	  into	  the	  effect	  of	  the	  microbiota	  on	  this	  subset.	  It	  has	  been	  demonstrated	  that	  its	  eradication	  leads	  to	   RORγt	   down-­‐regulation	   in	   NKp46+	   ILC3s,	   although	   their	   numbers	   remain	  unchanged	   (Vonarbourg	   et	   al.,	   2010).	   Moreover,	   signals	   from	   the	   microbiota	  were	  shown	  to	  regulate	  T-­‐bet	  expression	  in	  intestinal	  ILC3s,	  which	  is	  reflected	  in	  the	  selective	  reduction	  of	  the	  T-­‐bet+	  subset	  in	  germ-­‐free	  mice	  or	  mice	  deficient	  in	  TLR	   signaling.	   Similar	   effects	   were	   observed	   in	   absence	   of	   IL-­‐23	   (Klose	   et	   al.,	  2013).	  Spleen,	  colon	  and	  peripheral	  LNs	  have	  been	  shown	  to	  be	  permissive	   for	  RORγt	   loss	   in	   the	   NKp46+	   ILC3	   subset,	   demonstrated	   both	   through	   adoptive	  transfer	   experiments	   of	   RORγt-­‐reporter	   positive	   ILC3s	   and	   via	   lineage	   tracing	  studies	   employing	   Rorc(gt)-­‐CreTg	   x	   Rosa26RYfp/+	   (RORγt-­‐fate	   map	   (fm))	   mice	  (Klose	  et	  al.,	  2013;	  Vonarbourg	  et	  al.,	  2010).	  These	  NKp46+RORγt-­‐	  cells,	  termed	  ex-­‐ILC3s,	   express	   T-­‐bet	   but	   not	   Eomes	   and	   are	   unaffected	   in	   Eomes-­‐deficient	  mice	   (Klose	   et	   al.,	   2014).	   Therefore,	   tissue	   microenvironment	   has	   a	   profound	  impact	   on	   murine	   ILC3	   profile,	   which	   might	   display	   an	   ILC1	   phenotype	   even	  under	  homeostatic	  conditions.	  	  
B. In	  humans	  	  ILC2	  cells	  are	  activated	  by	  IL-­‐25,	  IL-­‐33	  and	  thymic	  stromal	  lymphopoietin	  (TSLP),	   produced	   by	   epithelial	   cells.	   Interestingly,	   circulating	   ILC2s	   have	   low	  transcripts	   for	  the	  corresponding	  receptors	  with	  no	  surface	  expression	  and	  are	  thus	  naïve	  in	  their	  effector	  functions	  (Lim	  et	  al.,	  2016;	  Ohne	  et	  al.,	  2016).	  	  Upon	  culture	  (5-­‐7	  d)	  with	  IL-­‐2,	  (-­‐7,	  -­‐25)	  and	  IL-­‐33,	  ILC2s	  quickly	  adopt	  their	  signature	  profile;	  this	  however	  is	  not	  stable	  and	  can	  be	  modified	  by	  addition	  of	  PBMCs	  as	  feeders	   or	   IL-­‐12.	   Already	   a	   short-­‐term	   stimulation	   (>	   48	   h)	   increases	   IL12RB1	  and	   IL12RB2	   expression	   and	   cultures	   from	  patients	  with	   biallelic	  mutations	   in	  the	   former	   fail	   to	   generate	   plastic	   ILC2s.	   IL-­‐12	   up-­‐regulates	   T-­‐bet	   and,	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consequently,	   augments	   IFNγ	   expression,	   which	   is	   mostly	   detected	   in	   IL-­‐13-­‐producing	  cells	  (Lim	  et	  al.,	  2016;	  Silver	  et	  al.,	  2016).	  	  As	  ILC2	  cells	  express	  IL-­‐1R1,	  IL-­‐1β	  stimulation	  has	  also	  been	  investigated.	  In	   short-­‐term	   cultures	   (6-­‐7	   d),	   IL-­‐1β	   in	   combination	   with	   IL-­‐2	   induces	  proliferation	  and	  cytokine	  production	  similar	  or	  even	  greater	  to	  that	  elicited	  by	  IL-­‐33	   (Bal	   et	   al.,	   2016;	   Ohne	   et	   al.,	   2016).	   Of	   note,	   neither	   leads	   to	   expansion	  without	   IL-­‐2,	  which	   by	   itself	   promotes	   only	   survival.	  Moreover,	   transcriptome	  analysis	  revealed	  that,	  relative	  to	  freshly	  isolated	  ILC2s,	  IL-­‐1β-­‐primed	  cells	  have	  increased	  expression	  of	  IL1RL1	  and	  IL17RB,	  thus	  improving	  their	  responsiveness	  to	  IL-­‐33,	  which	  also	  explains	  the	  observed	  synergistic	  effect	  of	  the	  two	  cytokines.	  Strikingly,	   IL-­‐1β	  boosts	  also	   transcription	  of	   ILC1-­‐related	  genes	  such	  as	  TBX21,	  
EOMES,	   IL12RB1	   and	   IL12RB2	   and	   in	   combination	   with	   IL-­‐12	   shifts	   their	  program	   to	   ILC1s	   (Bal	   et	   al.,	   2016;	  Ohne	  et	   al.,	   2016).	   	  Hence,	   human	   ILCs	   are	  also	   strongly	   influenced	   by	   the	   microenvironment,	   with	   IL-­‐12	   exposure	   able	  switch	  ILC2	  functionality	  towards	  IFNγ	  production.	  Tonsil	  stage	  3	  cells,	  defined	  as	  Lin-­‐CD117+CD94-­‐,	  comprise	  ILC3s	  and	  NK	  precursors.	  More	   than	  70%	  of	   those	  are	  IL-­‐1R1hi	   and	   IL22	   as	  well	   as	  AHR	  (but	  not	  RORC)	  expression	  is	  confined	  to	  this	  subset.	  As	  stage	  3	  cells	  give	  rise	  to	  NK	  cells	  under	  IL-­‐15	  containing	  conditions,	  Hughes	  et	  al	   investigated	  the	  impact	  of	  IL-­‐1β	  addition	  on	  NK	  cell	  differentiation.	  Whereas	  this	  selectively	  expanded	  the	  IL-­‐1R1hi	   subset,	   it	   significantly	   diminished	   progression	   to	   mature	   NK	   cells	  (Hughes	   et	   al.,	   2010).	  Moreover,	   the	   addition	   of	   IL-­‐1β	   in	   combination	  with	   an	  AHR	   agonist	   promoted	   the	   ILC3	   phenotype.	   In	   contrast,	   AHR	   pharmacological	  blockade	   or	   gene	   silencing	   induced	   NK	   cell	   maturation	   (Hughes	   et	   al.,	   2014).	  Thus,	   ILC3	  profile	   is	  maintained	   in	   the	  presence	  of	   IL-­‐1β,	  whereas	   IL-­‐15	   alone	  drives	  NK	  cell	  differentiation.	  Although	   in	  vitro	  only	  about	  20%	  of	  stage	  3	  cells	  acquire	   CD94,	   in	   vivo	   IL-­‐15	   treatment	   generates	   only	   NK	   cells	   (Freud	   et	   al.,	  2016).	   The	   drawback	   of	   these	   studies	   is	   however	   not	   refining	   the	   sort	   to	  delineate	  which	   population(s)	   within	   the	   Lin-­‐CD117+	   cells	   can	   give	   rise	   to	   NK	  cells.	  Even	  though	  the	  phenotype	  and	  function	  of	  stage	  3	  cells	  overlap	  with	  that	  of	  ILC3s	  and	  they	  might	  comprise	  the	  same	  cell	  type,	  it	   is	  possible	  that	  a	  minor	  NK	  precursor	  fraction	  within	  the	  former	  population	  exists.	  Crellin	  et	  al	  identified	  a	   small	   CD127-­‐	   population	   within	   tonsil	   Lin-­‐CD161+CD117+	   cells	   that	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preferentially	  generates	  NK	  cells,	   concluding	   that	  CD127	  delineates	   ILC3s	   from	  NK	   precursors	   (Crellin	   et	   al.,	   2010).	   However,	   CD94	   was	   not	   included	   in	   the	  lineage	   mix	   and	   others	   have	   demonstrated	   that	   tonsil	   NK	   cells	   are	   mostly	  positive	  for	  CD161	  and	  some	  show	  low	  levels	  of	  CD117	  expression	  (Freud	  et	  al.,	  2006;	  2016;	  Simoni	  et	  al.,	  2017),	  therefore	  it	  is	  likely	  that	  the	  starting	  population	  already	   contained	   NK	   cells.	   In	   the	   same	   study,	   LTi-­‐like	   cells	   (sorted	   as	   Lin-­‐CD127+CD56-­‐)	   were	   cultured	   in	   the	   presence	   of	   feeders	   plus	   IL-­‐2	   and	   despite	  maintaining	  some	  IL-­‐22	  and	  TNFα	  production	  as	  well	  as	  high	  RORC	  expression,	  they	   deviated	   towards	   IFNγ	   production,	   expressed	   low	   levels	   of	   perforin	   and	  GzmB	   and	   showed	  moderate	   cytolytic	   activity.	   This	  might	   either	   be	   attributed	  again	  to	  CD94+	  cells	  present	  in	  the	  sorted	  population,	  although	  the	  data	  suggests	  no	   rapidly	   dividing	   contaminating	   CD56+	   cells,	   or	   indeed	   acquisition	   of	   a	  cytotoxic	   program,	   previously	   associated	   solely	  with	  NK	   cells	   (CD94	   or	   Eomes	  expression	   was	   not	   checked).	   LTi-­‐like	   clones	   gave	   similar	   results	   but,	   despite	  comparable	   levels	   of	   cytotoxic	   proteins	   to	   bulk	   cultures,	   displayed	   no	   target	  killing	   (shown	   for	   3	   out	   of	   20	   clones)	   (Crellin	   et	   al.,	   2010).	   Also	   tonsil	   ILC3s,	  sorted	  as	  Lin-­‐CD56+NKp44+CCR6+CD103−	  cells,	  exposed	  to	  IL-­‐2	  exhibit	  increased	  IFNγ	   production	   and	   responsiveness	   to	   IL-­‐12	   as	   well	   as	   CD94	   up-­‐regulation	  (Cella	  and	  Colonna,	  2010).	  	  Using	   more	   strict	   purification	   procedures	   (Lin(including	   CD94)-­‐CD127+CD117+),	   Bernink	   et	   al	   reported	   that	   ILC3s	   derived	   from	   fetal	   gut	   or	  tonsil	  tissues	  partly	  lose	  their	  expression	  of	  CD117	  (and	  NKp44)	  when	  cultured	  for	   8	   days	   with	   IL-­‐2	   and	   IL-­‐12,	   as	   opposed	   to	   IL-­‐2,	   IL-­‐23	   and	   IL-­‐1β,	   thus	  acquiring	   a	   group	   1	   ILC	   phenotype.	   Furthermore,	   tonsil	   NKp44+	   ILC3	   cultures	  had	   significantly	   lower	   RORC	   but	   higher	   TBX21	   and	   IFNG	   transcripts	   as	  compared	  to	  freshly	  isolated	  cells	  (Bernink	  et	  al.,	  2013).	  This	  was	  observed	  also	  on	  a	  protein	   level.	  Although	  cytolytic	  activity	  was	  not	  assessed,	  Eomes	  was	  not	  up-­‐regulated	  (Bernink	  et	  al.,	  2015),	  suggesting	  that	  either	  previous	  results	  were	  impacted	   by	   NK	   (precursor)	   contamination	   and	   ILC3s	   cannot	   convert	   to	   cNK	  cells	   or	   that	   IL-­‐12	   is	   not	   required	   for	   this	   differentiation,	   as	   demonstrated	   by	  Freud	  et	  al	  (Freud	  et	  al.,	  2016).	  Collectively,	   these	   data	   demonstrates	   that	   the	   cytokine	   milieu	   strongly	  modulates	   ILC3	  phenotype.	  They	  can	  divert	   to	  a	   type	  1	  effector	  program	  when	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exposed	   to	   IL-­‐2	   or	   in	   combination	   with	   IL-­‐12,	   but	   whether	   they	   can	   acquire	  cytotoxic	  properties	  is	  not	  entirely	  clear.	  	  
VII. Mice	   reconstituted	   with	   human	   immune	   system	   components	  
(humanized	  mice)	  	  The	   need	   for	   a	   small	   animal	   model	   better	   suited	   for	   translation	   of	  biomedical	  research	  into	  clinical	  applications	  has	  resulted	  in	  the	  development	  of	  humanized	  mice,	  defined	  here	  as	  immunodeficient	  mice	  repopulated	  with	  human	  hematopoietic	  cells	  and	  for	  some	  studies	  additionally	  transplanted	  with	  human	  tissues.	   They	   have	   become	   useful	   tools	   to	   study	   human	   immune	   system	  development	   and	   function,	   especially	   in	   a	   disease	   setting.	   	   For	   example,	   their	  importance	   in	  the	  research	  of	   the	  pathogenesis	  and	   immune	  control	  of	  human-­‐tropic	   viruses	   such	   as	   human	   immunodeficiency	   virus	   (HIV)	   and	   EBV	   is	  undeniable.	  Moreover,	  they	  emerge	  as	  valuable	  models	  for	  preclinical	  evaluation	  of	   vaccine	   candidates	   and	   therapeutics	   (Gujer	   et	   al.,	   2015;	   Theocharides	   et	   al.,	  2016;	  Poluektova	  et	  al.,	  2015).	  The	  discovery	  of	  mice	  with	  a	  Prkdcscid	  (scid)	  mutation	  led	  the	  development	  of	   suitable	   hosts	   for	   xenotransplantation.	   These	   lack	   T	   and	   B	   cells,	   but	   due	   to	  their	   leakiness	   and	   radiosensitivity,	   mice	   with	   targeted	   Rag2	   mutations	   were	  thus	   generated.	   Still,	   crossing	   the	   scid	   mutation	   onto	   the	   non-­‐obese	   diabetic	  (NOD)	  background	  further	  improved	  human	  cell	  engraftment.	  One	  of	  the	  reasons	  for	  that	  is	  the	  reduced	  phagocytosis	  by	  murine	  macrophages	  due	  to	  a	  sufficient	  interaction	  of	  the	  NOD	  signal	  regulatory	  protein	  α	  (SIRPα)	  with	  human	  CD47	  to	  trigger	  an	  inhibitory	  signal.	  The	  last	  constraint	  to	  avoid	  transplant	  rejection	  was	  NK-­‐cell	   activity,	   which	   was	   abrogated	   by	   incorporation	   of	   an	   IL-­‐2	   receptor	  common	  gamma	  chain	  (γc)	  (Il2rg)	  mutation.	  Of	  note,	   formation	  of	  SLTs	  such	  as	  LNs	   and	   PPs	   is	   compromised	   due	   to	   the	   common	   γc	   deficiency.	   The	   NOD-­‐scid	  
Il2rgnull	   (NSG)	   strain	   supports	   high	   human	   reconstitution	   after	   CD34+	   HPC	  injection	  and	  is	  our	  choice	  of	  recipient.	  In	  addition	  to	  lack	  of	  rejection,	  engrafted	  cells	  need	  a	  niche,	  which	  is	  usually	  achieved	  by	  sub-­‐lethal	  total	  body	  irradiation	  (Theocharides	  et	  al.,	  2016;	  Poluektova	  et	  al.,	  2015).	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Notably,	  humanized	  mice	  only	  partially	   recapitulate	   the	  human	   immune	  system	   development.	   Among	   other	   shortcomings,	   reconstitution	   of	   NK	   cells	   is	  low	   and	   incomplete	   (Poluektova	   et	   al.,	   2015).	   Although	   having	   a	   less	  differentiated	   phenotype,	   NK	   cells	   were	   demonstrated	   to	   achieve	   functional	  competence	  after	  in	  vitro	  stimulation	  with	  IL-­‐15	  or	  in	  vivo	  treatment	  with	  TLR3-­‐agonist	   polyinosinic:polycytidylic	   acid	   (polyIC)	   (Strowig	   et	   al.,	   2010).	   The	  suboptimal	  human	  cell	  differentiation	  and	  maintenance	  in	  part	  reflects	  the	  lack	  of	   cross-­‐reactivity	   or	   biological	   activity	   of	   mouse	   cytokines,	   chemokines,	   or	  survival	   factors.	  There	  are	  numerous	  efforts	   to	  overcome	   these	   limitations,	   for	  example	   administration	   or	   transgenic	   expression	   of	   human	   cytokines	  (Theocharides	   et	   al.,	   2016).	   Nonetheless,	   humanized	   mice	   reproduce	   many	  features	  of	  the	  human	  immune	  response.	  For	  example,	  HIV-­‐1-­‐driven	  reduction	  of	  ILC3s	  has	  been	  reported	  in	  humanized	  mice,	  which	  is	  reversed	  by	  antiretroviral	  therapy	   (ART).	   Depletion	   is	   mediated	   by	   pDC-­‐produced	   type	   I	   IFNs	   that	   up-­‐regulate	  CD95	  (Fas)	  on	  activated	  ILC3s	  (Zhang	  et	  al.,	  2015).	  This	  data	  was	  later	  confirmed	   for	   HIV-­‐1	   patients,	   where	   transcriptome	   analysis	   also	   revealed	   up-­‐regulation	  of	  genes	  associated	  with	  cell	  death	  (Kløverpris	  et	  al.,	  2016).	  	  Immune	  responses	  against	  EBV	  can	  also	  be	  modeled	   in	  vivo	  only	  in	  humanized	  mice,	   for	  which	  it	  was	  shown	  that	  NK	  cells	  exert	  control	  over	  lytic	  EBV	  infection	  and	  their	  depletion	   enhances	   features	   of	   the	   symptomatic	   infection,	   termed	   infectious	  mononucleosis	   (IM)	   (Chijioke	   et	   al.,	   2013).	   This	   was	   later	   corroborated	   by	   a	  longitudinal	  analysis	  of	  NK	  subsets	  in	  pediatric	  IM	  patients	  (Azzi	  et	  al.,	  2014).	  	  
VIII. EBV	  	  EBV	   is	   a	   human-­‐specific	   γ-­‐herpesvirus	   that	   is	   transmitted	   via	   saliva	  exchange	   and	   establishes	   a	   life-­‐long	   infection	   in	   more	   than	   90%	   of	   the	   adult	  population.	   It	   has	   tropism	   primarily	   for	   B	   lymphocytes	   but	   also	   resides	   in	  epithelial	   cells.	   Upon	   entry	   into	   B	   cells,	   it	   initiates	   a	   latency	   program	   (III)	   by	  expressing	   six	   Epstein-­‐Barr	   nuclear	   antigens	   (EBNAs),	   two	   latent	   membrane	  proteins	   (LMPs),	   two	   EBV	   encoded	   RNAs	   (EBERs)	   and	   about	   40	   microRNAs.	  These	   induce	   B	   cell	   proliferation,	   with	   a	   concurrent	   EBV	   replication,	   and	   a	  subsequent	   differentiation	   into	   resting	   memory	   B	   cells,	   in	   which	   the	   virus	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persists	   with	   a	   restricted	   gene	   expression.	   Occasionally	   and	   likely	   upon	   BCR	  activation,	  EBV	  enters	   the	   lytic	  cycle,	   induced	  by	  expression	  of	  BZLF1	  (ZEBRA)	  and	  BRLF1	  (Rta).	  This	  leads	  to	  production	  of	  infectious	  viral	  particles	  that	  infect	  epithelial	   cells	   and	   shed	   into	   the	   saliva,	   completing	   the	   life	   cycle	   (Gujer	   et	   al.,	  2015;	  Münz,	  2015a;	  2015b).	  EBV	   is	   usually	   acquired	   before	   the	   age	   of	   5	   years	   when	   infection	   is	  believed	   to	   occur	  mostly	   asymptomatically,	  whereas	   above	   70%	  of	   individuals	  develop	   IM,	   often	   when	   primary	   infection	   occurs	   later	   in	   life	   (Balfour	   et	   al.,	  2013).	  IM	  is	  characterized	  by	  high	  EBV	  titer	  and	  a	  massive	  expansion	  of	  cytotoxic	  CD8+	   T	   cells,	  which	   are	   essential	   for	   containment	   of	   the	   disease.	   Patients	  with	  loss	  of	  T	  cell	  immunosurveillance,	  for	  example	  in	  AIDS	  or	  after	  transplant,	  are	  at	  risk	   for	  developing	  EBV-­‐associated	  tumors.	  Such	  malignancies	   include	  Burkitt's	  and	  Hodgkin's	  lymphomas,	  nasopharyngeal	  carcinoma	  and	  EBV	  Post-­‐Transplant	  Lymphoproliferative	   Disease	   (EBV-­‐PTLD)	   (Gujer	   et	   al.,	   2015;	   Münz,	   2015a;	  2015b).	  NK	  cell-­‐mediated	  control	  has	  also	  been	  reported	  for	  IM,	  in	  particular	  of	  lytic	   EBV	   infection	   (Azzi	   et	   al.,	   2014;	   Chijioke	   et	   al.,	   2013).	   Moreover,	   as	  previously	   discussed,	   patients	  with	   NK	   deficiencies	   have	   high	   susceptibility	   to	  EBV	   and	   associated	   tumors	   (Eidenschenk	   et	   al.,	   2006;	   Gineau	   et	   al.,	   2012;	  Orange,	  2006;	  Parolini	  et	  al.,	  2000;	  Shaw	  et	  al.,	  2012).	  Thus,	  EBV	   is	  a	  powerful	  infectious	  model	  to	  study	  human	  NK	  responses.	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Aim	  of	  the	  study	  	  Human	  ILC2	  and	  ILC3	  cells	  possess	  functional	  plasticity	  and	  under	  IL-­‐12	  containing	   conditions	   convert	   into	   T-­‐bet-­‐	   and	   IFNγ-­‐expressing	   cells	   (Bal	   et	   al.,	  2016;	  Bernink	  et	  al.,	  2013;	  2015;	  Lim	  et	  al.,	  2016;	  Ohne	  et	  al.,	  2016;	  Silver	  et	  al.,	  2016).	  Since	   in	  mice	  ex-­‐ILC3s	  acquire	  a	  helper	  and	  not	  cytotoxic	   ILC1	  program	  (Klose	  et	  al.,	  2014),	  this	  possibility	  has	  not	  been	  conclusively	  explored	  in	  humans	  with	  some	  controversial	  reports.	  Even	  though	  initial	  studies	  of	  ILC3	  cells	  showed	  CD94+	  expression	  or	  some	  cytolytic	  activity	  in	  in	  vitro	  expanded	  cells	  (Cella	  and	  Colonna,	   2010;	   Crellin	   et	   al.,	   2010),	   these	   failed	   to	   exclude	   CD94	   during	  purification	   and	   thus	   failed	   to	   exclude	   classical	   NK	   cells.	   On	   the	   other	   hand,	  CD94-­‐CD117+	   cells,	   which	   include	   ILC3s	   (CD127+	   in	   addition),	   are	   sorted	   as	   a	  precursor	   population	   in	   NK	   developmental	   studies	   and	   give	   rise	   to	   NK	   cells	  under	  IL-­‐15-­‐containing	  conditions	  (Freud	  et	  al.,	  2006;	  2016).	  	  Thus,	   to	   explore	   in	   detail	   whether	   human	   ILC3s	   can	   acquire	   also	   a	  cytotoxic	  program,	  which	  might	  be	  potentially	  harnessed	  in	  the	  context	  of	  viral	  infection	   or	   cancer	   at	  mucosal	   sites,	  we	   purified	  NKp44+	   and	  NCR-­‐	   ILC3s	   from	  tonsils	   and	   humanized	   mouse	   tissues	   and	   analyzed	   their	   functionality	   under	  inflammatory	  conditions	  in	  vitro	  and	  in	  vivo.	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I. ILC3s	  in	  tonsils	  and	  humanized	  mouse	  tissues	  	  Human	   ILC3s	   at	   steady	   state	   are	   most	   abundant	   in	   mucosal	   tissues,	   in	  particular	  in	  tonsils	  and	  the	  intestine	  (Bernink	  et	  al.,	  2015;	  Simoni	  et	  al.,	  2017).	  For	  our	  studies,	  we	  used	  ILC3s	  from	  pediatric	  tonsils	  and	  in	  order	  to	  be	  able	  to	  later	  investigate	  the	  relevance	  of	  our	  in	  vitro	  findings	  in	  vivo,	  we	  compared	  them	  to	  ILC3s	  isolated	  from	  tissues	  of	  our	  in-­‐house	  humanized	  mouse	  model	  (huNSG),	  specifically	   spleen	  and	   small	   intestine.	  Prior	   to	   flow	  cytometric	   sorting	   (FACS),	  tonsil	   and	   spleen	   mononuclear	   cells	   were	   depleted	   of	   T	   cells,	   B	   cells	   and	  monocytes/macrophages,	   which	   were	   also	   removed	   by	   FACS.	   We	   further	  excluded	  human	  hematopoietic	  progenitor	  cells	  (HPCs),	  myeloid	  cells,	  CD16+	  NK	  cells	  as	  well	  as	  ILC2s	  (CD294+)	  and	  sorted	  ILC3s	  as	  viable	  human	  hematopoietic	  (CD45+)	   cells	   that	   express	   CD127	   and	   CD117.	   We	   purified	   NKp44+	   and	   NCR-­‐	  (defined	   as	   NKp44-­‐NKp46-­‐)	   ILC3	   subsets	   as	   well	   as	   NK	   cells	   to	   be	   used	   as	  controls	  (Figure	  1A).	  	  NK	   cells	   and	   ILC3s	   were	   similarly	   represented	   in	   human	   tonsils	   (24	   ±	  10%	  and	  18	  ±	  10%	  of	   ILCs	  of	   interest,	   respectively)	  and	  at	  even	   increased	  but	  equal	  proportions	  in	  huNSG	  small	  intestine	  (SI),	  in	  contrast,	  NK	  cells	  were	  2-­‐fold	  higher	   and	   on	   average	   represented	   54%	   of	   ILCs	   in	   huNSG	   spleen.	   These	   two	  populations	   together	   constituted	   three-­‐quarters	   of	   ILCs	   both	   in	   spleen	   and	   SI,	  however	   NKp44+	   ILC3s	   were	   a	  minor	   fraction	   of	   ILC3s	   in	   spleen,	   unlike	   in	   SI	  (Figure	   1B).	   Importantly,	   spleen	   and	   SI	   differed	   not	   only	   in	   ILC	   subset	  distribution,	   but	   also	   in	   frequency	   of	   ILCs	   among	   overall	   human	   CD45+	   cells	  (Figure	   1C).	  Whereas	   each	   ILC3	   subset	   represented	   6-­‐9%	  of	   CD45+	   cells	   in	   SI,	  their	   percentage	   in	   spleen	   was	   below	   0.2.	   This	   was	   similar	   to	   their	   yield,	  indicating	  the	  high	  level	  of	  human	  reconstitution	  in	  spleen	  and	  the	  efficiency	  of	  the	  sort.	  ILC3s	  recovered	  from	  tonsil	  were	  7-­‐fold	  less	  than	  in	  spleen,	  in	  line	  with	  a	  previous	  report	  (Magri	  et	  al.,	  2014).	  Surprisingly,	  NK	  cells	  had	  lower	  yield	  than	  expected	  (Figure	  1D).	  	  
	   	   Results	  
	   40	  
	  
Figure	  1	  ILC3	  cells	  in	  tonsils	  and	  humanized	  mouse	  tissues	  	  (A)	  Gating	   strategy	   for	   isolation	  of	   ILCs	  of	   interest,	   defined	  as	  viable	  CD45+	  	  Lin-­‐	   (CD3-­‐CD19-­‐CD14-­‐CD16-­‐FcεRIα-­‐CD34-­‐TCRα/β-­‐TCRγ/δ-­‐CD294-­‐)	   CD127+	   and/or	   NKp46+;	   NK	  cells	   (yellow)	   are	   further	   sorted	   as	   CD94+CD127-­‐,	   NKp44+	   ILC3s	   (red)	   as	   CD94-­‐CD127+CD117+NKp44+	   and	   NCR-­‐	   ILC3s	   (dark	   blue)	   are	   identified	   as	   CD94-­‐CD127+CD117+NKp44-­‐NKp46-­‐.	   Transcription	   factor	   staining	   of	   purified	   populations	   is	  shown	   in	   the	   Appendix	   Figure	   13.	   Gating	   shown	   for	   a	   representative	   spleen	   MACS-­‐depleted	  sample.	  (B)	  Mean	  frequency	  (±	  SD)	  of	  the	  indicated	  populations	  among	  ILCs	  of	  interest	  within	  pediatric	   tonsils	   (N=16);	   spleen	   (N=20,	  2-­‐15	  mice	  per	  HFL	  donor)	   and	  small	  intestine	  (SI)	  (N=9,	  4-­‐15	  mice	  per	  HFL	  donor)	  of	  huNSG	  mice.	  For	  samples	  details	  refer	  to	  Tables	  1	  and	  2.	  (C)	  Frequency	  of	  the	  indicated	  populations	  within	  spleen	  (N=3,	  1-­‐8	  mice	  per	  donor)	  and	  SI	   (as	  above)	   from	  human	  CD45+	  cells.	   (D)	  Yield	   from	  tonsils	  and	   spleen,	   calculated	   as	   percentage	   of	   sorted	   cells	   from	   total	   isolated	   mononuclear	  cells.	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Of	   note,	   NKp46	   expression	   on	   ILC3s	   was	   variable,	   which	   is	   consistent	  with	   published	   results	   (Simoni	   et	   al.,	   2017),	   and	   also	   significantly	   lower	   in	  comparison	  to	  that	  on	  NK	  cells	  (data	  not	  shown);	  therefore,	  this	  marker	  was	  not	  included	  in	  the	  subset	  distribution	  assessment	  (Figure	  1B).	  	  Thus,	   both	   NCR	   positive	   and	   negative	   ILC3s	   could	   be	   recovered	   from	  tonsils	  of	  children,	  spleen	  and	  small	  intestine	  of	  humanized	  mice.	  	  	  
II. ILC3s	  up-­‐regulate	  NK	  cell	  markers	  in	  response	  to	  IL-­‐12	  and/or	  IL-­‐15	  	  To	   investigate	   whether	   ILC3s	   can	   acquire	   NK	   properties	   under	  inflammatory	  conditions,	  we	  expanded	  tonsil	  NKp44+	  ILC3s	  with	  IL-­‐2	  and	  IL-­‐7	  to	  gain	  sufficient	  numbers	   for	   stimulation	  of	   re-­‐sorted	  CD117+CD94-­‐	   cells	  with	  all	  possible	  combinations	  of	  IL-­‐2,	  -­‐12,	  -­‐15,	  and	  -­‐18	  (Figure	  2A).	  	  After	  1	  week	  (data	  not	   shown)	   and	   2	   weeks,	   we	   observed	   acquisition	   of	   CD94,	   an	   NK-­‐associated	  marker,	  in	  all	  conditions.	  CD94+	  cells	  had	  down-­‐regulated	  expression	  of	  the	  ILC3	  master	   regulator	   RORγt	   when	   compared	   to	   CD117+CD94-­‐	   cells,	   which	   still	  constituted	  the	  majority	  of	  the	  culture	  (Figure	  2B).	  These	  results	  indicated	  that	  cells	   that	   acquired	   CD94	   shifted	   away	   from	   their	   ILC3	   profile.	   Moreover,	   we	  detected	  a	  slight	  increase	  in	  T-­‐bet	  levels,	  which	  was	  previously	  demonstrated	  for	  freshly	  isolated	  tonsil	  and	  intestinal	  ILC3s	  after	  combined	  stimulation	  with	  IL-­‐2	  and	   IL-­‐12	   for	   4	   days	   (Bernink	   et	   al.,	   2013;	   2015).	   IL-­‐12	   was	   described	   to	  promote	  T-­‐bet	  expression	  and	  IFNγ	  production	  also	  in	  human	  ILC2	  cells	  (Bal	  et	  al.,	  2016;	  Lim	  et	  al.,	  2016;	  Ohne	  et	  al.,	  2016;	  Silver	  et	  al.,	  2016)	  and	  consistent	  with	   this	   data,	   conditions	   containing	   IL-­‐12	   most	   efficiently	   induced	   CD94	  expression	  (Figure	  2C).	  Importantly,	  in	  contrast	  to	  these	  studies	  and	  mouse	  data	  (Klose	   et	   al.,	   2014),	   we	   found	   up-­‐regulation	   of	   Eomes,	   which	   is	   known	   to	   be	  expressed	  solely	  in	  cytotoxic	  lymphocytes.	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Figure	  2	  IL-­‐12	  induces	  expression	  of	  NK	  cell	  markers	  in	  IL-­‐2	  and	  IL-­‐7	  expanded	  
tonsil-­‐derived	  NKp44+	  ILC3s	  	  (A)	   Experimental	   outline.	   All	   possible	   combinations	   of	   the	   indicated	   cytokines	   (15	  conditions)	  and	  IL-­‐2	  and	  IL-­‐7	  culture	  as	  a	  reference	  population	  (B)	  Representative	  flow	  cytometric	  analysis	  of	  stimulated	  NKp44+	  ILC3s.	  (C)	  Percentage	  of	  CD94-­‐expressing	  cells	  among	  the	  different	  conditions,	  IL-­‐2	  and	  IL-­‐7	  control	  is	  shown	  in	  blue.	  Cells	  stimulated	  with	  IL-­‐12	  and	  -­‐18	  alone	  or	  in	  combination	  did	  not	  survive	  for	  2	  weeks.	  Data	  obtained	  from	  1	  donor.	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  paired	  t	  test.	  	   We	   next	   sought	   to	   confirm	   this	   plasticity	   with	   respect	   to	   NK-­‐specific	  marker	   expression	   by	   stimulating	   freshly	   isolated	   tonsil	   NKp44+	   ILC3s	   for	   2	  weeks	  under	  different	  conditions.	  	  Culture	  with	  IL-­‐7	  alone	  was	  previously	  shown	  to	   be	   sufficient	   only	   for	   survival	   of	   cells	   with	   ILC3	   characteristics	   (sorted	   as	  CD56+NKp44+CCR6+CD103-­‐)	   and	   the	   addition	   of	   IL-­‐2,	   which	   promoted	  proliferation,	   changed	   their	   profile,	   even	   though	   RORC	   expression	   was	  maintained	   (Cella	   and	   Colonna,	   2010).	   Indeed,	   unlike	   IL-­‐7	   alone,	   exposure	   to	  both	   IL-­‐2	   and	   IL-­‐7	   up-­‐regulated	   Eomes	   but	   not	   T-­‐bet	   (Figure	   3).	   Of	   note,	   this	  condition	  was	  used	  as	  a	  control	  culture	  in	  later	  experiments.	  IL-­‐12	  induced	  low	  T-­‐bet	  expression,	  which	  was	  not	  observed	   in	  any	  of	   the	  other	  conditions.	  More	  importantly,	   IL-­‐12	   promoted	   expression	   of	   both	   Eomes	   and	   CD94,	   but	   not	   as	  much	  as	  stimulation	  with	  IL-­‐15.	  A	  combination	  of	  both	  had	  a	  strong	  synergistic	  effect	   (Figure	   3).	   Therefore,	   we	   focused	   on	   this	   condition	   for	   further	   in	   vitro	  investigation,	  the	  experimental	  outline	  for	  which	  is	  shown	  in	  Figure	  4A.	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Figure	  3	  Plasticity	  of	  NKp44+	  ILC3s	  	  Tonsillar	  NKp44+	  ILC3s	  were	  cultured	  on	  irradiated	  feeders	  with	  the	  indicated	  cytokines	  for	  2	  weeks	  and	  expression	  of	  CD94	  as	  well	   as	   ILC3	  and	  NK	   transcription	   factors	  was	  determined	   by	   flow	   cytometry.	   The	   human	   NK	   cell	   line	   Nishi	   was	   used	   as	   a	   positive	  control.	  Data	  obtained	  from	  1	  donor.	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ILC3s	  cultured	   for	  3	  weeks	  (4	  weeks	   for	  SI)	  with	  IL-­‐2	  plus	   IL-­‐7	  or	   IL-­‐12	  plus	  IL-­‐15	  expanded	  similarly	  (Figure	  4B).	  	  	  
	  
Figure	  4	  IL-­‐12	  and	  IL-­‐15	  promote	  expression	  of	  phenotypic	  NK	  cell	  markers	  on	  
ILC3s	  	  (A)	  Experimental	  outline.	  (B)	  Fold	  expansion	  of	  NKp44+	  and	  NCR-­‐	  ILC3s	  from	  pediatric	  tonsils	  and	  spleen	  after	  3	  weeks	  and	  from	  SI	  after	  4	  weeks.	  	  (C)	  Flow	  cytometric	  analysis	  of	   tonsillar	   NKp44+	   ILC3s	   and	   NK	   cells	   expanded	   for	   3	  weeks,	   each	   column	   gated	   on	  viable	   ILCs.	   Numbers	   indicate	   percent	   cells	   in	   each	   quadrant	   or	   gate.	   (D-­‐F)	  Quantification	   of	   the	   indicated	   subsets	   in	   cultures	   of	   (D	   and	   E)	   NKp44+	   and	   (F)	   NCR-­‐	  ILC3s	   in	   the	   indicated	   tissues.	   For	   tonsil	   N=6	   and	   3	   in	   D	   and	   F,	   respectively,	   and	   the	  same	  donors	  are	  color-­‐coded.	  For	   spleen	  N=14	   (10	  HFL	  donors)	   in	  D	  and	  N=6	   (6	  HFL	  donors,	  3-­‐8	  mice	  each)	  in	  F.	  For	  SI	  (assessed	  after	  4	  weeks)	  N=3	  (3	  HFL	  donors,	  4-­‐5	  mice	  each)	  in	  E.	  Red	  lines	  show	  mean	  and	  box-­‐and-­‐whiskers	  plot	  extend	  min	  to	  max	  with	  grey	  line	  representing	  median	  value.	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  paired	  t	  test.	  (G)	  Eomes	  vs	  T-­‐bet	  expression	  in	  IL-­‐12	  plus	  IL-­‐15	  condition.	  Subsets	  were	  further	  analyzed	  for	  RORγt	  expression,	   (H)	  which	  was	  quantified	   for	   total	  Eomes+	  cells	   in	   the	   indicated	  populations	  for	  tonsil-­‐	  and	  spleen-­‐derived	  ILC3	  cultures.	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  unpaired	  t	  test	  (H)	  Single-­‐cell	  sorted	  ILC3s	  were	  cultured	  onto	  irradiated	  Cell	  Trace	  Violet-­‐stained	  feeders	  with	  IL-­‐2	  plus	  IL-­‐7	  or	  IL-­‐12	  plus	  IL-­‐15.	  Clonal	  cultures	  were	  analyzed	  by	  flow	  cytometry	  after	  21	  days.	  C,	  F	  and	  H	  Gating	  shown	  for	  tonsillar	  NKp44+	  ILC3s.	   	   IL-­‐15-­‐expanded	  bulk	  NK	  cells	  were	  used	  as	  a	  positive	  control.	  Figure	  continues	  on	  the	  next	  pages.	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  IL-­‐12	   and	   IL-­‐15	   significantly	   up-­‐regulated	   Eomes	   in	   NKp44+	   ILC3s	  compared	   to	   controls,	  with	  average	   frequency	  of	   about	  20%	   in	   tonsils	   and	  35-­‐40%	  in	  tissues	  derived	  from	  huNSG	  mice	  (Figure	  4C,	  D	  and	  E).	  However,	  only	  a	  minor	   fraction	  of	  Eomes+	  cells	  co-­‐expressed	  CD94	  and,	   thus,	  resembled	  mature	  NK	   cells.	   Curiously,	   in	   tonsil-­‐derived	   cultures	  we	  observed	  a	  CD94+	  population	  that	  was	  negative	  for	  both	  Eomes	  and	  T-­‐bet	  (not	  shown)	  and	  was	  as	  frequent	  as	  CD94+Eomes+	  cells	   in	  IL-­‐2	  and	  IL-­‐7	  conditions	  but	  lower	  in	  the	  IL-­‐12	  and	  IL-­‐15	  ones.	   T-­‐bet	  was	   detected	   only	   upon	   IL-­‐12	   and	   IL-­‐15	   stimulation	   and	  was	   also	  expressed	  without	  Eomes,	  as	  previously	  described	  for	  IL-­‐2	  and	  IL-­‐12	  stimulation	  of	   tonsillar	   ILC3s	   (Bernink	   et	   al.,	   2015).	   Eomes-­‐T-­‐bet+	   cells	   were	   found	   at	   a	  similar	   frequency	   to	   Eomes+T-­‐bet+	   ones,	   but	   the	   former	   were	   less	   abundant	  compared	  to	  the	  total	  Eomes-­‐expressing	  cells	  (Figure	  4D	  and	  E).	  	  These	   phenotypic	   changes	   however	   could	   not	   be	   recapitulated	   for	  tonsillar	  NCR-­‐	  ILC3s	  (Figure	  4F).	  Compared	  to	  their	  NKp44+	  counterparts,	  splenic	  NCR-­‐	  ILC3	  stimulated	  with	  IL-­‐12	  plus	  IL-­‐15	  had	  lower	  expansion	  of	  Eomes+	  cells,	  which	   nonetheless	   were	   significantly	   higher	   than	   in	   controls.	   Notably,	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Eomes+CD94+	  and	  Eomes+Tbet+	  (also	  Eomes-­‐Tbet+)	  cells	  were	  found	  at	  a	  similar	  frequency	  (calculation	  not	  shown)	  (Figure	  4F).	  Surprisingly,	  Eomes+	  cells,	  derived	  from	  IL-­‐12	  and	  IL-­‐15	  stimulated	  ILC3s,	  irrespective	  of	  T-­‐bet	  presence,	  had	  a	  bi-­‐modal	  expression	  of	  RORγt	  (Figure	  4G).	  This	   was	   in	   contrast	   to	   the	   2-­‐week	   cultures,	   at	   which	   time	   point	   this	  transcription	   factor	  was	  almost	  entirely	  down-­‐regulated	  (Figure	  3).	   In	   fact,	  40-­‐65%	  of	  Eomes-­‐expressing	  cells	  were	  positive	  for	  RORγt	  in	  tonsil-­‐derived	  cells.	  In	  spleen,	   this	   number	   reached	   80%	   on	   average	   for	   NKp44+	   cultures,	   whereas	  Eomes+RORγt+	  cells	  were	  slightly	  less	  frequent	  in	  NCR-­‐	  ones	  and	  comparable	  to	  tonsil	  (Figure	  4H).	  Therefore,	  a	  significant	  fraction	  of	  the	  Eomes-­‐expressing	  cells	  arising	  in	  the	  culture	  differed	  from	  classical	  NK	  cells	  in	  RORγt	  and	  only	  partial	  T-­‐bet	  expression.	  These	  differences	  suggested	  that	  the	  observed	  Eomes+	  cells	  were	  indeed	  derived	  from	  ILC3s	  and	  not	  a	  NK	  contamination	  from	  the	  sort.	  To	  further	  address	  this	  issue,	  we	  cultured	  single-­‐cell	  sorted	  tonsil	  NKp44+	  ILC3s	  onto	  Cell	  Trace	  Violet-­‐stained	  feeders.	  	  In	  line	  with	  data	  from	  bulk	  cultures,	  we	  found	  few	  wells	  with	  a	  mixture	  of	  cells	  that	  acquired	  expression	  of	  CD94	  and	  Eomes,	   but	   down-­‐regulated	   RORγt,	   and	   cells	   that	   retained	   their	   ILC3	  CD117+RORγt+	  phenotype	  (Figure	  4H).	  	  Collectively,	  IL-­‐12	  plus	  IL-­‐15	  stimulation	  led	  to	  up-­‐regulation	  of	  Eomes,	  T-­‐bet	  and	  to	  a	   lesser	  extent	  CD94,	  although	  differentiated	  cells	  only	  partially	   lost	  their	  ILC3	  phenotype.	  	  
III. Transcriptional	  profile	  of	  NKp44+	  ILC3s	  upon	  IL-­‐12	  and	  IL-­‐15	  culture	  
is	  reminiscent	  of	  early	  differentiated	  NK	  cells	  	  	  To	   investigate	   the	   extent	   in	   which	   culture	   conditions	   transcriptionally	  change	  ILC3s	  and	  how	  close	  exposure	  to	  IL-­‐12	  and	  -­‐15	  brings	  their	  profile	  to	  that	  of	   NK	   cells,	   we	   performed	   RNA	   sequencing	   (RNAseq)	   of	   the	   two	   investigated	  culture	  conditions	  (IL-­‐2	  plus	  IL-­‐7	  and	  IL-­‐12	  plus	  IL-­‐15)	  and	  included	  untreated	  cells	   as	   a	   reference	   population.	   We	   used	   NKp44+	   ILC3s	   as	   they	   exhibited	   a	  significant	   increase	   in	   Eomes	   expression	   upon	   IL-­‐12	   and	   IL-­‐15	   exposure	  compared	  to	  IL-­‐2	  and	  IL-­‐7	  treated	  cells	  and	  this	  was	  higher	  than	  in	  NCR-­‐	  cells.	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In	   a	   principal	   component	   analysis	   (PCA)	   of	   the	   RNAseq	   data,	   samples	  formed	   individual	   clusters	   dependent	   on	   their	   tissue	   origin	   and	   cytokine	  exposure	   with	   the	   exception	   of	   those	   cultured	   with	   IL-­‐12	   and	   IL-­‐15.	   These	  surprisingly	   co-­‐segregated,	   whereas	   the	   rest	   of	   tonsil	   and	   spleen	   samples	  separated	  along	  PC2	  (Figure	  5A).	  Hierarchical	  clustering	  of	  the	  samples	  showed	  closer	  relationship	  between	  treatments	  than	  across	  tissues	  and	  also	  that	  freshly	  isolated	  cells	  were	  more	  closely	  related	  to	  the	  cells	  stimulated	  with	  IL-­‐2	  and	  IL-­‐7	  (Figure	  5B).	  	  Freshly	   sorted	  NKp44+	   ILC3s	   expressed	   genes	   encoding	   IL-­‐1R1,	   IL-­‐23R,	  TRANCE,	  BAFF,	  APRIL	  (variable)	  and	  CCL20	  (Figure	  5C),	  which	  were	  reported	  to	  be	  selectively	  transcribed	  in	  ILC3s	  among	  innate	   lymphocytes	  (Bjorklund	  et	  al.,	  2016).	  IL17A	  expression	  was	  not	  detected,	  as	  previously	  reported	  for	  adult	  ILC3s	  (Hoorweg	   et	   al.,	   2012),	   whereas	   IL17F	   transcripts	  were	   present	   in	   only	   a	   few	  tonsil	   samples.	   Splenic	   ILC3s	   showed	   higher	   amount	   of	   LTA,	   LTB,	   and	   TNF	  transcripts	   relative	   to	   tonsillar	   cells.	   Instead	   abundant	   expression	   of	   IL22	   was	  found	   within	   tonsil-­‐	   but	   not	   spleen-­‐derived	   ILC3s.	   These	   findings	   were	  consistent	   with	   a	   study,	   which	   in	   addition	   demonstrated	   that	   upon	   cytokine	  stimulation	  both	  populations	  secreted	  IL-­‐22	  at	  a	  similar	  level	  (Magri	  et	  al.,	  2014).	  Furthermore,	  we	   observed	   variable	   expression	   of	   IL2	   and	  CSF2	   (encoding	  GM-­‐CSF),	   even	  without	   ex	  vivo	  stimulation.	   Low	  but	   homogenous	  RORC	   expression	  was	   found	   in	   spleen	   samples,	   whereas	   tonsil	   ones	   exhibited	   a	   more	   diverse	  pattern.	   They	   however	   expressed	   transcripts	   encoding	   other	   transcription	  factors	  associated	  with	  ILC3s	  such	  as	  TOX2	  and	  AHR	  as	  well	  as	  for	  some	  that	  are	  shared	  with	  other	  ILCs	  such	  as	  GATA3	  and	  RORA	  (	  Bjorklund	  et	  al.,	  2016)	  (Figure	  5C).	   Taken	   together,	   ILC3s	   isolated	   from	   huNSG	   spleens	  were	   similar	   to	   those	  derived	   from	   human	   tissues,	   demonstrating	   that	   this	  model	   can	   be	   a	   valuable	  tool	  to	  study	  human	  ILC	  development	  and	  functionality	  in	  vivo.	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Figure	  5	  Transcriptional	  profile	  of	  NKp44+	  ILC3s	  upon	  IL-­‐12	  and	  IL-­‐15	  culture	  is	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We	   next	   assessed	   changes	   in	   NKp44+	   ILC3	   transcriptome	   induced	   by	  treatment	  with	   IL-­‐2	  and	  IL-­‐7.	  Although	  KIT	  and	  RORC	  expression	  was	  retained,	  expanded	   cells	   down-­‐regulated	   IL7R,	   IL1R1,	   IL23R	   and	   IL22	   (for	   tonsils).	  Concurrently,	   they	   up-­‐regulated	   EOMES,	   TBX21	   (variable	   in	   tonsils),	   PRF1	  (perforin)	  and	  transcripts	  encoding	  granzymes,	  in	  particular	  GZMA	  in	  tonsils	  and	  
GZMK	   in	   spleen	   (Figure	   5C),	   indicating	   they	   shifted	   away	   from	   an	   ILC3	  transcriptional	  program.	  Upon	   IL-­‐12	   and	   IL-­‐15	   culture	   NKp44+	   ILC3s	   up-­‐regulated	   genes	   that	  encode	  NK-­‐related	  markers	   such	  as	  CD56,	  CD94,	  NKG2A,	  NKG2C,	  DNAM-­‐1	  and	  CD2.	   Surprisingly,	   transcripts	   for	   NKG2D	   were	   lower	   compared	   to	   the	   other	  conditions.	  FCGR3A	  (encoding	  CD16)	  expression	  was	  also	  increased,	  however	  it	  was	  diverse	  across	  samples	  and	  tissues	  and	  detected	  only	  in	  a	  few	  Eomes+	  cells	  on	   the	   protein	   level	   (Appendix,	   Figure	   14).	   KIR3DL3	   expression	   partially	  overlapped	  with	   that	  of	  FCGR3A	  in	  spleen	  and	   less	  so	   in	   tonsils,	  whereas	  other	  inhibitory	  KIRs	  had	  lower	  and	  more	  scattered	  expression	  pattern	  in	  spleen	  and	  were	  absent	   in	  tonsils.	  We	  found	  higher	  expression	  of	  KIR2DL4,	  which	  encodes	  an	  activating	  receptor	  for	  HLA-­‐G	  that	  induces	  a	  pro-­‐inflammatory	  rather	  than	  a	  cytotoxic	   response	   in	   NK	   cells	   upon	   triggering	   (Rajagopalan	   and	   Long,	   2012;	  Vély	  et	  al.,	  2016b).	  Overall,	  IL-­‐12	  and	  IL-­‐15	  stimulated	  ILC3	  seemed	  to	  acquire	  a	  profile	   reminiscent	   of	   early	   differentiated	   NK	   cells	   (Béziat	   et	   al.,	   2010;	  Björkström	  et	  al.,	  2010).	  Moreover,	   they	  showed	  enrichment	  of	  genes	  encoding	  IFNγ,	   MIP-­‐1α,	   MIP-­‐1β,	   and	   IL-­‐8	   (in	   spleen)	   as	   well	   as	   subunits	   of	   the	   IL-­‐2/12/15/18	   receptors,	   thus	   IL-­‐12	   and	   IL-­‐15	   primed	   ILC3s	   towards	   a	   type	   1	  inflammatory	   response.	  Of	  note,	   in	   line	  with	   the	  maintained	  RORγt	  expression,	  they	   also	   displayed	   transcripts	   for	  LTA	   and	  LTB.	   Interestingly,	   splenic	  NKp44+	  ILC3s	   showed	   some	   TNFSF10	   (TRAIL)	   expression	   without	   stimulation,	   which	  was	  not	   influenced	  by	  IL-­‐12	  and	  IL-­‐15	  and	  was	  even	  down-­‐regulated	  after	  IL-­‐2	  and	  IL-­‐7	  culture.	  Conversely,	  TNFSF10	  transcripts	  were	  elevated	  in	  tonsillar	  cells	  upon	  IL-­‐12	  and	  IL-­‐15	  stimulation.	  IL-­‐12	  and	  IL-­‐15	  increased	  EOMES,	  FASLG,	  and	  granzyme	  expression	  also	  compared	  to	  IL-­‐2	  and	  IL-­‐7	  treated	  cells,	  whereas	  PRF1	  levels	   were	   similar	   between	   the	   two	   culture	   conditions.	   (Figure	   5C).	   Hence,	  depending	  on	   the	  cytokine	  milieu	   ILC3s	  can	  acquire	  a	   cytotoxic	   transcriptional	  profile.	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This	  data	  supported	  our	  findings	  that	  ILC3s	  stimulated	  with	  IL-­‐12	  and	  IL-­‐15	  shared	  features	  with	  NK	  cells	  and	  we	  next	  analyzed	  their	  functionality.	  	  
IV. Stimulation	  with	  IL-­‐12	  and	  IL-­‐15	  induces	  a	  functional	  program	  of	  NK	  
cells	  in	  ILC3s	  	  
A. Acquisition	  of	  an	  ILC1	  cytokine	  profile	  upon	  IL-­‐12	  and	  IL-­‐15	  
stimulation	  	  	  	  The	   transcriptome	   analysis	   revealed	   a	   shift	   in	   NKp44+	   ILC3s	   cultured	  with	   IL-­‐12	   and	   IL-­‐15	   towards	   an	   ILC1/NK	   cytokine	   profile;	   therefore	   we	  assessed	   the	   IFNγ	   and	   TNFα	   expression	   in	   response	   to	   stimulation	   with	   a	  prototypic	   NK	   cell	   target,	   erythroleukemic	   K562	   cells,	   as	   well	   as	   with	   PMAi	  (Figure	   6A-­‐C).	   In	   IL-­‐12	   and	   IL-­‐15	   cultures,	   IFNγ	   expression	   was	   almost	  undetectable	   unless	   cells	   were	   exposed	   to	   PMAi,	   which	   suggested	   that	   signals	  triggered	   by	   K562	   cells	   were	   insufficient	   to	   induce	   a	   proper	   IFNγ	   production	  (Figure	  6B	  and	  C).	  IFNγ	  expression	  was	  completely	  absent	  in	  IL-­‐2	  and	  -­‐7	  treated	  cells	   even	   upon	   PMAi	   stimulation	   (Figure	   6B	   and	   C),	   which	   is	   in	   contrast	   to	  published	   data	   from	   tonsils	   (Cella	   and	   Colonna,	   2010).	   On	   the	   other	   hand,	  expanded	   cells	   were	   potent	   TNFα	   producers	   but	   that	   potential	   was	   reduced	  upon	  treatment	  with	  IL-­‐12	  and	  -­‐15.	  In	  this	  condition	  however	  K562	  cells	  evoked	  a	  better	  response	  and	  TNFα	   expression	  was	   found	   in	  both	  CD117+	  and	  CD117-­‐	  cells	  (Figure	  6A	  and	  C).	  We	  further	  tested	  expression	  of	  IL-­‐22,	  as	  another	  study	  reported	   its	   induction	   upon	   stimulation	   of	   spleen	   ILC3s	   even	   though	   mRNA	  levels	   were	   low	   (Magri	   et	   al.,	   2014).	   PMAi	   however	   did	   not	   drive	   IL-­‐22	  expression	  (Figure	  6D	  and	  E).	  	  Previous	  studies	  on	  tonsil	  ILC3s	  are	  inconclusive	  with	  respect	  to	  IL-­‐22	  induction	  by	  PMAi	  alone	  (Cella	  and	  Colonna,	  2010;	  Cella	  et	  al.,	  2008)	  but	  cytokines	  combinations	  including	  IL-­‐23	  or	  IL-­‐1	  were	  demonstrated	  to	   promote	   it	   (Glatzer	   et	   al.,	   2013;	   Magri	   et	   al.,	   2014).	   Therefore,	   PMAi	   alone	  might	  not	  be	  sufficient	  or	  spleen-­‐derived	  NKp44+	  ILC3s	  (under	  these	  conditions)	  do	  not	  produce	  IL-­‐22.	  Thus,	   also	   on	   the	   protein	   level,	   IL-­‐12	   and-­‐15	   induced	   a	   cytokine	  profile	  associated	  with	  NK	  cells.	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Figure	  6	  Acquisition	  of	  an	  ILC1	  cytokine	  profile	  in	  spleen-­‐derived	  NKp44+	  ILC3s	  
upon	  IL-­‐12	  and	  IL-­‐15	  stimulation	  	  (A)	   Flow	   cytometric	   analysis	   of	   spleen-­‐derived	   NKp44+	   ILC3	   after	   4-­‐week	   culture.	  Intracellular	  staining	  for	  IFNγ	  and	  TNFα	  and	  expression	  of	  TNFα	  in	  CD117+	  and	  CD117-­‐	  cells	  after	  K562	  target	  cell	  and	  PMAi	  stimulation	  for	  4	  hr.	  (B)	  Expression	  of	  the	  indicated	  cytokines	  in	  differentially	  stimulated	  IL-­‐12	  and	  IL-­‐15	  cultured	  cells.	  (C)	  Quantification	  of	  IFNγ	  and	  TNFα	  in	  the	  indicated	  conditions.	  N=6	  (3	  HFL	  donors,	  4	  mice	  each)	  (D)	  Flow	  cytometry	  and	   (E)	  quantification	  of	   IL-­‐22	  expression	  after	  PMAi	   stimulation	   for	  4	  hrs.	  N=5	   (2	   HFL	   donors,	   4	   mice	   each).	   Red	   lines	   show	   mean	   and	   box-­‐and-­‐whiskers	   plot	  extend	  min	  to	  max	  with	  grey	  line	  representing	  median	  value.	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  paired	  t	  test.	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B. Up-­‐regulation	  of	  cytotoxic	  molecules	  and	  degranulation	  in	  response	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Figure	  7	  Up-­‐regulation	  of	  cytotoxic	  machinery	  in	  spleen-­‐derived	  NKp44+	  ILC3s	  
upon	  IL-­‐12	  and	  IL-­‐15	  exposure	  and	  degranulation	  in	  response	  to	  classical	  NK	  cell	  
targets	  K562	  	  (A)	   Flow	   cytometric	   analysis	   and	   (B)	   quantification	   of	   total	   GzmB	   and	   perforin	   in	  spleen-­‐derived	  NKp44+	  ILC3	  4-­‐week	  cultures	  after	  stimulation	  with	  K562	  cells,	  PMAi	  or	  without	   treatment	   (4	  hr),	  GzmB	  versus	  CD117	  expression	   is	   shown	   for	  PMAi	   exposed	  cells.	   Expanded	   NK	   cells	   were	   used	   as	   a	   positive	   control.	   (C)	   CD117	   and	   Eomes	  expression	   4-­‐week	   cultures.	   Numbers	   indicate	   percent	   cells	   in	   each	   quadrant.	   (D)	  Differences	   in	   the	  subsets	  shown	   in	  (C)	  and	  degranulation	  upon	  K562	  co-­‐culture	   for	  4	  hr.	   Δ%CD107a	   refers	   to	   the	   difference	   in	   degranulation	   with	   and	   without	   K562	  stimulation.	  For	  quantifications	  N=6,	  obtained	  from	  3	  HFL	  donors	  (4	  mice	  each).	  Same	  samples	  used	  in	  (B),	  (D)	  and	  Figure	  6.	  Red	  lines	  show	  mean	  and	  box-­‐and-­‐whiskers	  plot	  extend	  min	  to	  max	  with	  grey	  line	  representing	  median	  value.	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  paired	  t	  test.	  Figure	  continues	  on	  the	  next	  page.	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C. Cytotoxicity	  of	  IL-­‐12	  and	  IL-­‐15	  cultured	  ILC3s	  towards	  classical	  NK	  
cell	  targets	  and	  correlation	  with	  NK-­‐related	  markers	  	  To	   further	   demonstrate	   cytolytic	   activity,	   we	   co-­‐incubated	   expanded	  ILC3s	  with	  K562	  cells	  and	  measured	  target-­‐cell	  death	  via	  lactate	  dehydrogenase	  (LDH)	   release	   from	   damaged	   cells	   or	   by	   flow	   cytometry	   of	   Cell	   Trace	   Violet	  (CTV)-­‐stained	   K562	   cells.	   Consistent	   with	   the	   degranulation	   results,	   by	   flow	  cytometry	  we	  detected	  low	  NKp44+	  ILC3	  mediated	  cell	  lysis	  in	  tonsil	  (one	  donor)	  and	  SI	   (three	  donors)	  with	  no	  difference	  between	   culture	   conditions	   (data	  not	  shown).	  As	  IL-­‐12	  and	  IL-­‐15	  treated	  cells	  expressed	  cytotoxic	  effectors	  (on	  both	  mRNA	  and	  protein	   levels),	  we	   set	   out	   to	   investigate	  whether	   longer	   co-­‐culture	  would	   increase	   the	   level	   of	   killing,	   also	   because	   they	   might	   employ	   other	  mechanisms,	  such	  as	  TRAIL-­‐induced	  cell	  death	  that	  requires	  longer	  time	  periods.	  After	  an	  18-­‐hour	  incubation,	  IL-­‐12	  and	  -­‐15	  cultures	  of	  tonsillar	  NKp44+	  but	  not	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NCR-­‐	  ILC3s	  had	  4-­‐fold	  higher	  cytotoxicity	  compared	  to	  the	  IL-­‐2	  and	  IL-­‐7	  control	  condition,	  which	  still	  did	  not	  reach	  that	  of	  cNK	  cells.	  It	  is	  noteworthy	  that	  CD94+	  cells	   were	   not	   separated	   for	   the	   co-­‐culture	   and	   thus	   the	   effectors	   are	   a	  heterogeneous	  population	  of	  ILCs.	  Although	  we	  observed	  the	  same	  trend	  in	  the	  flow	   cytometry	   assay,	   the	   cytotoxicity	  was	   higher	   at	   a	   lower	   effector	   to	   target	  ratio	   (E:T),	   which	   might	   be	   explained	   by	   differences	   in	   assay	   sensitivity.	   In	  contrast,	   splenic	   NKp44+	   ILC3s	   showed	   no	   difference	   between	   the	   culture	  conditions,	  whereas	  NCR-­‐	  ILC3s	  had	  a	  3-­‐fold	  increase	  in	  cytolytic	  activity,	  which	  was	   still	   lower	   than	   in	   cNK	   cells.	   This	   however	   was	   not	   reflected	   in	   the	   flow	  cytometry	  assay	  (Figure	  8A).	  	  Next,	  we	  measured	  the	  cytolytic	  activity	  of	  spleen	  NCR-­‐	  ILC3s	  following	  4	  and	  18	  hours	  of	  co-­‐culture	  at	  different	  E:T	  ratios	  (Figure	  8B).	  With	  an	  increasing	  E:T	  ratio,	  cytotoxicity	  improved	  for	  both	  conditions	  (calculation	  not	  shown).	  We	  indeed	  did	  not	  observe	  differences	  between	  conditions	  after	  4	  hours,	  but	  target-­‐cell	  lysis	  was	  increased	  after	  18	  hours	  co-­‐incubation	  at	  higher	  E:T	  ratios.	  Of	  note,	  one	  more	  donor	  for	  the	  10:1	  E:T	  ratio	  at	  the	  18-­‐hour	  time	  point	  was	  included	  in	  Figure	  8A	  (marked	  in	  green).	  Importantly,	  the	  differences	  between	  IL-­‐12	  and	  IL-­‐15	   expanded	   cells	   and	   cultured	   NK	   cells	   became	   smaller	   with	   increasing	   E:T	  ratios	  and	  were	  no	  more	  significantly	  different	  at	  the	  20:1	  ratio.	  NK	  cytotoxicity	  itself	  was	   enhanced	   by	   increase	   in	   effectors	   (in	   4-­‐	   but	   not	   18-­‐hour	   assay)	   but	  largely	  remained	  constant	  over	  time	  (Figure	  8B).	  We	  then	  sought	  to	  determine	  which	  subset	  is	  responsible	  for	  the	  increase	  in	  cytotoxicity.	  For	  tonsil	  NKp44+	  ILC3s,	  this	  correlated	  best	  with	  Eomes+CD94+	  cells	  and	  both	  Eomes	  and	  T-­‐bet	  expression.	  The	  less	  frequent	  Eomes-­‐T-­‐bet+	  cells	  also	  correlated	  with	  cytolytic	  activity	  (Figure	  8C).	  Similar	  results	  were	  observed	  for	   spleen	  NCR-­‐	   ILC3s	  with	  Eomes+T-­‐bet+	   cells	   showing	   the	  highest	   correlation	  (Figure	  8D).	  Collectively,	  our	  data	  demonstrated	  that	  ILC3s	  cultured	  with	  IL-­‐12	  and	   IL-­‐15	   not	   only	   up-­‐regulated	   markers	   associated	   with	   NK	   cells	   but	   also	  acquired	  a	  cytotoxic	  program,	  which	  might	  however	  rely	  more	  on	  other	  cytolytic	  mechanisms	  than	  the	  perforin/granzyme	  mediated	  lysis	  of	  classical	  NK	  cells.	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Figure	  8	  Cytotoxicity	  of	  IL-­‐12	  and	  IL-­‐15	  cultured	  ILC3s	  towards	  classical	  NK	  cell	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V. NKp44+	  ILC3s	  might	  differentiate	  into	  CD94-­‐expressing	  cells	  in	  vivo	  	  To	  determine	  whether	  our	   in	  vitro	   data	   can	  be	   recapitulated	   in	  vivo,	  we	  took	   advantage	   of	   the	   humanized	  mouse	   (huNSG)	  model.	   To	   that	   end,	   freshly	  sorted	   spleen	   ILC3s	  were	   labeled	  with	   a	   cell	   tracker	   dye	   and	   i.v.	   injected	   into	  autologous	  reconstituted	  recipient	  mice.	  Differentiation	  was	  analyzed	  at	  steady	  state	   and	   under	   inflammatory	   conditions	   such	   as	   EBV	   infection	   and	   poly-­‐ICLC	  treatment.	   In	   this	  EBV	   infection	  model,	  NK	   cells	   (defined	  as	  CD3-­‐NKp46+	   cells)	  peaked	   at	   4	  weeks	   post	   infection	   (Chijioke	   et	   al.,	   2013)	   and,	   consequently,	  we	  chose	  this	  time	  point	  for	  the	  adoptive	  transfer	  of	  ILC3s.	  In	  comparison	  to	  other	  adjuvants	   tested	   in	   huNSG	  mice,	   poly-­‐ICLC	  was	   described	   to	   elicit	   the	   highest	  serum	   levels	   of	   IL-­‐12,	   which	  was	   detected	   between	   8-­‐14	   hours	   after	   injection	  (Meixlsperger	   et	   al.,	   2013).	   Therefore,	   we	   transferred	   ILC3s	   14	   hours	   after	  treatment.	   HuNSG	   mice	   were	   euthanized	   4	   days	   after	   transfer,	   which	   was	  previously	   described	   to	   be	   enough	   for	   in	   vivo	   ILC1	   to	   ILC3	   differentiation	  (Bernink	  et	  al.,	  2015),	  and	  presence	  of	  Cell	  Trace	  Violet	   (CTV)+	  cells	   in	  various	  tissues	  was	   analyzed.	  Most	   cells	   homed	   back	   to	   the	   spleen	   (Figure	   9)	  with	   no	  CTV+	  cells	  present	  in	  blood,	  lung	  or	  LNs	  and	  only	  few	  detected	  in	  the	  liver	  (data	  not	   shown).	   Under	   homeostatic	   conditions,	   ILC3s	   remained	   unchanged.	   	   At	   4	  weeks	   post	   EBV	   infection,	   some	   NKp44+	   but	   not	   NCR-­‐	   ILC3s	   acquired	   CD94	  expression	   at	   a	   frequency	   similar	   to	   that	   found	   in	   vitro	   (refer	   to	   Figure	   4D),	  whereas	   in	   poly-­‐ICLC	   treated	   mice	   the	   number	   of	   cells	   was	   too	   low	   to	   draw	  reliable	  conclusions	  (Figure	  9).	  We	  injected	  ILC3s	  in	  1-­‐2	  recipient	  mice	  to	  be	  able	  to	  detect	  enough	  CTV+	  cells	  for	  analysis.	  Importantly,	  for	  each	  adoptive	  transfer	  experiment,	  9-­‐15	  highly	  reconstituted	  donor	  mice	  were	  pooled	   to	  purify	   ILC3s.	  Thus,	  it	  was	  not	  feasible	  to	  increase	  the	  number	  of	  injected	  cells	  and	  also	  to	  find	  a	  time	  point	  at	  which	  proliferation	  does	  not	  occur	  but	  acquisition	  of	  NK-­‐related	  markers	   is	   detected.	   Overall,	   our	   in	   vivo	   data	   was	   inconclusive,	   but	   we	   did	  observe	  a	  tendency	  towards	  conversion	  to	  an	  NK-­‐like	  phenotype.	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Figure	  9	  NKp44+	  ILC3s	  might	  differentiate	  into	  CD94-­‐expressing	  cells	  in	  vivo	  HuNSG	  mice	  were	  inoculated	  i.v.	  with	  untreated	  autologous	  CTV-­‐stained	  ILC3s	  at	  steady	  state,	  at	  4	  weeks	  post	  EBV	  infection	  (1	  x	  105	  RIU)	  or	  14	  hrs	  after	  polyICLC	  treatment	  (2	  shots,	  24	  hrs	  apart,	  cells	  injected	  after	  1st	  dose).	  Mice	  were	  euthanized	  4	  days	  later	  and	  different	   organs	   were	   analyzed	   for	   presence	   of	   cell	   tracker-­‐positive	   cells	   (top	   value	  indicates	   number	   of	   detected	   cells	   and	   bottom	   ones	   represent	   frequency	   from	   viable	  cells.	   Flow	   cytometry	   shown	   for	   spleen.	   One	   experiment	   per	   treatment.	   ILC3s	   were	  obtained	  from	  one	  HFL	  donor	  with	  9-­‐15	  	  pooled	  mice.	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VI. NKp44+	  ILC3s	  seem	  not	  to	  affect	  EBV	  disease	  progression	  in	  vivo	  	  The	   striking	   similarities	   between	   ILC3s	   cultured	   under	   inflammatory	  conditions	  and	  NK	  cells	  prompted	  us	  to	  study	  their	  role	  in	  a	  disease	  setting.	  As	  NK	   cells	   play	   an	   important	   role	   in	   the	   control	   of	   herpes	   viruses	   and	   were	  demonstrated	  to	  prevent	   lytic	  EBV	  infection	   in	  humanized	  mice	  (Chijioke	  et	  al.,	  2013),	  	  we	  again	  used	  the	  same	  infection	  model	  to	  analyze	  the	  in	  vivo	  potential	  of	  ILC3s	   to	   take	   over	   NK–associated	   functions.	   As	   NK	   depletion	   without	  concomitant	   loss	   of	   transferred	   cells	   was	   not	   feasible	   and	   in	   order	   to	   gain	  sufficient	  numbers	   to	  draw	  any	   conclusions,	  we	  expanded	   ILC3s	  with	   IL-­‐2	  and	  IL-­‐7	  for	  5	  weeks	  and	  purified	  CD117+CD94-­‐	  cells	  before	  transfer.	  Because	  some	  NKp44+	   ILC3s	   converted	   to	   CD94+	   cells	   when	   placed	   under	   EBV-­‐driven	  inflammatory	   conditions,	   we	   focused	   on	   this	   population	   in	   our	   further	  investigation.	   Concurrently	   with	   ILC3	   transfer	   (1	   x	   106/mouse),	   huNSG	   mice	  were	  infected	  with	  EBV.	  	  In	   our	   first	   autologous	   experiment,	   in	   comparison	   to	   the	   control	   EBV	  group,	  animals	  that	  received	  expanded	  ILC3s	  showed	  no	  weight	  loss,	  associated	  with	  EBV	  disease	  progression,	  a	  tendency	  for	  lower	  EBV	  titers	  and	  lower	  tumor	  burden	   but	   no	   change	   in	   absolute	   numbers,	   determined	   at	   time	   of	   sacrifice	  (Figure	  10A).	  To	  investigate	  whether	  cells	  are	  still	  present	  5	  weeks	  post	  infection	  and	   to	   analyze	   their	   phenotype,	   we	   applied	   two	   strategies	   –	   transfer	   of	   ILC3s	  purified	   from	   HLA-­‐A2	   positive	   reconstitutions	   into	   humanized	   mice	  reconstituted	   from	  HLA-­‐A2	   negative	   donors	   (Figure	   9B)	   or	   of	   GFP-­‐transduced	  autologous	   ILC3s	   (11.6%	   GFP+)	   (Figure	   9C).	   In	   neither	   case	   we	   found	   the	  transferred	  cells	  when	  mice	  were	  euthanized	  (across	  different	  organs,	  data	  not	  shown),	   indicating	   they	  did	  not	   survive	   in	   that	  environment	   for	   this	  prolonged	  time	   period.	   Moreover,	   we	   could	   not	   recapitulate	   the	   results	   from	   the	   initial	  experiment,	   although	   not	   repeated	   with	   the	   exact	   same	   settings,	   suggesting	  (expanded)	  NKp44+	  ILC3s	  do	  not	  play	  a	   role	   in	  EBV	  disease	  progression	  under	  the	  conditions	  tested.	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Figure	  10	  NKp44+	  ILC3s	  seem	  not	  to	  affect	  EBV	  disease	  progression	  in	  vivo	  	  HuNSG	  mice	  were	  injected	  i.v.	  with	  IL-­‐2	  and	  IL-­‐7	  expanded	  (A)	  autologous	  (B)	  allogeneic	  or	  (C)	  GFP-­‐transduced	  autologous	  NKp44+	  ILC3s	  (11.6%	  GFP+).	  Cells	  were	  sorted	  from	  5	  mice,	   cultured	   for	   5	   weeks	   and	   re-­‐sorted	   for	   viable	   CD117+CD94-­‐	   cells	   before	  inoculation.	  1	  x	  106	  ILC3s	  were	  injected	  per	  mouse	  into	  1-­‐4	  mice	  per	  PBS	  group	  and	  3-­‐5	  per	  EBV	  group.	  EBV	  (1	  x	  105	  RIU)	  was	  injected	  i.p.	  at	  the	  same	  time	  point	  as	  ILC3s.	  Far-­‐left,	  weight	  changes	  in	  the	  course	  of	  a	  40-­‐42-­‐day	  EBV	  experiment.	  Left,	  EBV	  copies	  per	  spleen.	  Right,	  Tumor	  burden.	  Far	  right,	  Absolute	  numbers	  of	  the	   indicated	  populations	  in	  spleens.	  	  ns	  P	  >	  0.05,	  *	  P	  <	  0.05,	  **	  P	  <	  0.01	  using	  Mann-­‐Whitney	  test.	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Discussion	  
	   Although	  still	  under	  debate	  (Montaldo	  et	  al.,	  2014),	  previous	  studies	  have	  demonstrated	  NK	  cell	  development	  from	  a	  RORγt+	  progenitor	  in	  humans	  (Freud	  et	  al.,	  2016;	  Scoville	  et	  al.,	  2016).	  Whether	  ILC3s	  can	  be	  a	  direct	  precursor	  of	  NK	  cells	  however	  has	  not	  been	  established	  as	  differentiation	  towards	  NK	  cells	  could	  be	   attributed	   to	   a	   distinct	  NK	  precursor	  within	   the	   few	  CD127-­‐	   among	   stage	  3	  cells.	  	   In	   this	   study,	   we	   demonstrated	   that	   ILC3s	   from	   lymphoid	   and	   non-­‐lymphoid	   tissues	   can	   adopt	   NK-­‐related	   features	   and	   that	   this	   transition	   is	  enhanced	  by	  exposure	  to	  IL-­‐12.	  In	  such	  inflammatory	  settings,	  ILC3s	  gave	  rise	  to	  NK	  cells,	  defined	  as	  Eomes+CD94+,	  but	  also	  CD94-­‐	  cells	  with	  mutually	  exclusive	  expression	  of	  Eomes	   and	  T-­‐bet.	  Together	  with	   the	   emergence	  of	   cells	  with	   the	  unconventional	  Eomes+RORγt+	  phenotype,	  found	  in	  stage	  4a	  immature	  NK	  cells	  (Freud	   et	   al.,	   2016),	   this	   suggests	   that	   culture	   conditions	   are	   not	   sufficient	   to	  drive	  complete	  differentiation.	  Notably,	  these	  populations	  constituted	  only	  small	  fractions	  of	  the	  expanded	  cells	  and	  the	  majority	  stably	  remained	  negative	  for	  NK	  markers,	   which	   indicates	   that	   only	   a	   fraction	   of	   ILC3s	   has	   the	   potential	   to	   be	  diverted	  to	  an	  NK	  profile.	  	  Stimulation	   with	   IL-­‐12	   and	   IL-­‐15	   conditioned	   ILC3s	   for	   enhanced	  responsiveness	  to	  the	  type	  1	  response-­‐polarizing	  cytokines	  IL-­‐2,	  -­‐	  12,	  -­‐15	  and	  -­‐18	   (the	   last	   only	   in	   tonsil)	   and	   induced	   a	   program	   reminiscent	   of	   early-­‐differentiated	  NK	  cells	  (Béziat	  et	  al.,	  2010;	  Björkström	  et	  al.,	  2010),	  as	  revealed	  by	   transcriptional	   analysis.	   Relative	   to	   freshly	   isolated	   ILC3s,	   IL-­‐12	   and	   IL-­‐15	  expanded	  cells	  up-­‐regulated	  NK	  signature	  markers	  such	  as	  CD56,	  NKG2A,	  NKG2C	  and	  CD16.	   Furthermore,	  we	  observed	  an	   increase	   in	   genes	   associated	  with	  NK	  cell	   immunoregulatory	   functions	   such	   as	   IFNG,	   TNF,	   CCL3	   (MIP-­‐1α)	   and	   CCL4	  (MIP-­‐1β)	   but	   also	  with	   their	   cytotoxic	   functions	   like	   granzymes,	   perforin,	   and	  FasL.	  	   We	   showed	   in	  vitro	   that	   IL-­‐12	   and	   IL-­‐15	   induced	   expression	   of	   IFNγ	   in	  ILC3s	   but	   limited	   their	   capacity	   for	   TNFα	   production	   upon	   PMAi	   stimulation.	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Upon	   co-­‐culture	   with	   K562	   cells,	   however,	   IL-­‐12	   and	   IL-­‐15	   expanded	   ILC3s	  showed	  higher	  TNFα	  response,	  which	  suggests	  increased	  target	  cell	  recognition.	  	  Previous	   reports	   demonstrated	   such	  modulation	   of	   the	   cytokine	   profile	  by	  IL-­‐12	  for	  tonsil	  and	  intestinal	  NKp44+	  ILC3	  (Bernink	  et	  al.,	  2013;	  2015),	  here	  we	  showed	  that	  spleen	  ILC3s	  react	  in	  the	  same	  fashion,	  which	  also	  validates	  our	  huNSG	   mouse	   model	   for	   studying	   human	   ILC	   differentiation	   and	   immune	  response.	   However	   since	   ILC3s	   stimulated	   with	   IL-­‐12	   and	   IL-­‐2	   (4	   d)	   in	   these	  previous	  studies	  did	  not	  up-­‐regulate	  Eomes	  (Bernink	  et	  al.,	  2015),	  the	  cytotoxic	  potential	  of	  differentiated	  ILC3s	  was	  not	  investigated.	  The	  current	  study	  addressed	  this	  and	  found	  that	  IL-­‐12	  and	  IL-­‐15	  promote	  acquisition	  of	  cytotoxic	  properties	  in	  ILC3s,	  which	  correlates	  with	  Eomes	  and	  T-­‐bet	  expression.	  Although	  we	  observed	  tissue-­‐specific	  differences,	  both	  tonsil	  and	  spleen-­‐derived	   ILC3	   subsets	   showed	   moderate	   cytolytic	   activity,	   which	  improved	   with	   longer	   target	   cell	   incubation	   at	   higher	   effector	   to	   target	   cell	  ratios.	   The	   slower	   killing	   kinetics	   compared	   to	   NK	   cells	   suggested	   that	  differentiated	   ILC3s	   might	   use	   other	   mechanisms	   to	   induce	   cytotoxicity.	   For	  example,	  compared	  to	  controls,	   IL-­‐12	  and	  IL-­‐15	  expanded	  cells	  displayed	  more	  transcripts	   encoding	  TRAIL,	  which	   is	   constitutively	  expressed	  by	  murine	   ILC1s	  (Daussy	  et	  al.,	  2014;	  Gordon	  et	  al.,	  2012;	  Takeda	  et	  al.,	  2005)	  and	  detected	  on	  in	  
vitro	  differentiated	  human	  NK	  cells	  (Hughes	  et	  al.,	  2014).	  Since	  most	  granzymes	  showed	  much	  higher	  differential	  expression,	  alternatively,	  this	  might	  reflect	  the	  heterogeneity	   of	   the	   cultures	   or	   potentially	   the	   response	   intensity	   in	  differentiated	   ILC3s.	   This	   might	   be	   lower	   as	   a	   result	   of	   less	   efficient	   synapse	  formation,	   granule	   polarization,	   or	   differences	   in	   granule	   morphology	   and	  content	  (de	  Saint	  Basile	  et	  al.,	  2010;	  Mace	  et	  al.,	  2014).	  	  Interestingly,	  expanded	  tonsillar	  but	  not	  splenic	  NKp44+	  ILC3s	  showed	  enhanced	  cytotoxicity	   relative	   to	   controls.	   To	   address	   this	   tissue-­‐specific	   effect,	   we	  examined	  differential	  expression	  of	  the	  up-­‐regulated	  genes	  after	  culture	  with	  IL-­‐12	   and	   IL-­‐15.	   Since	   stimulatory	   NK	   cell	   receptors	   were	   reported	   to	   induce	  degranulation	  in	  a	  synergistic	  fashion,	  with	  the	  exception	  of	  CD16	  (Bryceson	  et	  al.,	  2009;	  Long	  et	  al.,	  2013),	  we	  speculated	  that	  the	  differences	  in	  cytolysis	  are	  a	  result	   of	   a	   distinct	   receptor	   repertoire.	   Among	   the	   investigated	   activating	  receptors	   only	   CD244	   encoding	   2B4	   was	   up-­‐regulated,	   albeit	   not	   significantly,	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however	  K562	  cells	  do	  no	  express	  its	  ligand	  CD48	  (Endt	  et	  al.,	  2007).	  When	  we	  performed	   a	   Gene	   Set	   Enrichment	   Analysis	   (GSEA)	   (Appendix,	   Figure	   15),	   top	  hits	   were	   rather	   associated	   with	   cell	   proliferation	   (Dimova	   and	   Dyson,	   2005;	  O'Donnell	   et	   al.,	   2005;	   Pelengaris	   et	   al.,	   2002).	   Comparison	   with	   the	  immunological	   signatures	  database	  revealed	  an	  overlap	  with	  a	  gene	  set	   from	  a	  study	  reporting	  a	  role	  for	  TNF-­‐	  receptor-­‐associated	  factor	  6	  (TRAF6)	  in	  fatty	  acid	  metabolism	   and	   consequently	   in	   generation	   of	   memory	   CD8	   T	   cell	   responses	  (Pearce	   et	   al.,	   2009).	   TRAF6	   is	   involved	   in	   signal	   transduction	   of	   the	   TNF	  receptor	   (TNFR)	   and	   IL-­‐1R/TLR	   superfamilies	   as	  well	   as	   of	   IL-­‐17R	   (Cao	   et	   al.,	  1996;	  Lomaga	  et	  al.,	  1999;	  Naito	  et	  al.,	  1999;	  Wu	  et	  al.,	  2015).	  Since	  IL17RB	  and	  
IL1R1	  were	  among	  the	  significantly	  up-­‐regulated	  genes	   in	  tonsils,	   this	  hit	   likely	  relates	  to	  general	  differences	   in	  ILC3s	  across	  tissues	  rather	  than	  explaining	  the	  increased	  cytotoxic	  activity	  relative	  to	  controls	  of	  tonsil-­‐	  but	  not	  spleen-­‐derived	  differentiated	  NKp44+	  ILC3s,	  which	  necessitates	  further	  investigation.	  	  Splenic	   NKp44+	   ILC3s	   acquired	   more	   NK	   cell	   markers	   and	   GzmB	   (also	  
TNFSF10,	   GzmA,	   etc.)	   upon	   IL-­‐12	   and	   IL-­‐15	   stimulation,	   however	   these	  phenotypic	   features	   did	   not	   translate	   into	   higher	   cytotoxicity.	   This	   suggested	  that	   differentially	   expanded	   ILC3s	   might	   mount	   distinct	   cytotoxic	   responses,	  triggered	   or	   exerted	   in	   a	   different	   fashion.	   Expansion	   with	   IL-­‐2	   and	   IL-­‐7	   up-­‐regulated	   genes	   associated	   with	   a	   type	   1	   immune	   response	   such	   as	   EOMES,	  
TBX21,	  STAT1,	  PRF1,	   and	  GZMA,	   relative	   to	   their	   expression	   in	   freshly	   isolated	  ILC3s.	  We	  did	  not	  detect	  appreciable	  differences	  in	  perforin	  (mRNA	  and	  protein)	  between	   the	   conditions,	  which	   could	  explain	   the	  modest	   cytolytic	   activity	   seen	  upon	  stimulation	  with	  IL-­‐2	  and	  IL-­‐7.	  Of	  note,	  FASLG	  expression	  was	  also	  similar	  but	   K562	   cells	   are	   Fas-­‐negative	   (Hodgson	   et	   al.,	   1999).	   In	  mice,	   expression	   of	  perforin	   and	   GzmB	   seems	   primarily	   regulated	   by	   Eomes	   (Cruz-­‐Guilloty	   et	   al.,	  2009;	  Pearce	  et	  al.,	  2003;	  Pipkin	  et	  al.,	  2010),	  whereas	  Eomes-­‐T-­‐bet+	   ILCs	  were	  shown	   to	   express	   TRAIL	   (Gordon	   et	   al.,	   2012;	   Takeda	   et	   al.,	   2005).	   The	   lower	  
TNFSF10	  expression	  and	  the	  absence	  (or	  low	  levels)	  of	  Eomes-­‐T-­‐bet+	  population	  in	   IL-­‐2	   and	   IL-­‐7	   expanded	   ILC3s	   suggest	   they	   exert	   perforin-­‐mediated	  cytotoxicity,	  whereas	  both	  pathways	  are	  probably	   triggered	   in	   IL-­‐12	  and	   IL-­‐15	  cultures.	   Transcriptional	   analysis	   revealed	   small	   differences	   in	   the	  NCR	   family	  genes	  and	  significantly	  higher	  KLRK1	  (encoding	  NKG2D)	  expression	  in	  IL-­‐2	  and	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IL-­‐7	  compared	  to	  IL-­‐12	  and	  IL-­‐15	  cultured	  cells;	  together	  these	  receptors	  could	  potentially	  induce	  degranulation	  (Long	  et	  al.,	  2013).	  	  Collectively,	   this	   data	   demonstrated	   that	   ILC3s	   can	   be	   diverted	   to	   a	  cytotoxic	   program,	   most	   efficiently	   so	   in	   the	   presence	   of	   IL-­‐12	   and	   IL-­‐15.	  Blocking	   perforin,	   granzymes	   and	   TRAIL	   could	   delineate	   the	   exact	   cytolytic	  mechanism(s)	  involved	  and	  different	  target	  cell	   lines	  should	  be	  used	  to	  explore	  the	  full	  potential	  of	  cytotoxic	  differentiated	  ILC3s.	  These	   results	   substantiate	   previous	   observations	   that	   environmental	  signals	   strongly	   modulate	   the	   functional	   profile	   of	   ILC3	   cells	   (Bernink	   et	   al.,	  2013;	   2015)	   (less	   stringently	   sorted,	   tonsil-­‐derived	   in	   these	   studies	   (Cella	   and	  Colonna,	  2010;	  Crellin	  et	  al.,	  2010;	  Hughes	  et	  al.,	  2010;	  2014)).	  For	  example,	  IL-­‐2	  in	   the	   presence	   of	   IL-­‐7	   promoted	   IFNγ	   production	   in	   ILC3s,	   whereas	   its	  substitution	   with	   IL-­‐1β	   resulted	   in	   constitutive	   IL-­‐22	   expression	   and	   acute	  exposure	  to	  IL-­‐12	  did	  not	  affect	  their	  cytokine	  profile	  (Cella	  and	  Colonna,	  2010).	  Moreover,	   addition	   of	   IL-­‐1β	   to	   IL-­‐15	   containing	   cultures	   of	   stage	   3	   cells	   could	  inhibit	  differentiation	  towards	  NK	  cells	  and	  sustain	  IL-­‐22	  expression	  (Hughes	  et	  al.,	  2010).	  On	  the	  other	  hand,	  we	  showed	  that	  culture	  with	  IL-­‐12	  and	  IL-­‐15	  down-­‐regulated	   IL1R1	   expression	   (together	   with	   that	   of	   IL23R	   and	   IL7R).	   Thus,	   an	  outstanding	   question	   is	   when	   both	   pro-­‐inflammatory	   cytokines	   are	   present	   in	  the	   microenvironment,	   whether	   IL-­‐12	   is	   able	   to	   override	   IL-­‐1β	   signals	   and	  switch	   ILC3	  profile.	   It	   is	   also	  essential	   to	  address	  whether	  constant	   signals	  are	  necessary	   to	   sustain	   this	   adopted	   program	   if	   this	   plasticity	   is	   to	   be	   exploited	  therapeutically.	   Bernink	   et	   al	   demonstrated	   that	  murine	   ex-­‐ILC3s	   (RORγt-­‐fm+)	  revert	  back	   to	   their	   ILC3	  profile	  when	   transferred	   into	  a	  different	   steady	   state	  environment.	  In	  the	  same	  study,	  the	  authors	  reported	  that	  human	  CD127+	  ILC1s	  can	  give	  rise	  to	  ILC3s	  (Bernink	  et	  al.,	  2015).	  However,	  in	  light	  of	  recent	  findings	  (Simoni	  et	  al.,	  2017)	  we	  are	   tempted	   to	   speculate	   that	   ILC1	  cells,	  distinct	   from	  NK	   cells,	   do	   not	   exist	   in	   humans,	   although	   they	   are	   a	   separate	   lineage	   in	  mice	  (Klose	  et	  al.,	  2014).	  In	  our	  study,	  in	  addition	  to	  IFNγ	  production,	  expanded	  ILC3s	  also	   showed	   cytolytic	   activity,	   albeit	   that	   the	   response	   was	   slower	   and	   lower	  than	   that	   of	   NK	   cells.	   Moreover,	   we	   attempted	   to	   purify	   the	   described	   ILC1	  population	   (Bernink	   et	   al.,	   2013;	   2015)	   and	   tested	   them	   alongside	   our	   ILC3	  cultures	   (Appendix,	   Figure	   16).	   The	  majority	   of	   expanded	   cells	  were	   indeed	   T	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cells	  (and	  showed	  no	  cytotoxicity	  against	  K562),	  similar	  to	  the	  findings	  of	  Simoni	  et	  al.	  The	  lack	  of	  ILC1	  specific	  markers	  and	  the	  down-­‐regulation	  of	  the	  TCR-­‐CD3	  complex	   after	   activation	   make	   this	   population	   prone	   to	   T	   cell	   contamination	  (Burkhard	  et	  al.,	  2014).	  Single-­‐cell	  RNAseq	  revealed	  presence	  of	   transcripts	   for	  TCR	  variable	  regions	  (Bjorklund	  et	  al.,	  2016),	  whereas	  un-­‐biased	  mass	  cytometry	  analysis	   could	   not	   distinguish	   this	   cell	   type	   and	   after	   back-­‐gating	   they	  overlapped	  with	  T	  cells	  (mostly)	  and	  ILC3s	  among	  others	  (Simoni	  et	  al.,	  2017).	  Thus,	  reported	  differentiation	  towards	  IL-­‐22-­‐producing	  ILC3s	  could	  come	  from	  a	  contamination	   from	   the	   sort,	   especially	   since	   putative	   ILC1s	   produced	   IL-­‐22	  already	  in	  the	  presence	  of	  the	  type	  1	  response-­‐polarizing	  cytokines	  IL-­‐2	  and	  IL-­‐12	   (Bernink	   et	   al.,	   2015).	   Thus,	   whether	   differentiated	   ILC3s	   can	   retain	   their	  immunomodulatory/cytotoxic	  profile	  in	  the	  absence	  of	  pro-­‐inflammatory	  signals	  remains	  to	  be	  determined.	  	  To	  explore	  whether	  such	  plasticity	  can	  be	  induced	  in	  vivo,	  we	  transferred	  freshly	  sorted	  ILC3s	  in	  the	  steady	  state	  or	  under	  inflammatory	  conditions,	  in	  the	  setting	   of	   EBV	   infection	   or	   after	   treatment	   with	   the	   adjuvant	   poly-­‐ICLC.	   The	  results	   were	   inconclusive	   due	   to	   low	   number	   of	   the	   recovered	   tracer-­‐labeled	  cells,	  which	   potentially	   could	   be	   improved,	   for	   example	   by	   IL-­‐7/anti-­‐IL-­‐7	  mAb	  complexes	  that	  were	  previously	  shown	  to	  induce	  T	  cell	  expansion	  (Boyman	  et	  al.,	  2008).	   Nevertheless,	   in	   accordance	   with	   our	   in	   vitro	   findings,	   we	   observed	   a	  modest	   increase	   in	   CD94	   expression	   of	   the	   adoptively	   transferred	   cells	   in	   the	  course	  of	  EBV	  infection.	  	  Interestingly,	  helper	  CD4+	  T	  cell	  cells	  capable	  of	  cytotoxic	  activity	  expand	  during	  chronic	  viral	   infections	  such	  as	  HIV	  (Appay	  et	  al.,	  2002).	  These	  cytolytic	  CD4+	  T	  cells	  express	  Eomes	  (Hirschhorn-­‐Cymerman	  et	  al.,	  2012;	  Raveney	  et	  al.,	  2015)	  and	  mediate	  cytotoxicity	  via	  perforin	  (Appay	  et	  al.,	  2002;	  Yasukawa	  et	  al.,	  2000)	  or	  FasL	  (Nikiforow	  et	  al.,	  2003;	  Paludan	  et	  al.,	  2002).	  Thus,	  both	  innate	  (as	  reported	  here)	  and	  adaptive	  helper	  lymphocytes	  can	  adopt	  cytotoxic	  properties	  during	  inflammation.	  As	  such	  cytolytic	  CD4+	  T	  cell	  cells	  are	  also	  markedly	  increased	  upon	  acute	  EBV	  infection	  (Appay	  et	  al.,	  2002)	  and	  since	  early-­‐differentiated	  NK	  cells	  restrict	  EBV	  through	  both	  IFNγ	  production	  and	  killing	  of	  lytically	  EBV-­‐replicating	  B	  cells	  (Azzi	   et	   al.,	   2014;	   Chijioke	   et	   al.,	   2013;	   Lünemann	   et	   al.,	   2013;	   Strowig	   et	   al.,	  
	   	   Discussion	  
	   71	  
2008),	  we	  explored	  the	  role	  of	  ILC3s	  in	  EBV	  infection	  and	  disease	  pathogenesis.	  HuNSG	  mice	   that	   received	   IL-­‐2	  and	   IL-­‐7	  expanded	   ILC3s	  before	  virus	   injection	  did	   not	   show	   any	   consistent	   differences	   with	   respect	   to	   viral	   load	   or	   tumor	  burden.	   Although	   we	   observed	   a	   trend	   towards	   protection	   in	   the	   initial	  experiment,	  we	   could	   not	   confirm	   this	   in	   the	   two	   subsequent	   ones,	  where	  we	  also	  sought	   to	  address	   the	   ILC3	   fate.	  Notably,	  killing	  of	   transferred	  cells	  due	   to	  MHC	   class	   I-­‐mismatch	   or	   an	   unexplained	   effect	   from	   the	   transduction	   might	  account	  for	  the	  results	  of	  the	  last	  two	  experiments.	  Also,	  the	  experimental	  set-­‐up	  has	  likely	  been	  too	  long	  to	  detect	  the	  cells	  as	  with	  this	  protocol	  they	  undergo	  5	  weeks	  of	   expansion	   in	  vitro	   and	  we	  harvest	   the	  organs	  6	  weeks	  post	   infection.	  Nevertheless,	   the	   humanized	   mouse	   model	   is	   a	   powerful	   tool	   to	   study	   ILC3	  functional	  plasticity,	  especially	  since	  in	  mice	  ILC3s	  cannot	  acquire	  an	  NK	  profile.	  Of	   note,	   murine	   ILC3	   plasticity	   has	   been	   investigated	   predominantly	   under	  homeostatic	   conditions	   (Bernink	  et	   al.,	   2015;	  Klose	  et	   al.,	   2014;	  Vonarbourg	  et	  al.,	  2010)	  or	  intestinal	  inflammation	  (Klose	  et	  al.,	  2013;	  Vonarbourg	  et	  al.,	  2010),	  but	  not	  in	  virus	  infection	  or	  cancer,	  in	  which	  NK	  cells	  are	  important.	  	  To	  our	  knowledge	  only	  two	  studies	  addressed	  ILC3	  function	  in	  cancer.	  In	  human	  NSCLC,	   NCR+	   ILC3s	   might	   have	   a	   protective	   role	   via	   a	   contribution	   to	   the	  formation	  of	   tertiary	   lymphoid	  structures	   (Carrega	  et	  al.,	  2015).	   In	  mice,	   ILC3s	  inhibited	  B16	  melanoma	  tumor	  growth	  in	  an	  IL-­‐12-­‐dependent	  manner.	  The	  exact	  mechanism	   however	   remained	   unresolved,	   with	   perforin	   shown	   to	   be	  dispensable	   for	   tumor	   rejection	   (Eisenring	   et	   al.,	   2010).	   According	   to	   our	  findings,	   ILC3s	   in	   that	   model	   might	   for	   example	   mediate	   antitumor	   activity	  through	  TRAIL-­‐mediated	  cytotoxicity.	  The	  role	  of	  IL-­‐12	  in	  tumor	  suppression	  has	  been	  extensively	  demonstrated	   in	  various	  mouse	   tumor	  models	  and	  thus	   IL-­‐12	  therapy	  is	  currently	  tested	  in	  clinical	  trials.	  It,	  however,	  has	  inconsistent	  effects	  with	  respect	  to	  antitumor	  efficacy,	  which	  to	  some	  extent	  might	  be	  attributed	  to	  the	  mode	   of	   delivery	   as	   local	   administration	   showed	   better	   results.	  Moreover,	  patients	  may	  exhibit	  adverse	  reactions	  such	  as	  cytokine	  toxicity	  or	  induction	  of	  IL-­‐10.	  Therefore,	  tumor-­‐targeted	  administration	  in	  combination	  with	  additional	  anti-­‐immunosuppressive	   therapies	  might	   be	   a	   promising	   approach	   in	   inducing	  innate	  and	  adaptive	  cytotoxicity	  to	  combat	  cancer	  (Tugues	  et	  al.,	  2014).	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Thus,	   with	   this	   study,	   we	   provided	   evidence	   that	   ILC3s	   can	   adapt	   to	   an	  inflammatory	   tissue	  milieu	  not	  only,	   as	  previously	  believed,	  by	  acquisition	  of	  a	  helper	  but	  also	  a	   cytotoxic	  NK	  cell	  profile,	   a	  mechanism	   that	   likely	  evolved	   for	  protection	  against	  pathogens	  at	  mucosal	  sites.	  This	  cytotoxic	  potential,	  triggered	  most	  efficiently	  by	  IL-­‐12	  and	  IL-­‐15,	  can	  be	  potentially	  harnessed	  in	  the	  treatment	  of	  chronic	  viral	  infections	  and	  cancer.	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Materials	  and	  Methods	  
	  
Tissue	  collection	  Tonsils	  were	  collected	  from	  patients	  undergoing	  tonsillectomy	  at	  the	  University	  Children’s	  Hospital	  of	  Zurich.	  A	  description	  of	  the	  samples	  used	  for	  ILC	  isolation	  and	  in	  which	  experiments	  they	  were	  included	  is	  provided	  in	  Table	  1.	  Human	   fetal	   liver	   tissues	  were	  procured	   from	  Advanced	  Bioscience	  Resources.	  Tissues	  were	  collected	  after	  patients	  provided	   informed	  consent	   in	  accordance	  with	   the	   Declaration	   of	   Helsinki.	   All	   studies	   involving	   human	   samples	   were	  reviewed	  and	  approved	  by	  the	  cantonal	  ethical	  committee	  of	  Zurich,	  Switzerland	  (protocol	  no.	  KEK-­‐StV-­‐Nr.19/08).	  
	  
Humanized	  mice	  NOD.Cg–PrkdcscidIl2rgtm1Wjl/SzJ	   (NOD-­‐scid	   γcnull	   or	   NSG)	   and	   HLA-­‐A2	   transgenic	  NSG	  (A2-­‐NSG)	  mice	  were	  purchased	  from	  the	  Jackson	  Laboratory	  and	  housed	  at	  the	   Institute	   of	   Experimental	   Immunology,	   University	   of	   Zurich,	   under	   specific	  pathogen-­‐free	   conditions.	   All	   animal	   protocols	  were	   approved	   by	   the	   Cantonal	  Veterinary	  Office	  Zurich,	  Switzerland	   (protocol	  Nos.	  148/2011	  and	  209/2014).	  Newborn	  NSG	  mice	  (1	  to	  5	  days	  old)	  were	  irradiated	  with	  1	  Gy	  using	  X-­‐ray	  or	  Cs-­‐source	   and	   5-­‐7	   hours	   later	   injected	   intrahepatically	   with	   on	   average	   2	   ×	   105	  CD34+	   hematopoietic	   progenitor	   cells	   (HPCs)	   derived	   from	   human	   fetal	   liver	  (HFL)	   tissues.	   Reconstitution	   of	   human	   immune	   system	   components	   was	  analyzed	   in	  blood	   circa	  12	  weeks	   after	   engraftment	   (Figure	  11)	   or	  1	  day	  prior	  EBV	  infection	  (Figure	  12).	  A	  detailed	  description	  of	  cohorts	  used	  for	  ILC	  isolation	  and	  in	  which	  experiments	  they	  were	  included	  is	  provided	  in	  Table	  2.	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Figure	  11	  Reconstitution	  of	  human	  immune	  system	  components	  in	  huNSG	  and	  
HLA-­‐A2	  huNSG	  used	  for	  ILC3	  purification.	  	  Sample	  details	  shown	  in	  Table	  2	  	  
	  
Figure	  12	  Reconstitution	  and	  group	  distribution	  of	  humanized	  mice	  used	  for	  
adoptive	  transfer	  EBV	  experiments	  	  	  Sample	  details	  shown	  in	  Table	  2	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μg/ml	   gentamicin.	   All	   culture	   reagents,	   unless	   otherwise	   indicated,	   were	  purchased	  from	  Life	  Technologies.	  	  
Cell	  isolation	  and	  purification	  Human	  fetal	  liver	  tissues	  were	  minced	  and	  digested	  with	  2	  mg/ml	  collagenase	  D	  (Roche)	  and	  20	  μg/ml	  DNase	  I	  (Roche)	  in	  HBSS	  (with	  Ca2+	  and	  Mg2+,	  Gibco)	  for	  25	  min	  at	  RT.	  Reaction	  was	  stopped	  by	  addition	  of	  10	  mM	  EDTA	  (5	  min	  at	  RT)	  and	   tissue	   was	   mashed	   through	   a	   70	   μm	   cell	   strainer	   before	   separation	   by	  density	  gradient	  centrifugation	  on	  Ficoll-­‐Paque	  (GE	  Healthcare)	  (1000	  g,	  30	  min,	  RT).	   CD34+	   HPCs	   were	   isolated	   by	   magnetic-­‐activated	   cell	   sorting	   (MACS)	   via	  double	  positive	  selection	  using	  CD34	  MicroBead	  kit	  (Miltenyi).	  Tonsil	   tissues	   were	   mechanically	   dissociated,	   filtered	   through	   a	   70	   μm	   cell	  strainer	   and	   mononuclear	   cells	   were	   obtained	   via	   Ficoll-­‐Paque	   fractionation	  (2100	  rpm,	  25	  min,	  RT;	  used	  for	  all	  tissues	  except	  HFL).	  Mice	   were	   euthanized	   using	   CO2,	   organs	   were	   harvested	   and	   processed	   as	  follows:	  Whole	  blood	  erythrocyte	  lysis	  was	  done	  using	  NH4Cl	  solution	  for	  5	  min	  at	  RT.	  Spleen	  and	  lymph	  nodes	  were	  processed	  the	  same	  way	  as	  tonsillar	  tissue.	  	  Livers	  were	  digested	  with	  0.4	  mg/ml	  collagenase	  D	  and	  20	  µg/ml	  DNase	  I	  in	  PBS	  for	  45	  min	  at	  37°C	  under	  agitation	  (stopped	  with	  10	  mM	  EDTA,	  5	  min	  at	  37°C).	  Tissues	  were	  mechanically	   disrupted	   and	   filtered	   before	   leukocyte	   enrichment	  using	  Percoll	  (GE	  Healthcare)	  centrifugation	  (1450	  g,	  30	  min,	  4°C)	  (lower	  ring).	  	  Lungs	   were	   perfused	   with	   PBS	   and	   cut	   into	   small	   pieces	   in	   5	   ml	   R10	  supplemented	  with	  2	  mg	  collagenase	  A	  (Sigma	  Aldrich),	  250	  µg/ml	  DNase	  I	  and	  25	   mM	   Hepes	   (Invitrogen).	   Digestion	   was	   done	   for	   45	   min	   at	   37°C	   under	  agitation	   and	   stopped	   with	   5mM	   EDTA	   (5	   min	   at	   37°C).	   Tissue	   was	   filtered	  through	  a	  70	  μm	  cell	  strained	  and	  separated	  by	  Percoll	  (2590	  rpm,	  30	  min,	  4°C).	  Small	   intestines	   were	   cleaned	   of	   feces	   and	  mesenteric	   fat	   tissue,	   then	   opened	  longitudinally	  and	  cut	  into	  1-­‐2	  cm	  pieces.	  These	  were	  incubated	  in	  30	  mM	  EDTA	  solution	  (Ca2+	  and	  Mg2+	  free	  PBS)	  for	  30	  min	  on	  ice	  and	  then	  washed	  in	  PBS	  until	  solution	   was	   clear.	   Tissues	   were	   cut	   into	   smaller	   pieces	   and	   digested	   with	   1	  mg/ml	  collagenase	  D	  and	  25	  µg/ml	  DNase	  I	  in	  DMEM	  for	  15	  min	  at	  37°C	  under	  agitation.	  After	  addition	  of	  DMEM,	  pieces	  were	  homogenized	  using	  1	  ml	  pipette	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(tip	   cut	   smaller	   in	   every	   step),	   supernatant	   was	   collected	   and	   procedure	   was	  repeated	   3x	   with	   addition	   of	   fresh	   collagenase.	   Digested	   tissue	   was	   mashed	  through	  a	  70	  μm	  strainer	  and	  subjected	  to	  Percoll	  separation	  (1800	  rpm,	  30	  min,	  RT)	  to	  isolate	  the	  lamina	  propria	  (LP)	  leukocytes.	  Prior	  to	  sort	  splenocytes	  were	  depleted	  of	  CD19+/CD14+/CD4+/CD8+	  cells	  using	  microbeads	  (Miltenyi),	  tonsillar	  cells	  as	  indicated	  in	  Table	  2,	  whereas	  LP	  cells	  were	  not	  MACS-­‐separated.	  	  
Flow	  Cytometry	  and	  cell	  sorting	  All	  antibodies	  used	  for	  flow	  cytometric	  analysis	  are	  listed	  in	  Table	  3.	  Dead	  cells	  were	  excluded	  with	  LIVE/DEAD	  Fixable	  Aqua	  or	  Near-­‐IR	  kit	  (Invitrogen),	  7-­‐AAD	  (Biolegend)	   or	   TO-­‐PRO-­‐3-­‐Iodide	   (ThermoFisher).	   For	   surface	   markers,	   cells	  were	   stained	   for	   20	   min	   on	   ice.	   	   For	   cytokine/granzymeB/perforin	   detection,	  cells	   were	   fixed	   and	   permeabilized	   with	   Cytofix/Cytoperm	   Kit	   from	   BD	  Biosciences	   and	   stained	   for	   30	   min	   on	   ice.	   For	   intranuclear	   stainings,	  Foxp3/Transcription	  Factor	  Staining	  Buffer	  Set	  from	  eBiosciences	  was	  used	  and	  cells	   were	   stained	   for	   45	   min	   at	   RT	   or	   ON	   at	   4°C.	   Data	   was	   acquired	   on	  FACSCanto	   or	   LSR	   II	  Fortessa	   cytometers	   (BD	   Biosciences).	   For	   cell	   sorting	  FACSAria	  III	  instrument	  (BD	  Biosciences)	  was	  used.	  Fresh	  innate	  lymphoid	  cells	  were	   sorted	   as	   shown	   in	   Figure	   1A	   from	   tonsils	   (from	   individual	   subjects),	  humanized	   mouse-­‐derived	   splenocytes	   or	   LP	   cells	   (both	   pooled	   from	   several	  animals	  reconstituted	  with	  CD34+	  HPCs	  from	  the	  same	  donor).	  Expanded	  ILC3s	  were	  purified	   as	   live	  CD117+CD94-­‐	   cells.	  Analysis	  was	  performed	  using	  FlowJo	  software	  (TreeStar).	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Table	  3	  List	  of	  antibodies	  used	  in	  flow	  cytometry	  	  
Marker Fluorochrome Company Cat No clone isotype
CD107a FITC BD 555800 H4A3 Mouse IgG1, 
CD117 BV605 Biolegend 313218 104D2 Mouse IgG1, 
CD117 PE Biolegend 313204 104D2 Mouse IgG1, 
CD127 PerCP-Cy5.5 eBioscience 45-1278-41 eBioRDR5 Mouse IgG1, 
CD127 PE-Dazzle-594 Biolegend 351336 A019D5 Mouse IgG1, 
CD14 BV510 Biolegend 301842 M5E2 Mouse IgG2a, 
CD14 AF700 Biolegend 325614 HCD14 Mouse IgG1, 
CD14 FITC BD 561712 M5E2 Mouse IgG2a
CD158a FITC Biolegend 339503 HP-MA4 Mouse IgG2b, 
CD158b FITC Biolegend 312603 DX27 Mouse IgG2a, 
CD16 BV785 Biolegend 302045 3G8 Mouse IgG1, 
CD16 BV510 Biolegend 302047 3G8 Mouse IgG1, 
CD16 APC-Cy7 Biolegend 302018 3G8 Mouse IgG1, 
CD161 BV711 BD 563865 DX12 Mouse IgG1, 
CD19 BV510 Biolegend 302242 HIB19 Mouse IgG1, 
CD19 AF700 eBioscience 56-0199-41 HIB19 Mouse IgG1, 
CD19 PE-Cy7 Biolegend 302216 HIB19 Mouse IgG1, 
CD19 BV785 Biolegend 302239 HIB19 Mouse IgG1, 
CD19 FITC Biolegend 302205 HIB19 Mouse IgG1, 
CD196 (CCR6) AF647 BD 560466 11A9 Mouse IgG1, 
CD294 (CRTH2) PerCP-Cy5.5 BD 561660 BM16 Rat WI IgG2a, 
CD294 (CRTH2) BIOT eBioscience 13-2949-80 BM16 Rat IgG2a
CD3 BV510 Biolegend 300447 UCHT1 Mouse IgG1, 
CD3 PE-CF594 BD 562310 UCHT1 Mouse IgG1, 
CD3 PerCP-Cy5.5 Biolegend 300429 UCHT1 Mouse IgG1, 
CD3 PB Invitrogen MHCD0328 S4.1 Mouse IgG1, 
CD3 PE Biolegend 300408 UCHT1 Mouse IgG1, 
CD3 BV785 Biolegend 317330 OKT3 Mouse IgG1, 
CD303 (BDCA-2) FITC Miltenyi 130-090-510 AC144 Mouse IgG1, 
CD314 (NKG2D) PE-CF594 BD 562498 1D11 Mouse IgG1, 
CD335 (NKp46) PE-Cy7 BD 562101 9E2 Mouse IgG1, 
CD335 (NKp46) APC BD 558051 9E2 Mouse IgG1, 
CD335 (NKp46) BV650 Biolegend 331928 9E2 Mouse IgG1, 
CD336 (NKp44) PE Biolegend 325108 P44-8 Mouse IgG1, 
CD336 (NKp44) APC Biolegend 325109 P44-8 Mouse IgG1, 
CD34 BV510 Biolegend 343528 581 Mouse IgG1, 
CD34 APC Invitrogen CD34-581-05 581 Mouse IgG1, 
CD38 PE Biolegend 303506 HIT2 Mouse IgG1, 
CD4 APC-Cy7 Biolegend 300518 RPA-T4 Mouse IgG1, 
CD45 PB Biolegend 304029 HI30 Mouse IgG1, 
CD56 PE-Cy7 BD 335826 NCAM16 Mouse IgG2b, 
CD62L FITC BD 561914 DREG-56 Mouse IgG1, 
CD69 FITC Invitrogen MHCD6901 CH/4 Mouse IgG2a
CD8 PerCP Biolegend 344708 SK1 Mouse IgG1, 
CD94 APC-Vio770 Miltenyi 130-101-146 REA113 recomb Human IgG1
CD94 FITC Biolegend 305504 DX22 Mouse IgG1, 
CD94 PE BD 555889 HP-3D9 Mouse IgG1, 
EOMES FITC eBioscience 11-4877-41 WD1928 Mouse IgG1, 
EOMES PerCP-eFluor710 eBioscience 46-4877-42 WD1928 Mouse IgG1, 
FceR1 BV510 Biolegend 334626 AER-37 Mouse IgG2b, 
Granzyme B AF700 BD 561016 GB11 Mouse IgG1, 
HLA-A2 FITC Biolegend 343303 BB7.2 Mouse IgG2b, 
HLA-DR APC Biolegend 307610 L243 Mouse IgG2a, 
HLA-DR FITC Biolegend 307604 L243 Mouse IgG2a, 
IFNg APC eBioscience 17-7319-82 4S.B3 Mouse IgG1, 
IL-22 PE-Cy7 eBioscience 25-7229-41 22URTI Mouse IgG1, 
KI67 AF647 BD 558615 B56 Mouse IgG1, 
mCD45 AF700 BioLegend 103127 30-F11 Rat IgG2b, 
Perforin AF488 BD 563764 G9 Mouse IgG2b, 
RORgt APC eBioscience 17-6988-82 AFKJS9 Rat IgG2a
streptavidin BV510 Biolegend 405233
T-bet BV650 BD 564142 O4-46 Mouse IgG1, 
T-bet PE eBioscience 12-5825-80 eBio4B10 Mouse IgG1, 
T-bet PerCP-Cy5.5 eBioscience 45-5825-80 eBio4B10 Mouse IgG1
T-bet PE-CF594 BD 562467 O4-46 Mouse IgG1, 
TCRab BIOT Biolegend 306703 IP26 Mouse IgG1, 
TCRab PerCP-Cy5.5 Biolegend 306723 IP26 Mouse IgG1, 
TCRgd BV510 Biolegend 331219 B1 Mouse IgG1, 
TCRgd PerCP-Cy5.5 Biolegend 331223 B1 Mouse IgG1, 
TNFa PE-Cy7 BD 560923 MAb11 Mouse IgG1, 
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Expansion	  of	  ILCs	  ILCs	  were	  seeded	  with	  irradiated	  allogeneic	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  and	  B-­‐lymphoblastoid	  cell	   line	  (LCL)	  721.221	  (details	   in	  Tables	  1	  and	  2)	   in	   the	   presence	   of	   phytohemagglutinin	   (PHA-­‐L)	   (2.5 μg/ml,	   EMD	  Millipore)	  and	  cytokines	  (Peprotech);	  the	  latter	  were	  replenished	  every	  3-­‐4	  days	  from	  day	  5.	  ILCs	  were	  stimulated	  with	  IL-­‐2	  (600 U/ml),	  IL-­‐7	  (10 ng/ml),	  IL-­‐12	  (50	  ng/ml),	  IL-­‐15	  (20	  ng/ml),	  IL-­‐18	  (50	  ng/ml),	  or	  combinations	  thereof	  as	  described	  in	  the	  figures.	  Cytokine	  mixes	  stated	  in	  Figure	  2A	  are	  shown	  in	  Table	  4.	  Medium	  for	  NK	  cells	  was	  supplemented	  with	   IL-­‐15;	   IL-­‐12	  was	  added	   in	   the	   initial	  experiments	  but	   it	   diminished	   their	   viability.	   Cultures	   were	   maintained	   in	   RPMI	   +	   10%	  human	   serum	  AB	   (Bioconcept)	   +	   L-­‐glutamine	   (2	  mM,	   Gibco)	   +	   gentamicin	   (20	  μg/ml)	   at	  37°C	  with	  5%	  CO2	   for	  2-­‐6	  weeks	   as	   indicated	   in	   the	   figures.	   For	   the	  clonal	   assay,	   ILC3s	   were	   single-­‐cell	   sorted	   into	   96-­‐well	   plates	   preseeded	  with	  irradiated	  Cell	  Trace	  Violet-­‐labeled	  feeders,	  expanded	  with	  IL-­‐2	  +	  IL-­‐7	  or	  IL-­‐12	  +	  IL-­‐15	  and	  analyzed	  after	  21	  days.	  	  
Cytokine	  production,	  degranulation	  and	  cytotoxicity	  assays	  The	   human	   erythroleukemia	   cell	   line	   K562	   served	   as	   target	   in	   all	   functional	  assays.	   For	   flow	   cytometric	   analyses,	   K562	   cells	   were	   labeled	   with	   Cell	   Trace	  Violet	   (Invitrogen),	   according	   to	   the	   manufacturers	   instructions,	   in	   order	   to	  distinguish	  them	  from	  ILCs.	  	  For	   cytokine	   production	   or	   cytotoxic	   effector	   molecule	   release,	   cultured	   ILCs	  were	  stimulated	  with	  K562	  cells	  at	  an	  effector	   to	   target	  ratio	  of	  1:1	  or	  with	  10	  ng/ml	   PMA	   and	   500	   ng/ml	   ionomycin	   (both	   from	   Sigma	   Aldrich)	   for	   4	  hours.	  After	  45	  minutes	  2	  μM	  monensin	  (eBioscience)	  and	  5	  μg/ml	  Brefeldin	  A	  (Sigma	  Aldrich)	  were	  added.	  	  For	  degranulation	  assays,	  cultured	  ILCs	  were	  co-­‐incubated	  with	  K562	  cells	  at	  a	  ratio	  of	  1:1	   in	   the	  presence	  of	  FITC-­‐conjugated	  anti-­‐CD107a	  mAb.	  After	  1	  hour	  degranulation	  was	  blocked	  by	  addition	  of	  GolgiStop	  (BD	  Biosciences)	  according	  to	  manufacturer’s	  protocol	  and	  after	  a	  total	  of	  4	  hrs	  CD107a	  surface	  expression	  on	  effector	  cells	  was	  assessed.	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To	   detect	   spontaneous	   degranulation	   or	   constitutive	   expression	   of	  cytokines/cytotoxic	  effectors,	  a	  control	  without	  target	  cells	  was	  included.	  	  For	  cytotoxicity	  evaluated	  by	  flow	  cytometry,	  target	  cells	  were	  labeled	  with	  Cell	  Trace	  Violet	  and	  plated	  (1	  ×	  104	  cells/well)	  with	  effectors	  at	  the	  indicated	  ratios	  for	  4	  or	  18	  hours.	  Cells	  were	   then	  stained	  with	  0.1	  μM	  TO-­‐PRO-­‐3,	  a	  membrane	  impermeable	  DNA	  dye,	  and	  analyzed	  by	  flow	  cytometry.	  Spontaneous	  lysis	  was	  determined	   from	   target	   only	   wells.	   Percent	   specific	   lysis	   was	   calculated	  according	  to	  the	  formula:	  
	  For	   cytolytic	   activity	   determined	   by	   LDH	   assay	   (ThermoFisher),	   K562	   cells	  (2	  ×	  103	   cells/well)	  were	   incubated	   	  with	  effectors	  at	   the	   indicated	   ratios	   for	  4	  and/or	  18	  hours.	  Percent	  cytotoxicity	  was	  calculated	  according	  to	  the	  formula:	  
	  	  
EBV	  production	  and	  infection	  293/EBV-­‐wt	  cells	  were	  seeded	  onto	  poly-­‐D-­‐lysine	  (Sigma	  Aldrich)	  pre-­‐coated	  10	  cm2	   plates	   (CORNING)	   at	   high	   density	   (3	   x	   106	   cells)	   and	   maintained	   ON	   in	  antibiotic-­‐free	  medium.	   They	   were	   then	   lytically	   induced	   by	   transfection	   with	  p509	  (carrying	  BZLF1)	  and	  p2670	  (carrying	  BALF4)	  plasmids	  using	  Metafectene	  PRO	   (Biontex).	   Plasmids	   (1.5	   μg	   each/plate/600	   μl	   RPMI)	   were	   mixed	   with	  Metafectene	  (16	  μl	  /plate/600	  μl	  RPMI)	  and	  after	  15-­‐min	  incubation	  at	  RT	  added	  to	  the	  cells.	  The	  medium	  was	  replaced	  after	  4-­‐5	  hours.	  After	  3	  days	  supernatants	  were	  harvested,	   centrifuged	   (2000	  g,	  10	  min),	   filtered	   (0.45	  μm),	   concentrated	  via	  ultra-­‐centrifugation	  (30	  000	  g,	  2	  hrs)	  and	  stored	  at	  4°C.	  The	  virus	  was	  titered	  on	  Raji	  cells	  and	  infection	  assessed	  after	  2	  days	  by	  expression	  of	  GFP	  (encoded	  on	   p2089	   (Delecluse	   et	   al.,	   1998)).	   Humanized	   mice	   were	   infected	   via	  intraperitoneal	  injection	  of	  1-­‐2	  ×	  105	  Raji-­‐infecting	  units	  (RIUs).	  	  
 % alive cells at end 
% alive cells at start
% Speci!c lysis = x 100 1 -( )
% alive cells at start = average % alive cells in target only wells
 % alive cells at end 
% alive cells at start
% Speci!c lysis = x 100 1 -( )
% alive cells at start = average % alive cells in target only wells
 Experimental value - E"ector Cells Spontaneous Control - Target Cells Spontaneous Control
Target Cell Maximum Control - Target Cells Spontaneous Control
% Cytotoxicity = x 100 ( )
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Lentiviral	  vector	  production	  and	  infection	  
GFP-encoding lenvirus was produced by transient transfection of 293T cells with the self-inactivating 
pCLX-UBI-GFP, psPAX2 (encoding gag/pol), and pCAG-VSVG (encoding the G protein of vesicular 
stomatitis virus glycoprotein (VSV-G)) as described previously (Giry-­‐Laterrière	   et	   al.,	   2011).	   The	  following	  modifications	   were	  made	   –	   4.6	   x	   106	   cells	   were	   seeded	   per	   10	   cm2	  plate,	   0.25	  M	  CaCl2	  was	   used	   for	   transfection,	   plasmid	   concentration	   per	   plate	  was	   5	   μg	   for	   pCAG-­‐VSVG	   and	   10	   μg	   of	   the	   other	   two,	   and	   supernatant	   was	  collected	   30-­‐32	   hours	   after	   addition	   of	   fresh	  medium.	   Virus	  was	   concentrated	  the	   next	   day	   using	   Vivapure	   Lentiselect	   40	   (Sartorius	   stedim)	   according	   to	  manufacturers	   instructions	   and	   stored	   at	   -­‐80°C.	   Plasmids	   (Figure	   13)	   and	  protocols	  were	  kindly	  provided	  by	  Dr.	  Renier	  Myburgh	  and	  Prof.	  Roberto	  Speck.	  ILC3s	  were	  transduced	  ON	  (MOI	  not	  determined).	  After	  circa	  6	  weeks	  expansion	  cells	  were	  sorted	  as	  live	  CD117+CD94-­‐	  cells	  and	  GFP	  expression	  was	  assessed.	  	  
Adoptive	  transfer	  experiments	  ILC3s	   defined	   as	   CD45+Lin-­‐CD127+CD117+(NKp44+	   or	   NCR-­‐)	   cells	   were	   sorted	  from	  pooled	  spleens.	  	  For	  short-­‐term	  experiments	  freshly	  isolated	  ILC3s	  were	  labeled	  with	  Cell	  Trace	  Violet	  and	  injected	  intravenously	  into	  recipient	  mice	  from	  the	  same	  HFL	  cohort	  (Table	   2).	   Cells	   were	   injected	   at	   steady	   state,	   at	   week	   4	   post	   EBV	   infection	  (1	  ×	  105	  RIU/mouse)	  or	  14	  hours	  after	  treatment	  with	  polyICLC	  (Hiltonol,	  kindly	  provided	   by	   Andres	   Salazar,	   Oncovir).	   PolyICLC	   was	   injected	   according	   to	  supplier’s	  recommendation	  –	  twice	  at	  24	  hours	  interval,	  50	  μg/mouse	  per	  shot,	  intraperitoneal.	  After	  4	  days	  mice	  were	  sacrificed	  and	  organs	  (PB,	  spleen,	   liver,	  lung,	  LNs)	  were	  harvested	  for	  analyses.	  	  For	   long-­‐term	   experiments	   ILC3s	   were	   expanded	   with	   IL-­‐2	   and	   IL-­‐7	   for	   5-­‐6	  weeks,	   re-­‐sorted	   as	   CD117+CD94-­‐	   cells	   and	   injected	   intravenously	   at	   1	   ×	   106	  cells/mouse,	   one	   day	   before	   EBV	   injection	   (1-­‐2	  ×	  105	   RIU/mouse).	   For	  autologous	  I	  and	  II	  experiments	  recipient	  mice	  were	  from	  the	  same	  HFL	  cohort,	  in	   the	   latter	   11.6%	   of	   ILC3	   were	   GFP+.	   For	   the	   allogeneic	   experiment	   ILC3s	  derived	   from	  HLA-­‐A2+	   reconstitutions	  were	   transferred	   in	  mice	  engrafted	  with	  CD34+	   HPCs	   from	   HLA-­‐A2-­‐	   donors.	   Body	   weight	   (BW)	   measurements	   were	  performed	  at	  3	  day	  intervals	  as	  weight	  loss	  is	  associated	  with	  symptomatic	  EBV	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infection	   (Chijioke	   et	   al.,	   2013).	   Mice	   were	   sacrificed	   circa	   6	   weeks	   after	   virus	  inoculation	   and	   organs	   (PB,	   spleen,	   liver,	   lung,	   LNs	   and	   small	   intestine)	   were	  collected	   for	   analyses.	   Splenomegaly	   (ratio	   spleen	   to	   BW)	  was	   assessed,	   as	   an	  indicator	   for	   CD8+	   T	   cell	   expansion	   in	   response	   to	   EBV	   (Chijioke	   et	   al.,	   2013);	  inversion	  of	  the	  CD4:CD8	  ratio	  was	  evaluated	  by	  flow	  cytometry.	  Tumor	  burden	  was	  determined	  macroscopically.	  	  	  
Quantification	  of	  viral	  load	  DNA	   from	  whole	   blood	  was	   extracted	   using	  NucliSENS	   (bioMérieux)	   and	   from	  splenic	  tissue	  with	  QIAamp	  tissue	  Kit	  (QIAGEN)	  according	  to	  the	  manufacturers	  protocols.	   Quantification	   of	   EBV	   DNA	   was	   performed	   by	   TaqMan	   (Applied	  Biosystems)	   real-­‐time	   PCR	   as	   previously	   described	   (Berger	   et	   al.,	   2001),	   with	  modified	  primers	   for	   the	  BamH1	  W	  fragment	  (5′-­‐CTTCTCAGTCCAGCGCGTTT-­‐3′	  and	   5′-­‐CAGTGGTCCCCCTCCCTAGA-­‐3′)	   and	   a	   fluorogenic	   probe	   (5′-­‐(FAM)-­‐CGTAAGCCAGACAGCAGCCAATTGTCAG-­‐(TAMRA)-­‐3′).	   The	   amplification	   was	  performed	  using	  ABI	  Prism	  7700	  Sequence	  Detector	  (Applied	  Biosystems).	  Mice	  were	  considered	  uninfected	  if	  EBV	  DNA	  was	  below	  detection	  limit	  in	  blood	  and	  spleen	  during	  the	  course	  of	  infection.	  	  
RNA	  sequencing	  Total	  RNA	  was	  isolated	  using	  PicoPure	  RNA	  isolation	  kit	  (ThermoFisher)	  by	  Dr.	  Frank	  Lehmann.	  NKp44+	  ILC3s	  were	  either	  transferred	  to	  lysis	  buffer	  right	  after	  sorting	  or	  differentially	  cultured	  for	  3	  weeks.	  Samples	  were	  stored	  at	  -­‐80°C	  until	  use.	  2	  000	  –	  15	  000	  freshly	  isolated	  spleen	  ILC3s,	  900	  –	  9	  000	  tonsil	  ILC3s	  and	  10	  000	  expanded	  cells	  were	  used	  for	  RNA	  isolation.	  Quality	  control	  and	  sequencing	  was	   performed	   by	   the	   Genomics	   Facility	   Basel	   (Department	   of	   Biosystems	  Science	  and	  Engineering,	  ETH).	  Data	  was	  analyzed	  by	  Dr.	  Robert	  Ivanek.	  	  
Statistical	  analysis	  Comparison	   between	   differentially	   cultured	   ILCs	   was	   done	   via	   paired	   t-­‐test.	  Spearman	   coefficient	   was	   used	   to	   determine	   correlation	   between	   cytotoxicity	  (LDH	   assay)	   and	   expression	   of	   NK	   markers.	   Data	   from	   adoptive	   transfer	  experiments	  was	  analyzed	  using	  Mann-­‐Whitney	   test.	  p-­‐values	  below	  0.05	  were	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considered	   statistically	   significant	   (*	   p	   <	   0.05,	   **	   p	   <	   0.01,	   ***	   p	   <	   0.001).	  Statistical	   analysis	   was	   performed	   using	   Prism	   software	   (GraphPad).	   Data	   is	  displayed	  as	  mean	  ±	  standard	  deviation	  (SD),	  unless	  otherwise	  stated.	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Figure	  13	  Expression	  of	  lineage-­‐specific	  transcription	  factors	  in	  the	  purified	  ILC	  
populations	  	  
	  
Figure	  14	  Frequency	  of	  CD16+CD56+	  among	  Eomes-­‐expressing	  CD94+	  or	  CD94-­‐	  
cells	  ILC3s	  were	  cultured	  for	  3	  weeks	  and	  analyzed	  for	  expression	  of	  NK	  markers.	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Figure	  15	  GSEA	  analysis	  for	  tonsillar	  NKp44+	  ILC3s	  To	  address	  the	  enhanced	  cytotoxicity	  over	  controls	   in	  tonsil	  (To)-­‐	  but	  not	  spleen	  (Sp)-­‐derived	  NKp44+	  ILC3s	  we	  assessed	  differential	  expression	  of	  IL-­‐12	  plus	  IL-­‐15	  (c)	  and	  IL-­‐2	   plus	   IL-­‐7	   (b)	   treated	   cells	   between	   the	   tissues.	   To	   c-­‐a	   indicates	   up-­‐regulated	   gene	  signatures	   in	   IL-­‐12	   and	   IL-­‐15	   cultures	   relative	   to	   freshly	   sorted	   cells,	  whereas	   To	   c-­‐b	  relative	  to	  the	  IL-­‐2	  and	  IL-­‐7	  condition	  	  
#( #' $&&"( $#  &( $# '$1 ") !**"
0464/,5,,0/,5,,7,, 083 /*/0 % 0*0/050668 6*77+21 2*73+17
0464/,5,,0/,,7,, 083 /*/0 % 0*/8572303 0*67+15 3*23+12
02436,,,	,	,	,,01, 067 /*/0 % 0*/2386705 3*37+11 6*16+08
28445,7,,,,,,2,,	,	
, 086 /*/0 % /*757/4201 0*63+10 1*01+07
2/851,	,,,,,	,7,, 08/ /*/0 % /*8667826 3*33+10 3*22+07
25365,,,,,61,,3,,, 1// /*/0 % /*8/717/85 3*05+08 2*27+05
26421,,,,,	,	,	,, 085 /*/0 % /*6512/118 1*83+07 1*/4+04
16130,,,,,06,	,3,, 033 /*/0 % /*84502668 2*50+07 1*1/+04
03304,,,2,,	,, 070 /*/0 % /*682/713 4*22+07 1*78+04
07782,,,,13,,	, 1// /*/0 % /*57044184 1*6/+06 0*1/+03
gsea_camera_Immunologic Signatures_(groupTo_c - groupTo_b) - (groupSp_c - groupSp_b)
 %  $ !##%! #%! $!. & ''

).) .,, ,',- " ,'4.004-40 -'20(.3 4'..(.2

).)
	 -53 ,',- " ,'34.1,/-2 .'3,(., 2'32(-5

)))- .,, ,',- " ,'/14,3./3 -'01(-, .'0.(,5

)		)	 -52 ,',- " ,'2/130/,. ,',,,0/53 ,',,0/53

)	 42 ,',- " ,'204.1.5. ,',,,12/2 ,',,02.-

)	)) 52 ,',- " ,'11134-1 ,',,,203 ,',,02.-

))	 -03 ,',- " ,'0,-02052 ,',--13 ,',0-//

)-)		 .,, ,',- " ,'013/5-01 ,',-.5/ ,',0/-

)		)	 -55 ,',- " ,'.04/1-45 ,',.,.4 ,',2//3

))). 14 ,',- " ,'/32.4044 ,',./,. ,',2051

))) .- ,',- " ,'1/-00433 ,',.2- ,',2425

))	) --. ,',- " ,'//43.4-/ ,'-.23 ,'./02





))		 50 ,',- " ,'/31,5532 ,'/42- ,'15,1

)	)	 5, ,',- " ,'.40-534- ,'/453 ,'15,1

)))		 1. ,',- " ,'043-5304 ,'14/4 ,'3040

)	 5, ,',- " ,'0004/245 ,'1551 ,'305/

)		 -40 ,',- " ,'0152543 ,'34/1 ,'45,/

)	)) -52 ,',- " ,'113---1 ,'51/. ,'5201

))) -11 ,',- " ,'302-.-5- ,'5152 ,'5201

)	 -33 ,',- " ,'12124-55 ,'5201 ,'5201
gsea_camera_Hallmark Signatures_(groupTo_c - groupTo_b) - (groupSp_c - groupSp_b)
 %  $ !##%! #%! $!. & ''
..442)	))	-1)	)
) -55 ,',- " ,'422..5./ -'/-(/, 2'/5(.3
/54.))0)))-) -55 ,',- " -',14-.0.1 1'23(.3 -'/4(./
..442)	))	.)	)
) .,, ,',- " ,'4/1.005- /',4(.2 1',,(./
/.542)	))))))	)) -53 ,',- " -',.,./,2. 2'.3(.2 3'20(./
-/103).))-.))	)	)	)) -4, ,',- " -',-404.5- 4'2-(.0 4'/5(.-
/2032)))))3.))0))) .,, ,',- " -',1-/32,1 -'0/(./ -'-2(.,
..442)	)0)))04))-) .,, ,',- " ,'333,1,51 0'50(./ /'00(.,
.33,)	-.))))))0))2) -50 ,',- " ,'51-3,333 .'14(.. -'13(-5
.43.2)	)0)))	).0)
) -52 ,',- " ,'532/-.,. /'.2(.. -'33(-5
/54.))0))).) -55 ,',- " ,'50/505-4 1'4/(.. .'40(-5
.2-12))		))0)	)		)) -53 ,',- " ,'5-5512/3 4'31(.. /'43(-5
gsea_camera_Immunologic Signatures_groupTo_c - groupTo_b
 %  $ !##%! #%! $!. & ''
-131,)2))-,))4)) -50 ,',- " .'2-35,.4. .'05(// -'.-(.5
-131,)2))-,)2
))4)) -50 ,',- " .'2-,254- 3'./(// -'32(.5
/2032)))))3.))0))) .,, ,',- " .'./3355.3 -'1/(/- .'04(.4
/2032)))))3.))0))) .,, ,',- " .',1.54253 1'10(/- 2'31(.4
..442)	))	-1)	)
) -55 ,',- " -'10,014,4 3'4/(/- 3'2/(.4
/2032)))))0,))0))) -55 ,',- " .'-0/14244 -'-0(.3 5'./(.1
.-,2/)))-)
)4)	)	)	)) -55 ,',- " .'.1...,10 /'-5(.2 .'-3(./
-/103).))-.))	)	)	)) -4, ,',- " -'45.2514/ /'12(.2 .'-3(./
-/103)))	)	)	))-.) -34 ,',- " .'/551.213 2'2,(.2 /'.1(./
/2032)))))0,))0))) .,, ,',- " -'432-2352 2'24(.2 /'.1(./
gsea_camera_Immunologic Signatures_groupTo_c - groupTo_a
Figure 15
	   	   Appendix	  
	   87	  
	  
Figure	  16	  Analysis	  of	  putative	  ILC1s	  Putative	   ILC1s	   sorted	   as	   viable	   CD45+	   Lin-­‐CD94-­‐CD127+CD117-­‐NKp44-­‐	   cells	   were	  cultured	  for	  3	  weeks	  with	  IL-­‐12	  and	  IL-­‐15	  and	  analyzed	  for	  CD3	  and	  T-­‐box	  transcription	  factors.	   Cytolytic	   activity	   determined	   though	   LDH	   release	   was	   compared	   to	   the	   ILC3	  differential	  cultures	  in	  an	  18-­‐hour	  assay	  against	  K562	  cells.	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Abbreviations	  
	  EBV	   	   Epstein	  Barr	  Virus	  	  ILC	   	   innate	  lymphoid	  cell	  cNK	   	   conventional	  natural	  killer	  cell	  TCR	   	   T	  cell	  receptor	  CLP	   	   common	  lymphoid	  progenitor	  RAG	   	   recombination-­‐activating	  genes	  Lin	   	   lineage	  Th	   	   T	  helper	  PB	   	   peripheral	  blood	  BM	   	   bone	  marrow	  ieILC1	  	   intraepithelial	  ILC1	  HSC	   	   hematopoietic	  stem	  cells	  αLP	   	   α4β7+	  lymphoid	  progenitor	  Flt3	   	   FMS-­‐like	  tyrosine	  kinase	  3	  EILP	   	   early	  ILC	  progenitor	  FL	   	   fetal	  liver	  CHILP	   	   common	  helper-­‐like	  ILC	  precursor	  PLZF	   	   promyelocytic	  leukemia	  zinc	  finger	  LTi	   	   lymphoid	  tissue	  inducer	  cells	  RORγt	  	   RAR-­‐related	  orphan	  receptor	  gamma	  LN	   	   lymph	  node	  PP	   	   Peyer’s	  patches	  fm	   	   fate	  map	  LP	   	   lamina	  propria	  Eomes	  	   eomesodermin	  hILC1	   	   helper	  ILC1	  DC	   	   dendritic	  cell	  NKP	   	   NK	  precursor	  TNF	   	   tumor	  necrosis	  factor	  TRAIL	  	  	   tumor	  necrosis	  factor	  (TNF)–related	  apoptosis-­‐inducing	  ligand	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KO	   	   knock-­‐out	  Tg	   	   transgenic	  HPC	   	   hematopoietic	  progenitor	  cell	  UCB	   	   umbilical	  cord	  blood	  AHR	   	   aryl	  hydrocarbon	  receptor	  SCF	   	   stem	  cell	  factor	  NSG	   	   NOD/SCIDγcnull	  mice	  SCID	   	   severe	  combined	  immunodeficiency	  Gzm	   	   granzyme	  KIR	   	   killer	  immunoglobulin-­‐like	  receptor	  NKG2	   	   natural-­‐killer	  group	  2	  (receptor)	  HLA	   	   human	  leukocyte	  antigen	  MICA	   	   MHC	  class	  I	  chain-­‐related	  protein	  A	  ULBP	   	   UL-­‐16	  binding	  proteins	  HCMV	   	   human	  cytomegalovirus	  ADCC	   	   antibody-­‐dependent	  cellular	  cytotoxicity	  DNAM-­‐1	   DNAX	  Accessory	  Molecule-­‐1	  SLT	   	   secondary	  lymphoid	  tissues	  S1P	   	   sphingosine	  1-­‐phosphate	  HVEM	  	   herpes	  virus	  entry	  mediator	  TLR	   	   Toll-­‐like	  receptor	  IFN	   	   interferon	  CRTH2	   prostaglandin	  D2	  receptor	  2	  HSCT	   	   hematopoietic	  stem	  cell	  transplantation	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